Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.6 - coagulation factor Xa

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
Severe factor X deficiency in pregnancy: case report and review of the literature.
The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction.
Abortion, Septic
Connective tissue disease associated with sclerodermoid features, early abortion, and circulating anticoagulant.
Abortion, Spontaneous
Activated partial thromboplastin time is a predictive parameter for further miscarriages in cases of recurrent fetal loss.
Activation of the novel prothrombinase, fg12, as a basis for the pregnancy complications spontaneous abortion and pre-eclampsia.
Anticardiolipin antibodies in pathogenesis of infertility.
Antiphospholipid and other autoantibodies in a cohort of habitual aborters and healthy multiparous women in Jamaica.
Antiphospholipid antibody syndrome: an unusual cause of stroke in a 22-year-old female.
Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids.
Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus.
Hypercoagulability. Should every patient with venous thrombosis be tested?
LPS-induced occult loss in mice requires FGL2.
Pregnancy outcome in recurrent aborters is not influenced by Chlamydia IgA and/or G.
Primary antiphospholipid syndrome presenting as thrombotic microangiopathy: Successful treatment with steroids, plasma exchange and anticoagulants.
Sjögren's syndrome and pregnancy.
The emerging role of immunoregulation of fibrinogen-related procoagulant Fgl2 in the success or spontaneous abortion of early pregnancy in mice and humans.
The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population.
The same immunoregulatory molecules contribute to successful pregnancy and transplantation.
[Antiphospholipid antibodies in systemic lupus erythematosus: study of a caseload of 120 patients]
Abruptio Placentae
A rapid test for abruptio placentae: evaluation of a D-dimer latex agglutination slide test.
Activation of thromboplastin in a case of abruptio placentae with hypofibrinogenemia.
Disseminated intravascular coagulation.
New approach to the risk variables for administration of fibrinogen in patients with postpartum hemorrhage by using cluster analysis.
Abscess
Abscess in bilateral ovarian haematomas in a girl with factor X deficiency, necessitating oopherectomy.
The omentoplasty: a neglected ally in gynecologic surgery.
Use of preprocedural tests by interventional radiologists.
Acidosis
Acidosis and coagulopathy: the differential effects on fibrinogen synthesis and breakdown in pigs.
Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations.
Diagnostic evaluation of risk for bleeding in cardiac surgery with extracorporeal circulation.
Disseminated intravascular coagulation.
Effects of emergency treatment mode of damage-control orthopedics in pelvic fracture complicated with multiple fractures.
Evaluation of tris-hydroxymethylaminomethane on reversing coagulation abnormalities caused by acidosis in pigs.
Factors associated with the increased bleeding in the postoperative period of cardiac surgery: A cohort study.
Neuroleptic Malignant Syndrome Associated With Metoclopramide Use in a Boy: Case Report and Review of the Literature.
Polytrauma Defined by the New Berlin Definition: A Validation Test Based on Propensity-Score Matching Approach.
Pulmonary tractotomy as an abbreviated thoracotomy technique.
Rodenticide Poisoning: Critical Appraisal of Patients at a Tertiary Care Center.
Thromboelastometry-guided hemostatic therapy for hemorrhagic shock in the postoperative period of vascular surgery: a case report.
[Dengue infection with fatal ending]
[Strategy of the metabolic acidosis correction and indices of coagulation profile in patients with severe traumatic shock].
Acidosis, Lactic
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.
Acquired Immunodeficiency Syndrome
Acquired circulating anticoagulants in children with acquired immunodeficiency syndrome.
Common variable immune deficiency syndrome associated with lupus anticoagulant.
Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.
Lupus anticoagulant associated with specific inhibition of factor VII in a patient with AIDS.
Lupus anticoagulant in the acquired immunodeficiency syndrome.
PLASMA prothrombin, serum prothrombin and thromboplastin generation tests; aids in study of defects in coagulation. No. 1.
THE THROMBOPLASTIN generation test; aids in the study of coagulation defects. II.
Update on the Clot Waveform Analysis.
Activated Protein C Resistance
A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
A chromogenic assay for activated protein C resistance.
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study.
A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array.
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
A rare case of unprovoked venous thromboembolism manifestation in a young patient with antithrombin Type IIB deficiency combined with inferior vena cava anomaly from Lithuania.
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Activated protein C resistance associated with lupus anticoagulants is a high risk in acute mesenteric venous thrombosis.
Activated Protein C Resistance in Behçet's Disease.
Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome.
Activated protein C resistance--a major risk factor for thrombosis.
Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
Activated protein C resistance: prevalence and implications in peripheral vascular disease.
Activated protein C resistance: the influence of ABO-blood group, gender and age.
Activated-protein-C resistance in cancer patients.
Alteration of haemostasis in non-metastatic gastric cancer.
APC resistance during the normal menstrual cycle.
Are women with polycystic ovary syndrome resistant to activated protein C?
Association between adverse pregnancy outcomes and maternal factor V G1691A (Leiden) and prothrombin G20210A genotypes in women with a history of recurrent idiopathic miscarriages.
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population.
Coagulation factor V gene 1691G>A polymorphism as an indicator for risk and prognosis of lower extremity deep venous thrombosis in Chinese Han population.
Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables.
Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C.
Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay.
Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
Early cerebral sinovenous thrombosis in a child with acute lymphoblastic leukemia carrying the prothrombin G20210A variant: a case report and review of the literature.
Effect of Freezing Plasma at -20°C for 2 Weeks on Prothrombin Time, Activated Partial Thromboplastin Time, Dilute Russell Viper Venom Time, Activated Protein C Resistance, and d-Dimer Levels.
Effect of oral contraceptives on the anticoagulant activity of protein S in plasma.
Effects of hormone replacement on hemostasis in spontaneous menopause.
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Elevated prothrombin and activated protein C resistance in patients with thoracic aortic atheroma.
Genetic determinants of hemostasis phenotypes in Spanish families.
Hemostasis during normal pregnancy and puerperium.
Hemostatic alterations in patients with acute, unilateral vestibular paresis.
High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.
Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.
Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance.
Is elevated level of soluble endothelial protein C receptor a new risk factor for retinal vein occlusion?
Lack of association between inherited thrombophilic risk factors and idiopathic sudden sensorineural hearing loss in Italian patients.
Low prevalence of the factor V Leiden among patients with ischemic stroke.
Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system.
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis.
Physical activity and hemostatic and inflammatory variables in elderly men.
Prevalence and patient profile in activated protein C resistance.
Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease.
Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
Quality standards for sample collection in coagulation testing.
Resistance to activated protein C in thalassaemic patients: an underlying cause of thrombosis.
Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.
Resistance to activated protein C: a major cause of inherited thrombophilia.
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Screening for thrombophilia: a laboratory perspective.
Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis.
Shortened activated partial thromboplastin time, a hemostatic marker for hypercoagulable state during acute coronary event.
Snake Venoms in Diagnostic Hemostasis and Thrombosis.
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
The carbohydrate moiety of factor V modulates inactivation by activated protein C.
The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
The effect of dabigatran on select specialty coagulation assays.
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade.
[A case report of syphilitic uveitis and deafness.]
[Hematological changes and related gene mutation of post-severe acute respiratory syndrome patients with osteonecrosis]
Acute Coronary Syndrome
A new regimen for heparin use in acute coronary syndromes.
A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml.
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
Acute coronary syndromes: oral factor Xa inhibitors in acute coronary syndromes.
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
Apixaban in Acute Coronary Syndromes.
Apixaban with antiplatelet therapy after acute coronary syndrome.
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case-control study.
Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants.
Clinical and experimental experience with factor Xa inhibitors.
Clinical pharmacology of direct and indirect factor Xa inhibitors.
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials.
Drug evaluation: the directly activated Factor Xa inhibitor otamixaban.
Dual pathway therapy in acute coronary syndrome.
Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis.
Enantiomeric characterization and structure elucidation of Otamixaban.
Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Factor X inhibitors.
Factor Xa inactivation in acute coronary syndrome.
Factor Xa inhibitors for acute coronary syndromes.
Factor Xa Inhibitors in Acute Coronary Syndromes and Venous Thromboembolism.
Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality.
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
Fondaparinux in the management of patients with ST-elevation acute myocardial infarction.
Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Heparin dosing and therapeutic activated partial thromboplastin times (aPTT) in acute coronary syndrome (ACS).
High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes.
High-Risk Non-ST Elevation Acute Coronary Syndrome Outcomes in Patients Treated with Unfractionated Heparin Monitored Using Anti-Xa Concentrations Versus Activated Partial Thromboplastin Time.
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.
Intravenous Thrombolysis for Acute Ischemic Stroke in a Patient Receiving Rivaroxaban.
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.
Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
Monitoring the anticoagulant effect after a massive rivaroxaban overdose.
Myocardial infarctions and other acute coronary syndromes in rare congenital bleeding disorders: a critical analysis of all reported cases.
New anticoagulants.
Novel anticoagulant therapy: principle and practice.
Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes.
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Promise of factor Xa inhibition in acute coronary syndromes.
Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium.
Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation.
Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.
Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
Rivaroxaban in acute coronary syndromes--is it prime time?
Rivaroxaban in patients with a recent acute coronary syndrome.
Rivaroxaban in the contemporary treatment of acute coronary syndromes.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?
Role of oral factor Xa inhibitors after acute coronary syndrome.
Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban.
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: A pilot study.
Spotlight on fondaparinux sodium in acute coronary syndromes.
TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1.
The 'chest pain kit' study: A 'pill in the pocket' concept to improve the pre-hospital therapy of acute coronary syndrome.
The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit.
The ATLAS ACS 2-TIMI 51 Trial and the Burden of Missing Data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.
The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.
The ineffectiveness of a non-weight based heparin regimen in achieving therapeutic activated partial thromboplastin time (aPTT) in acute coronary syndrome.
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.
What did we learn from new oral anticoagulant treatment?
[New oral anticoagulants: recommendations, precautions and perspectives for use].
Acute Kidney Injury
Acute respiratory failure in adult patients with dengue virus infection.
Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury.
Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions.
Clinical assessment and pathophysiology of Bothrops venom-related acute kidney injury: a scoping review.
Early Postoperative Acute Kidney Injury Among Pediatric Liver Transplant Recipients.
The epidemiology of acute kidney injury in critically ill patients in the Gansu Province: The EACG study.
Thromboelastometry-guided hemostatic therapy for hemorrhagic shock in the postoperative period of vascular surgery: a case report.
Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
[Combined predictive value of the risk factors influencing the short-term prognosis of sepsis].
[The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding].
Acute Lung Injury
Coagulation and inflammation in acute lung injury.
Direct factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2/NF-?B signaling pathway.
Multivariate regression modeling for the prediction of inflammation, systemic pressure, and end-organ function in severe sepsis.
Adenocarcinoma
Fatal hemoperitoneum after fine-needle aspiration of a liver metastasis.
Fc Receptor is Involved in Nk Cell Functional Anergy Induced by Miapaca2 Tumor Cell Line.
[Clinical and Imaging Features of Acute Cerebral Infarction ?in Non-small Cell Lung Cancer Patients with Trousseau Syndrome].
Adenoma
[Mixed corticomedullary tumor]
Adenomyosis
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
Adenoviridae Infections
Adrenal gland infection by serotype 5 adenovirus requires coagulation factors.
Adrenocortical Hyperfunction
Evaluation of coagulation status in dogs with naturally occurring canine hyperadrenocorticism.
Afibrinogenemia
An instructive case of presumed brown snake (Pseudonaja spp.) envenoming.
Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Clinical audit of inherited bleeding disorders in a developing country.
Congenital afibrinogenemia in Hasan Sadikin Hospital.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Studies on the role of adhesive proteins in maintaining pregnancy.
The activated partial thromboplastin time may not reveal even severe fibrinogen deficiency.
Treatment of afibrinogenemia in a chihuahua.
[Inherited Afibrinogenemia Caused by Compound Heterozygous Mutations in the Beta beta-Chain of Fibrinogen.]
[Studies on the presence of active thrombokinase in the amniotic fluid; a contribution to the etiology of afibrinogenemia during labor.]
Agammaglobulinemia
Case Report: An Adult Patient With Deficiency of Adenosine Deaminase 2 Resembled Unilateral Frosted Branch Angiitis.
Follow-up of renal transplant recipients after acute COVID-19-A prospective cohort single-center study.
Alopecia
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience.
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
alpha 1-Antitrypsin Deficiency
[Thrombokinase inhibitors and alpha 1-antitrypsin deficiency in liver cirrhosis as a cause for hemorrhage in ascites shunt]
Alzheimer Disease
Proteolysis of Alzheimer's disease beta-amyloid precursor protein by factor Xa.
Amyloidosis
A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X.
A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma.
A Rare Cause of Coagulopathy in a Patient with Rapidly Progressive Renal Failure.
A reproducible model for the study of factor X kinetics in AA amyloidosis.
Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone.
Acquired factor X deficiency and amyloidosis.
Acquired factor X deficiency associated with atypical AL-amyloidosis.
Acquired factor X deficiency in a patient with amyloidosis.
Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
Acquired factor x deficiency in light chain amyloidosis: a report of 2 korean cases.
Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis.
Acquired factor X deficiency in systemic amyloidosis.
Acquired factor X deficiency in systemic amyloidosis: management of two cases.
Acquired factor X deficiency. Altered plasma antithrombin activity and association with amyloidosis.
Acquired isolated factor X deficiency associated with systemic amyloidosis. Case report and review of literature.
Acquired-transient factor X deficiency in a teenager with extensive burns.
Amyloidosis and factor X deficiency.
AMYLOIDOSIS ASSOCIATED WITH FACTOR X (STUART) DEFICIENCY; CASE REPORT.
Amyloidosis with factor X deficiency.
An acquired, calcium-dependent, factor X inhibitor.
Atraumatic splenic rupture in amyloidosis.
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients.
Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency.
Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy.
Direct Factor X sequestration by systemic amyloid light-chain amyloidosis.
Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis.
Factor X and its deficiency states.
Factor X deficiency and systemic amyloidosis.
Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib: A Case Report and Review of the Literature.
Factor X deficiency in systemic amyloidosis.
Factor X deficiency.
Hemostatic abnormalities in multiple myeloma and related disorders.
Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses.
Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.
Importance of pharmacokinetic studies in the management of acquired factor X deficiency.
Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis.
Isolated factor X deficiency in amyloidosis. Case report and review of the literature.
Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis.
Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications.
Massive Upper and Lower GI Bleed from Simultaneous Primary (AL) Amyloidosis of the Stomach and Transverse Colon in a Patient with Multiple Myeloma.
Mechanism of factor X deficiency in systemic amyloidosis.
Normalization of plasma factor X levels in amyloidosis after plasma exchange.
Poor recovery and short survival of infused factor X in a case of acquired factor X deficiency and amyloidosis.
Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency.
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency.
Recurrent, isolated factor X deficiency in myeloma: repeated normalization of factor X levels after cytostatic chemotherapy followed by late treatment failure associated with the development of systemic amyloidosis.
Refractory hematuria from amyloidosis successfully treated by splenectomy.
Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy.
Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.
Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.
Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis.
Spontaneous resolution of acquired factor X deficiency in amyloidosis.
Spontaneous spinal epidural hematoma in a patient with acquired Factor X deficiency secondary to systemic amyloid light-chain amyloidosis.
Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis.
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X.
Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.
Systemic amyloidosis associated with factor X deficiency.
Systemic amyloidosis associated with micro-angiopathic haemolytic anaemia and factor X (Stuart factor) deficiency.
The 13-year bleed: Exuberant amyloid angiopathies, angiodysplasias, and acquired coagulopathies of the gut.
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Treatment of amyloidosis associated factor X deficiency.
Use of prothrombin complex concentrate for prophylaxis of bleeding in acquired factor X deficiency associated with light-chain amyloidosis.
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis.
[A case of primary hepatic amyloidosis with factor X deficiency.]
[A case of retroperitoneal hemorrhage due to multiple myeloma complicated with factor X deficiency and amyloidosis]
[A deficiency of blood coagulation factor X in a female patient with primary generalized amyloidosis]
[Acquired deficit in factor X associated with amyloidosis. One case (author's transl)]
[Acquired factor X deficiency associated with A.L.type amyloidosis. A case report]
[Acquired isolated factor X deficiency in generalized amyloidosis]
[Decreased Quick percentage, acquired factor X deficiency, hemarthrosis and ecchymosis: amyloidosis]
[Factor X deficiency in amyloidosis (author's transl)]
[Factor X deficiency in systemic amyloidosis. Presentation of a case]
[Systemic light chain amyloidosis with acquired factor X deficiency: a case report].
Amyloidosis, Familial
[Familial amyloidosis of AL type and factor X deficiency. The valve of long-term colchicine administration]
Anaphylaxis
An unusual cause of spontaneous bleeding in the intensive care unit - mastocytosis: a case report.
Anemia
A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia.
A pilot study of the effect of rivaroxaban in sickle cell anemia.
A Retrospective Analysis of the Clinical and Epidemiological Characteristics of COVID-19 Patients in Henan Provincial People's Hospital, Zhengzhou, China.
Acquired factor VIII deficiency presenting with compartment syndrome.
Acquired hemophilia A developing cerebral infarction 36 days after the frequent administration of bypass hemostatic agents.
Acquired Hemophilia A in a Patient with Essential Thrombocythemia.
Acquired von Willebrand's syndrome caused by primary hypothyroidism in a 5-year-old girl.
Acquired Von Willebrand's Syndrome in Systemic Lupus Erythematosus.
Activated coagulation times in normal cats and dogs using MAX-ACT tubes.
Adenoviral pneumonia in children.
Bleeding manifestations in males with von Willebrand disease.
Blood cells diseases and thrombosis.
Clinical Assessment of Postoperative Anemia Associated with Edoxaban in Patients Undergoing Total Knee Arthroplasty Compared to Fondaparinux.
Connective tissue disease associated with sclerodermoid features, early abortion, and circulating anticoagulant.
Crimean-Congo hemorrhagic fever.
Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man.
Deficiency of the contact phase of intrinsic coagulation in a horse.
Diffuse hemangiomatosis, coagulopathy and microangiopathic hemolytic anemia.
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Experimental Sarcocystis suicanis infections: disease in growing pigs.
Factor X Deficiency: A Rare Cause of Puberty Menorrhagia.
Hematologic manifestation of childhood celiac disease.
Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder.
Immunologic reactions associated with anemia, thrombocytopenia, and coagulopathy in experimental African trypanosomiasis.
Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells.
Malignant histiocytosis in a cat.
Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review.
Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience.
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Pharmaceutical Approval Update.
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
Preoperative laboratory testing of children undergoing elective surgery.
Prevalence of retinopathy in patients with anemia or thrombocytopenia.
Primary pulmonary hypertension. Its association with microangiopathic hemolytic anemia and thrombocytopenia.
Prognostic indicators for canine monocytic ehrlichiosis.
Renal hemorrhage caused by acquired inhibitors to coagulation factors VIII and V in a hemodialysis patient.
Severe adenovirus infection in children.
Splenic infarction, warm autoimmune hemolytic anemia and antiphospholipid antibodies in a patient with infectious mononucleosis.
Spontaneous hemoperitoneum in cats: 65 cases (1994-2006).
Spontaneous Retrobulbar Hemorrhage in a Previously Healthy Infant.
The clinical impact of edoxaban for the patients with postoperative anemia after total hip arthroplasty.
The hemostatic effect of packed red cell transfusion in patients with anemia.
Thromboelastometry-guided hemostatic therapy for hemorrhagic shock in the postoperative period of vascular surgery: a case report.
Unusual metastatic behavior and clinicopathologic findings in eight cats with cutaneous or visceral hemangiosarcoma.
Unusual Presentation of Diffuse Large B-Cell Lymphoma With Splenic Infarcts.
Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
[Abdominal inflammatory pseudotumor (plasma cell granuloma) with anemia and hypergammaglobulinemia]
[An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment.]
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
[Clinical evaluation of three elderly cases with acquired hemophilia A].
[Crimean-Congo hemorrhagic fever]
[Effective immunosuppresive therapies including steroid pulse treatment for intramuscular hematoma in iliopsoas in acquired hemophilia]
[Perioperative management of a patient with systemic lupus erythematosus, myasthenia gravis, and pemphigus foliaceous]
[Significance of blood tests prior to adenoidectomy]
[Successful total gastrectomy of gastric cancer in a congenital factor V deficient patient]
Anemia, Aplastic
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Anemia, Hemolytic
Complement in Secondary Thrombotic Microangiopathy.
Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia.
Impaired and exhausted platelets in modified generalized Shwartzman reaction: an analogue of hemolytic uremic syndrome associated with endotoxemia.
Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies.
Systemic amyloidosis associated with micro-angiopathic haemolytic anaemia and factor X (Stuart factor) deficiency.
Zinc toxicosis in a dog secondary to prolonged zinc oxide ingestion.
[Catastrophic antiphospholipid syndrome and rituximab: a new report]
[Hemostatic disorders as a complication of autoimmune hemolytic anemia in dogs]
[Treatment of fulminant falciparum malaria with erythrapheresis]
Anemia, Iron-Deficiency
A bleeding disorder (von Willebrand's disease) in a Himalayan cat.
Celiac disease with diffuse cutaneous vitamin K-deficiency bleeding.
Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review.
Anemia, Sickle Cell
A pilot study of the effect of rivaroxaban in sickle cell anemia.
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.
Plasma levels of some blood coagulation parameters in Nigerian homozygous sickle cell patients (HbSS) in steady state.
Prolongation of the prothrombin time and activated partial thromboplastin time in children with sickle cell disease.
SICKLE CELL DISEASE. A SERUM DEFECT IN THE THROMBOPLASTIN GENERATION TEST.
Aneurysm
Active aneurysm thrombosis after Kawasaki disease in an adult: Insight into anticoagulation therapy.
Coagulopathy induced by aortoiliac aneurysms.
Low-Dose versus Therapeutic Range Intravenous Unfractionated Heparin Prophylaxis in the Treatment of Patients with Severe Aneurysmal Subarachnoid Hemorrhage After Aneurysm Occlusion.
Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency.
Primary fibrinolysis during supraceliac aortic clamping.
Thrombosis of Large Aneurysm Induced by Flow-Diverter Stent and Dissolved by Direct Factor Xa Inhibitor.
Aneurysm, Dissecting
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.
Aneurysm, Ruptured
Recent risk factors for open surgical mortality in patients with ruptured abdominal aortic aneurysm.
Angina Pectoris
Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis.
Angina, Stable
The effect of different nitrate preparations on plasma heparin concentrations and the activated partial thromboplastin time.
Angina, Unstable
A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml.
Antithrombin-III plasma activity during and after prolonged use of heparin in unstable angina.
Assessment of the drug interaction between intravenous nitroglycerin and heparin.
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Intracoronary recombinant tissue-type plasminogen activator in unstable angina: a pilot angiographic study.
Low molecular weight heparin in acute stroke.
Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
Spotlight on fondaparinux sodium in acute coronary syndromes.
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention.
Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris.
ZK-807834. Berlex.
Angiodysplasia
Gastrointestinal angiodysplasia: a possible component of von Willebrand's disease.
The 13-year bleed: Exuberant amyloid angiopathies, angiodysplasias, and acquired coagulopathies of the gut.
Angioedema
Shortened Activated Partial Thromboplastin Time May Help in Diagnosing Hereditary and Acquired Angioedema.
Anisocoria
The sequential trauma score - a new instrument for the sequential mortality prediction in major trauma.
Antiphospholipid Syndrome
A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter.
A patient with pleuritic chest pain and abnormal blood clotting tests.
Activated protein C resistance: molecular mechanisms.
An increase of blood anti-beta2-glycoprotein I antibody in Japanese encephalitis associated with cerebral ischemia.
Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin.
Antiphospholipid antibody syndrome: an unusual cause of stroke in a 22-year-old female.
Antiphospholipid syndrome and factor V Leiden. Three cases with recurrent venous thrombosis.
Antiphospholipid syndrome and thrombosis.
Antiphospholipid syndrome presenting as intracardiac thrombus with pulmonary embolism.
Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
Association of lupus anticoagulant and anticardiolipin antibodies with thrombosis in patients with systemic lupus erythematosus, primary antiphospholipid syndrome and other disorders.
Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
Dilute Russell viper venom time interpretation and clinical correlation: A two-year retrospective institutional review.
Etanercept and venous thromboembolism: a case series.
Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study.
Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: additional information.
Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome.
FcRn augments induction of tissue factor activity by IgG-containing immune complexes.
Heparin monitoring in acute thrombosis associated with antiphospholipid antibody syndrome.
Identification of anti-prothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activity.
Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.
Lupus erythematosus with antiphospholipid syndrome and erythema multiforme-like lesions.
Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time.
Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome.
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin.
Perioperative anticoagulation management in antiphospholipid syndrome.
Prolonged activated partial thromboplastin time in patients with antiphospholipid antibody syndrome.
Pulmonary embolism, thrombocytopenia, and antiphospholipid syndrome.
Pyoderma gangrenosum and extensive caval thrombosis associated with the antiphospholipid syndrome--a case report.
Rowell's syndrome and associated antiphospholipid syndrome.
Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.
Secondary severe factor X deficiency associated with antiphospholipid syndrome.
Successful delivery in a pregnant woman with lupus anticoagulant positive systemic lupus erythematosus treated with double filtration plasmapheresis.
Successful Peritoneal Dialysis Catheter Placement in a New End-Stage Renal Disease Patient with Combined Antiphospholipid Syndrome and Factor XI Deficiency.
The activated seven lupus anticoagulant assay detects clinically significant antibodies.
The anaesthetist and the antiphospholipid syndrome.
Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome.
Transient lupus anticoagulant: an unusual cause of bruising in children.
Vascular disease in the antiphospholipid syndrome: a comparison with the patient population with atherosclerosis.
Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant.
[Diagnosis of secondary antiphospholipid syndrome in children by means of screening tests]
[Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range].
[Splenic vein thrombosis with pancytopenia and fever: antiphospholipid antibody syndrome]
Antithrombin III Deficiency
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
Measurement of markers of activated coagulation in antithrombin III deficient subjects.
[Reasons for fresh frozen plasma transfusion in a general hospital]
Aortic Aneurysm
Coagulopathy induced by aortoiliac aneurysms.
Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
Aortic Aneurysm, Abdominal
Factor Xa inhibition by Rivaroxaban modified mitochondrial-associated proteins in human abdominal aortic aneurysms.
Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation.
FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.
Aortic Coarctation
Attributable fraction for cardiac malformations.
Aortic Valve Stenosis
Oral Anticoagulation Therapy and Progression of Calcific Aortic Valve Stenosis: Factor Xa versus Factor IIa Inhibition?
Appendicitis
Alterations of the preoperative coagulation profile in patients with acute appendicitis.
[Unsuspected prolonged activated partial thromboplastin time in emergency surgery. Diagnostic and therapeutic guide]
Arrhythmias, Cardiac
The role of hypothermia in the management of severe brain injury: a meta-analysis.
Arterial Occlusive Diseases
[Hemorheologic and blood coagulation studies in 94 patients with chronic obstructive peripheral arterial disease]
Arteriosclerosis Obliterans
Accelerated thromboplastin generation in acute arterial occulusion complicating arteriosclerosis obliterans.
Arteriovenous Fistula
A case of a severe factor XI deficiency in patient undergoing hemodialysis without the use of heparin.
[Acquired factor XI inhibitor and chronic lymphocytic leukemia.]
Arteriovenous Malformations
Acquired hemophilia A that required surgical hemostasis of hematomas occupying oral cavity: a case report.
Arthralgia
Alkhumra (Alkhurma) virus outbreak in Najran, Saudi Arabia: Epidemiological, clinical, and Laboratory characteristics.
Arthritis
Activated partial thromboplastin time sensitivity to lupus anticoagulant in a patient with transient arthritis and lupus anticoagulant-hypoprothrombinemia syndrome.
Altered regulation of in-vivo coagulation in orthopedic patients prior to knee or hip replacement surgery.
Effects on leukocyte function by arthroplasty. Thromboplastin activity and oxygen-derived free radicals studied in rheumatoid arthritis and arthrosis.
Leech thrombin inhibitors.
The prothrombinase activity of FGL2 contributes to the pathogenesis of experimental arthritis.
[Acquired pseudohemophilia caused by an anticoagulant factor inhibiting the formation of thromboplastin during chronic evolutive polyarthritis.]
[Hemorrhagic diathesis due to anticoagulant inhibiting the formation or action of thromboplastin; concerning a personal case observed during chronic evolutive polyarthritis.]
Arthritis, Gouty
The inflammatory process in acute gouty arthritis. II. The presence of Hageman factor and plasma thromboplastin antecedent in synovial fluid.
Arthritis, Rheumatoid
Apixaban exhibits anti-arthritic effects by inhibiting activated factor X-mediated JAK2/STAT3 and MAPK phosphorylation pathways.
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Effects of intravenous high doses of ketoprofen on blood clotting, bleeding time and platelet aggregation in man.
Effects on leukocyte function by arthroplasty. Thromboplastin activity and oxygen-derived free radicals studied in rheumatoid arthritis and arthrosis.
Factor VIII inhibitors. Laboratory diagnosis of inhibitors.
Macrophages synthesize factor X and secrete factor X/Xa-containing prothrombinase activity into the surrounding medium.
Microparticles as biomarkers in autoimmunity: from dust bin to center stage.
Arthus Reaction
TLT-1-CONTROLS EARLY THROMBUS FORMATION AND STABILITY BY FACILITATING AIIBB3 OUTSIDE-IN SIGNALING IN MICE.
Ascorbic Acid Deficiency
Effect of ascorbic acid deficiency on plasma prothrombin time and partial thromboplastin time in guinea pigs.
Aspergillosis
[Blood coagulation in domestic deep-seated mycoses]
Asthma
Coagulation factor Xa modulates airway remodeling in a murine model of asthma.
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
The Coagulant Factor Xa Induces Protease-Activated Receptor-1 and Annexin A2-Dependent Airway Smooth Muscle Cytokine Production and Cell Proliferation.
[Changes in platelet function, activated partial thromboplastin time and plasminogen activator inhibitor in patients with bronchial asthma after prednisone treatment]
Atherosclerosis
Activated partial thromboplastin time and risk of future venous thromboembolism.
Anticoagulant properties of the anti-inflammatory cytokine IL-10 in a factor Xa-activated human monocyte model.
Antithrombin III and factor Xa inhibitor in atherosclerosis.
Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.
Clinical significance of increased thromboplastin activity on the monocyte surface--a brief review.
Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
Effects of vitamin K2 (menatetrenone) on atherosclerosis and blood coagulation in hypercholesterolemic rabbits.
Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
Peripheral vascular disease in patients with systemic lupus erythematosus.
Pleiotropic actions of factor Xa inhibition in cardiovascular prevention - mechanistic insights and implications for anti-thrombotic treatment.
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice.
Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial.
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.
Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.
Sulphur: the vulnerable factor X in atherosclerosis.
Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice.
Targeting factor Xa and thrombin: impact on coagulation and beyond.
Tissue factor-driven thrombin generation and inflammation in atherosclerosis.
Two Cu(II) coordination polymers: Heterogeneous catalytic Knoevenagel condensation reaction and treatment activity on atherosclerosis via regulating the expression of the COX-2 in vascular endothelial cells.
[Experimental cholesterin atherosclerosis in the rabbit: action of a duodenal heparinoid. III. Modifications in the factors of hemocoagulation, plasmin and plasminogen, and in the thromboplastin and fibrinolytic activity of the aortic wall.]
[Immunohistochemical characteristics of thromboplastin and beta-lipoproteins of the human aorta in atherosclerosis]
Atrial Fibrillation
A cost-analysis model for anticoagulant treatment in the hospital setting.
A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate.
A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
ABO Blood Type and Response of Activated Partial Thromboplastin Time to Dabigatran in Nonvalvular Atrial Fibrillation Patients.
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Activated Factor X Signaling Pathway via Protease-Activated Receptor 2 Is a Novel Therapeutic Target for Preventing Atrial Fibrillation.
Acute management of bleeding in patients on novel oral anticoagulants.
An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.
An Inhibitor of Activated Blood Coagulation Factor X Shows Anti-Endothelial Senescence and Anti-Atherosclerotic Effects.
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice.
Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation.
Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Anticoagulation in atrial fibrillation with factor X deficiency-A management dilemma.
Anticoagulation in atrial fibrillation.
Anticoagulation-related intracranial hemorrhages.
Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions.
Apixaban and atrial fibrillation: no clear advantage.
Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries.
Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients.
Apixaban to prevent stroke in patients with atrial fibrillation: a review.
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients with Atrial Fibrillation.
Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Assessing Safety of Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors and Vitamin K Antagonists in Patients with Atrial Fibrillation: A Nation-Wide Propensity Score Matched Cohort from Sweden.
Association between activated partial thromboplastin time, age and bleeding events in NVAF patients receiving dabigatran.
Association between Coagulation Function and Cerebral Microbleeds in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease.
Atrial fibrillation in 2011: Stroke prevention in AF.
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute.
Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants.
Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects.
Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Characteristics, Management, and Outcomes of Patients with Atrial Fibrillation Experiencing a Major Bleeding Event While on Rivaroxaban.
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.
Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation.
Clinical management of rivaroxaban-treated patients.
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.
Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation - patient considerations.
Clopidogrel hydrogen sulphate for atrial fibrillation.
Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran.
Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue.
Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.
Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation.
Comparative effectiveness of oral anticoagulants in everyday practice.
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism.
Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Comparing Safety and Efficacy of Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Hemophiliacs with Non-Valvular Atrial Fibrillation.
Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.
Controversies: Stroke Prevention in Chronic Kidney Disease.
Correction to: Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation.
Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.
Cost-Effectiveness of High-Dose Edoxaban Compared to Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
Critique of Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation trial.
Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time.
Defining nonvalvular atrial fibrillation: A quest for clarification.
Delayed Vesicular Urticarial Dermatosis Due to Apixaban.
Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Direct Factor Xa Inhibitors for Long-term Stroke Prevention in Atrial Fibrillation: Could the Lower Dose Fit All?
Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding.
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Direct oral factor Xa inhibitors for the prevention of non-central nervous systemic embolism patients with non-valvular atrial fibrillation - a systematic review and meta-analysis.
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor.
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
Edoxaban in patients with atrial fibrillation.
Edoxaban suppresses the progression of atrial fibrosis and atrial fibrillation in a canine congestive heart failure model.
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†
Edoxaban: a new oral direct factor xa inhibitor.
Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-Valvular Atrial Fibrillation and Venous Thromboembolism.
Edoxaban: a review in nonvalvular atrial fibrillation.
Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial.
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
Effectiveness and Safety of Factor Xa Inhibitors in Patients with Atrial Fibrillation.
Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
Efficacy and Safety of Direct Factor Xa Inhibitors Versus Warfarin in Prevention of Primary and Secondary Ischemic Strokes in Non-Valvular Atrial Fibrillation: A Literature Review.
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
Efficacy and safety of oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
Efficacy of direct factor Xa inhibitors compared to warfarin in preventing stroke in adults with non-valvular atrial fibrillation: a systematic review protocol.
Emerging antithrombotic agents: what does the intensivist need to know?
ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation.
Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation.
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis.
Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase.
Factor Xa Inhibitor, Rivaroxaban, Regulates the Burden of Atrial Fibrillation and Ventricular Premature Captures.
Factor Xa inhibitors differently modulate electrical activities in pulmonary veins and the sinoatrial node.
Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices.
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolismin patients with atrial fibrillation.
Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation.
Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.
Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban.
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report.
Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors.
Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment.
Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Imaging of Hemorrhagic Stroke.
Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation.
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors.
Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes.
Insights into atrial fibrillation.
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Intracranial hemorrhage in patient treated with rivaroxaban.
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
Intravenous Thrombolysis for Acute Ischemic Stroke in a Patient Receiving Rivaroxaban.
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation.
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants.
Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis.
Management of Periprocedural and Early Pericardial Effusions with Tamponade Following Ablation of Atrial Fibrillation with Uninterrupted Factor Xa Inhibitors: A Case Series.
Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks.
Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation.
Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Monitoring and reversal strategies for new oral anticoagulants.
Monitoring the roles of prothrombin activation fragment 1 and 2 (F1?+?2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
More light at the end of the tunnel - apixaban in atrial fibrillation.
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.
New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials.
New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery.
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Novel anticoagulant therapy: principle and practice.
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban.
Off-label use of reduced dose direct oral factor Xa-inhibitors in subjects with atrial fibrillation: a review of clinical evidence.
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
Optimising stroke prevention in non-valvular atrial fibrillation.
Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis.
Oral anticoagulants. New oral anticoagulants for atrial fibrillation: the factor Xa inhibitors rivaroxaban and apixaban.
Oral anticoagulation and vitamin K deficiency.
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation.
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Paroxysmal atrial fibrillation during acute myocardial infarction associated with subclinical hyperthyroidism, severe three vessels coronary artery disease and elevation of prostate-specific antigen after TURP.
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Perinephric Hematoma Induced by Factor Xa Inhibitor in a Patient with a Vascular Renal Mass.
Periprocedural management of rivaroxaban-treated patients.
Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects.
Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination.
Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination.
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm.
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor.
Platelet aggregation in direct oral factor Xa inhibitors-treated patients with atrial fibrillation: a pilot study.
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Population Pharmacokinetic-Pharmacodynamic Modeling Analysis of Intrinsic FXa and Bleeding From Edoxaban Treatment.
Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation.
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Preclinical and clinical data for factor Xa and "universal" reversal agents.
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.
Promise of factor Xa inhibition in atrial fibrillation.
Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis.
Quick reference guide to apixaban.
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis.
Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation.
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.
Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Rectus Sheath Hematoma Associated with Apixaban.
Reduced Smoke-like Echo and Resolved Thrombus in the Left Atrium with Rivaroxaban Therapy in an Acute Cardioembolic Stroke Patient.
Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation.
Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy.
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH.
Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).
Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation.
Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies.
Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.
Rivaroxaban in atrial fibrillation.
Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results.
Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1.
RIVAroxaban TWICE daily for lysis of thrombus in the left atrial appendage in patients with non-valvular atrial fibrillation: the RIVA-TWICE study.
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
Rivaroxaban: a review of its use in acute coronary syndromes.
Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation.
Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban.
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation.
Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.
Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban.
Spontaneous Hemopericardium in a Patient Receiving Apixaban Therapy: First Case Report.
Spontaneous rectus sheath hematoma during rivaroxaban therapy.
Spontaneous rectus sheath hematoma in a patient treated with apixaban.
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions.
Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
Sudden Loss of Vision: An Insight into Rivaroxaban.
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis.
The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
The pharmacology of novel oral anticoagulants.
The Potential Role of Edoxaban in Stroke Prevention Guidelines.
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.
Therapeutic Plasma Exchange for Urgent Rivaroxaban Reversal.
Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke.
Transitions of care in anticoagulated patients.
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Use of rivaroxaban in patients with stroke.
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
Vitamin K antagonists. Ready to be replaced?
What did we learn from new oral anticoagulant treatment?
[Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure].
[Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism].
[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].
[Dabigatran, a New Oral Anticoagulant.]
[Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
[Effect of low-dosage intravenous nitrate therapy on the anticoagulant effect of heparin]
[Evidence of novel oral anticoagulants (NOAC)].
[Factor Xa inhibitor (rivaroxaban and drugs under investigation)].
[New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring].
[New oral anticoagulants for the prevention of stroke : Open questions in geriatric patients].
[New oral anticoagulants: recommendations, precautions and perspectives for use].
[Novel oral anticoagulants (NOAC)].
[Occurrence of acquired factor V inhibitor during antibiotic therapy for a surgical wound infection].
[Perioperative management and therapy of bleeding complications].
[Pharmacology of the new oral anticoagulants].
[Preventing cerebrovascular accidents during atrial fibrillation]
[Prevention of stroke in nonvalvular atrial fibrillation. Oral direct factor Xa inhibitor apixaban: positive experiences in general medical practice].
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
[Rivaroxaban use in prevention of stroke in patients with non-valvular atrial fibrillation in clinical practice, results of observational studies and our experience].
[Rivaroxaban-resistant right ventricular thrombus, successfully treated with vitamin K antagonist in a patient with dilated cardiomyopathy].
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Atypical Hemolytic Uremic Syndrome
A case of atypical hemolytic uremic syndrome due to anti-factor H antibody in a patient presenting with a factor XII deficiency identified two novel mutations.
Autoimmune Diseases
Characterization and acute phase modulation of canine apolipoprotein H (beta 2-glycoprotein I).
Cutaneous histopathologic findings in 'antiphospholipid syndrome'. Correlation with disease, including human immunodeficiency virus disease.
Immunological analogy between allograft rejection, recurrent abortion and pre-eclampsia - the same basic mechanism?
[GFHT proposals for management of discordance between the International normalized ratio measured in the laboratory and by self-testing].
Avitaminosis
[Blood coagulation in C avitaminosis. Part II. The change in the prothrombin and thrombotropin concentration and causes of decreased thromboplastin activity of the blood in C avitaminosis in guinea pigs.]
Azotemia
A recalcitrant, erythematous, desquamating disorder associated with toxin-producing staphylococci in patients with AIDS.
Acquired hemophilia complicated by cardiorenal syndrome type 3.
Acute intrinsic renal failure and blood coagulation disorders after a snakebite in a dog.
Acute renal failure as a complication of acquired hemophilia due to autoantibody to factor VIII.
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
The successful treatment of multiple organ dysfunction syndrome and severe hypernatremia, secondary to joint supplement toxicity in a dog.
[Heatstroke in dogs in southern Germany. A retrospective study over a 5.5-year period].
[Indications for liver transplantation in severe amanita phalloides mushroom poisoning]
Bacteremia
Prolonged partial thromboplastin times in children with fever and petechiae without bacteremia or sepsis.
Bacterial Infections
Acute respiratory failure in adult patients with dengue virus infection.
Assessment of aPTT-based clot waveform analysis for the detection of haemostatic changes in different types of infections.
Chest radiographic presentation in patients with dengue hemorrhagic Fever.
Cytochemical determination of intracellular polymorphonuclear leukocyte elastase content in patients with severe bacterial infection and septicaemia correlated with coagulation parameters.
Endogenous heparin-like activity detected by anti-Xa assay in infected cirrhotic and non-cirrhotic patients.
Perioperative management and postoperative outcome of patients undergoing cytoreduction surgery with hyperthermic intraperitoneal chemotherapy.
Procalcitonin and Other Common Biomarkers Do Not Reliably Identify Patients at Risk for Bacterial Infection After Congenital Heart Surgery.
Procalcitonin, C-reactive protein, neutrophil gelatinase-associated lipocalin, resistin and the APTT waveform for the early diagnosis of serious bacterial infection and prediction of outcome in critically ill children.
Bernard-Soulier Syndrome
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Platelet prothrombin converting activity in hereditary disorders of platelet function.
The spectrum of bleeding disorders in women with menorrhagia: a report from Western India.
beta-Thalassemia
Demonstration of kallikrein-like protease activity in nonactivated plasma of patients with Cooley's anemia.
Intracranial hemorrhage and circulating coagulation inhibitor in beta-thalassemia major.
Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes.
Thalassemia major - on the verge of bleeding or thrombosis?
Bile Duct Neoplasms
Management of postoperative hemorrhage associated with factor VIII inhibitor: report of a case.
Blood Coagulation Disorders
An evaluation of the partial thromboplastin time in the detection of blood coagulation disorders.
Analysis of the activated partial thromboplastin time test using mathematical modeling.
Should We Postpone Elective Cardiovascular Procedures and Percutaneous Coronary Interventions During the COVID-19 Pandemic?
[Blood coagulation disorder in a 7-year-old child with a partial factor X or Stuart-Prower factor deficiency]
[Congenital blood coagulation disorder caused by abnormal factor X]
[Suggestions and propositions to resolve some issues for standardization of prothrombin time and activated partial thromboplastin time]
Blood Coagulation Disorders, Inherited
A rare cause of intracranial hemorrhage: factor X deficiency.
A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency.
A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking.
Factor X and its deficiency states.
Factor X deficiency in North Pakistan.
Factor X deficiency--a rare disorder.
Factor X deficiency.
Factor XI deficiency and obstetrical anesthesia.
Membranoproliferative glomerulonephritis and a rare bleeding disorder: factor X deficiency.
Routine preoperative coagulation screening detects a rare bleeding disorder.
Severe Factor X Deficiency Presenting as Febrile Seizure in an Infant.
The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency.
[Factor X deficiency and pregnancy]
Blood Platelet Disorders
Functional and morphological studies on blood platelets in a thrombasthenic horse.
Bluetongue
Experimentally induced bluetongue virus infection in white-tailed deer: coagulation, clinical pathologic, and gross pathologic changes.
Bone Diseases, Metabolic
Effect of antithrombotic drugs on bone health.
Borna Disease
Autogenous translational regulation of the Borna disease virus negative control factor X from polycistronic mRNA using host RNA helicases.
Polymerase read-through at the first transcription termination site contributes to regulation of borna disease virus gene expression.
Bradycardia
Acute Q fever in southern Taiwan: atypical manifestations of hyperbilirubinemia and prolonged fever.
Brain Contusion
Emergent surgical evacuation of traumatic intracranial hematoma in patients with preoperative thrombocytopenia: surgical risk and early outcome.
Brain Diseases
Poor prediction of blood transfusion requirements in adult liver transplantations from preoperative variables.
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Pretransplant status and patient survival following liver transplantation.
[Predictive value of changes in the hemostasis system in patients with ischemic brain diseases]
Brain Edema
Edema from intracerebral hemorrhage: the role of thrombin.
Brain Injuries
Disseminated intravascular coagulation as a complication of ventricular catheter placement. Case report.
Disturbances of the coagulatory system in patients with severe cerebral trauma. I.
Impaired fibrinolysis and traumatic brain injury in mice.
Machine Learning Without Borders? An Adaptable Tool to Optimize Mortality Prediction in Diverse Clinical Settings.
Prognostic value of coagulation tests for in-hospital mortality in patients with traumatic brain injury.
[Secondary blood coagulation disturbances after severe head injuries (author's transl)]
Brain Injuries, Traumatic
Impaired fibrinolysis and traumatic brain injury in mice.
Predictors of 30-Day Mortality in Traumatic Brain-Injured Patients after Primary Decompressive Craniectomy.
Trauma Early Mortality Prediction Tool (TEMPT) for assessing 28-day mortality.
[Study on the difference of blood coagulation function in patients with traumatic brain injury in plain and plateau area].
Brain Ischemia
An increase of anticardiolipin antibody in association with stroke and chronic chemical exposure.
Coagulation factor Xa activates thrombin in ischemic neural tissue.
Human umbilical cord blood-derived CD34+ cells cause attenuation of multiorgan dysfunction during experimental heatstroke.
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation.
Use of rivaroxaban in patients with stroke.
Breast Neoplasms
Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients.
Coagulation factor VII is regulated by androgen receptor in breast cancer.
Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients.
Interaction of human tumor cells with human platelets and the coagulation system.
Mechanism of the high coagulation state of breast cancer tissue factor.
PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.
Project for the National Program of Early Diagnosis of Endometrial Cancer Part I.
Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa.
Systemic Delivery of a Novel Liver-Detargeted Oncolytic Adenovirus Causes Reduced Liver Toxicity but Maintains the Antitumor Response in a Breast Cancer Bone Metastasis Model.
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Bronchiectasis
São paulo lung transplantation waiting list: patient characteristics and predictors of death.
Brown-Sequard Syndrome
Rivaroxaban-induced acute cervical spine epidural hematoma: Report of a case and review.
Budd-Chiari Syndrome
Primary sclerosing cholangitis in the presence of a lupus anticoagulant.
Spectrum of hemostatic derangements, in Budd-Chiari syndrome.
CADASIL
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy with severe factor XII deficiency.
Calciphylaxis
Direct oral anticoagulant medications in calciphylaxis.
Carcinogenesis
Ovarian cancer, the coagulation pathway, and inflammation.
Somatic and germline mutations in the pathogenesis of pituitary adenomas.
[Expression of RAD51 and MAX in pancreatic cancer rats.]
Carcinoma
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
Acquired factor X deficiency and disseminated intravascular coagulation in a case of metastasizing carcinoma of the stomach and its course under chemotherapy.
Acquired Hemophilia in an Elderly Patient with Carcinoma of the Ampulla of Vater.
Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity.
Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa.
Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va.
Cellular localization of activated factor X by Xa-specific probes.
Coagulation/fibrinolysis balance and lung cancer.
Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma.
Evidence for a warfarin-sensitive serum factor that participates in factor X activation by Lewis lung tumor cells.
Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients.
Factor VIIa/tissue factor-catalyzed activation of factors IX and X on a cell surface and in suspension: a kinetic study.
gamma-Glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant.
Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine.
Identification of a thrombin receptor with factor Xa receptor and tissue factor in human pancreatic carcinoma cells.
Inhibition of recombinant human blood coagulation factor VIIa amidolytic and proteolytic activity by zinc ions.
Loss of metastatic and primary tumor factor X activator capabilities by Lewis lung carcinoma cells cultured in vitamin K-dependent protein deficient serum.
Mechanism of the high coagulation state of breast cancer tissue factor.
Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues.
Preoperative D-dimers as an independent prognostic marker in cervical carcinoma.
Prognostic significance of blood coagulation tests in carcinoma of the lung and colon.
Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions.
Serum proteomics analysis of feline mammary carcinoma based on label-free and PRM techniques.
Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics.
The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma.
The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor.
The influence of thymus factor X (TFX) and of anti-TFX globulin on the growth of Lewis lung carcinoma in mice.
The inhibition of human factor VIIa-tissue factor by antithrombin III-heparin is enhanced by factor X on a human bladder carcinoma cell line.
Tumor volume estimation by the percentage carcinoma method in uterine cervix carcinoma.
[Clinical and Imaging Features of Acute Cerebral Infarction ?in Non-small Cell Lung Cancer Patients with Trousseau Syndrome].
[Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma]
[Establishment and characterization of a human squamous cell carcinoma cell line LK-52 which produce direct activator of coagulant factor X]
[Prolonged activated partial thromboplastin time (aPTT): not always indicative of increased risk of bleeding]
Carcinoma, Ductal
Mechanism of the high coagulation state of breast cancer tissue factor.
Carcinoma, Hepatocellular
Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va.
Characterisation of a prothrombinase activator on the hepatoma derived cell-line, PLC/PRF/5.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Human hepatoma cells secrete single chain factor X, prothrombin, and antithrombin III.
Improved survival of patients presenting with acute variceal bleeding. Prognostic indicators of short- and long-term mortality.
Interaction of thrombin and factor Xa with bovine vascular endothelial cells, smooth muscle cells and rat hepatoma cells.
Liver-enriched transcription factor HNF-4 and ubiquitous factor NF-Y are critical for expression of blood coagulation factor X.
Quantitative study on thromboplastin in various strains of Yoshida ascites hepatoma cells of rat.
Rat factor X is synthesized as a single chain precursor inducible by prothrombin fragments.
Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor.
Steady state levels of factor X mRNA in liver and Hep G2 cells.
The influence of insulin, beta-estradiol, dexamethasone and thyroid hormone on the secretion of coagulant and anticoagulant proteins by HepG2 cells.
Tissue factor pathway inhibitor and protease nexin-1 are major factor Xa binding proteins on the HepG2 cell surface.
Carcinoma, Large Cell
[Clinical and Imaging Features of Acute Cerebral Infarction ?in Non-small Cell Lung Cancer Patients with Trousseau Syndrome].
Carcinoma, Lewis Lung
Loss of metastatic and primary tumor factor X activator capabilities by Lewis lung carcinoma cells cultured in vitamin K-dependent protein deficient serum.
The influence of thymus factor X (TFX) and of anti-TFX globulin on the growth of Lewis lung carcinoma in mice.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of blood coagulation tests in carcinoma of the lung and colon.
Carcinoma, Ovarian Epithelial
Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.
Carcinoma, Renal Cell
Cellular localization of activated factor X by Xa-specific probes.
[Contribution to the aetiology of "reversible hepatic dysfunction" (Stauffer's syndrome) associated with renal tumours]
Carcinoma, Small Cell
Cellular localization of activated factor X by Xa-specific probes.
Prognostic significance of blood coagulation tests in carcinoma of the lung and colon.
Carcinoma, Squamous Cell
Preoperative D-dimers as an independent prognostic marker in cervical carcinoma.
[Clinical and Imaging Features of Acute Cerebral Infarction ?in Non-small Cell Lung Cancer Patients with Trousseau Syndrome].
[Establishment and characterization of a human squamous cell carcinoma cell line LK-52 which produce direct activator of coagulant factor X]
Carcinoma, Transitional Cell
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
Cardiac Tamponade
Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation.
Inherited Moderate Factor X Deficiency Presenting as Cardiac Tamponade.
Cardiomegaly
Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload.
Cardiomyopathies
Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.
Cardiomyopathy, Hypertrophic
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
Cardiovascular Diseases
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy.
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex.
Leech thrombin inhibitors.
Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors.
Novel inhibitors of factor X for use in cardiovascular diseases.
Preventive Effects of Aspirin on Cardiovascular Complications in Prostate Cancer Cases after Endocrinotherapy.
Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.
The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.
Thromboembolic risk factors in patients undergoing kidney transplant: implication of abnormally short activated partial thromboplastin time.
Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences.
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Carotid Artery Diseases
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.
Carotid Artery Injuries
A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Carotid Artery Thrombosis
Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis.
Antiplatelet and antithrombotic activities of Korean Red Ginseng.
Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure.
Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.
Carotid Stenosis
Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness.
Effects of asymptomatic abdominal aortic aneurysm on the soluble coagulation system, platelet count and platelet activation.
Cataract
Circulating anticoagulant in CREST syndrome.
Preoperative prediction of hyphemas.
Catheter-Related Infections
Internal jugular versus subclavian vein catheterization for central venous catheterization in orthotopic liver transplantation.
Cellulitis
Apparent cellulitis with a prolonged APTT. Activated partial thromboplastin time.
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.
Cerebral Hemorrhage
Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage.
Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
Evidence for Andexanet Alpha in Reversing Intracerebral Hemorrhage due to Factor Xa Inhibitors?
Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation.
Intracerebral hemorrhage in stroke patients anticoagulated with heparin.
Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Interspecies Scaling of Recombinant Human Coagulation Factor Xa(I16L).
Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding.
Sensitivity and specificity of fluid-blood levels for coagulopathy in acute intracerebral hematomas.
Unusual Initial Manifestation of Acquired Hemophilia A: A Normal Activated Partial Thromboplastin Time, Intramuscular Hematoma and Cerebral Hemorrhage.
Vitamin K deficiency in newborns: a case report in alpha-1-antitrypsin deficiency and a review of factors predisposing to hemorrhage.
[Factor Xa Inhibitor for the Treatment of Cerebral Venous Thrombosis with Intracerebral Hemorrhage during Anticoagulation Therapy:A Case Report].
Cerebral Infarction
Antiphospholipid antibodies and stroke in the young--a study of three cases.
Coagulation Assay and Stroke Severity upon Admission of Patients with Cardioembolic Cerebral Infarction during Direct Oral Anticoagulant Use.
Correlations of acute myocardial infarction complicated by cerebral infarction with insulin resistance, adiponectin and HMGB1.
Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis.
Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
Factor V inhibitor associated with Sjögren's syndrome.
Hematologic abnormalities occur in both cortical and lacunar infarction.
[Clinical and Imaging Features of Acute Cerebral Infarction ?in Non-small Cell Lung Cancer Patients with Trousseau Syndrome].
Cerebral Palsy
Clotting parameters and thromboelastography in children with neuromuscular and idiopathic scoliosis undergoing posterior spinal fusion.
Cerebrospinal Fluid Leak
[Effect of long-term and short-term mild hypothermia in severe traumatic brain injury: a comparative study].
Cerebrovascular Disorders
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes.
Cholangiocarcinoma
Activated partial thromboplastin time abnormality in patients with cholangiocarcinoma.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Cholangitis, Sclerosing
Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography.
Choledocholithiasis
Safety of immediate endoscopic sphincterotomy in acute suppurative cholangitis caused by choledocholithiasis.
Cholestasis
Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder.
Pulsus alternans in a critically ill dog hospitalized for xylitol toxicity.
Quantitative aspects of the parenchyma-stroma relationship in experimentally induced cholestasis.
Reversibility of cholestatic changes following experimental common bile duct obstruction: fact or fantasy?
Ciliopathies
Fine tuning of RFX/DAF-19-regulated target gene expression through binding to multiple sites in Caenorhabditis elegans.
RFX7 is required for the formation of cilia in the neural tube.
coagulation factor ixa deficiency
A Candidate Activation Pathway for Coagulation Factor VII.
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
coagulation factor viia deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A NlaIII polymorphism within the human factor VII gene.
A novel factor X mutation Cys81 by Arg and a reported factor VII polymorphism Arg353 replaced by Gln co-occured in a patient.
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Another patient with a congenital hemorrhagic disorder intermediate between factor X and factor VII deficiency.
Asymptomatic factor VII deficiency: gene analysis and structure-function relationships.
Clinical audit of inherited bleeding disorders in a developing country.
Combined factor VII/protein C deficiency results in intrauterine coagulopathy in mice.
Combined mild PTC (plasma thromboplastin component) and factor VII deficiencies.
Congenital combined defects of factor VII: a critical review.
Determinants of coagulation activation in humans.
Determinants of plasma factor VIIa levels in humans.
Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds.
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Factor VII deficiency detected in pregnancy: a case report.
Factor VII deficiency with intracranial hemorrhage: a case report.
Factor VII Deficiency: A Rare Case Report.
Fatal intracranial hemorrhage in a newborn with factor VII deficiency.
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
Hereditary factor VII deficiency in two siblings: two different clinical presentation.
Homozygous FVII deficiencies with different reactivity towards tissue thromboplastins of different origin.
Inherited bleeding disorders in Indian women with menorrhagia.
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Models of blood coagulation.
Multiple intracranial hemorrhages at the time of a transiently prolonged activated partial thromboplastin time in an infant with congenital factor VII deficiency.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Paracetamol poisoning unmasking factor VII deficiency.
Rare inherited coagulation disorders in India.
Sensitivity of different thromboplastin reagents to factor VII deficiency in the blood of beagle dogs.
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
[Congenital factor VII deficiency: about two family cases].
[Significant decrease in factor VII activity by tissue thromboplastin derived from rabbit brain in a patient with congenital factor VII deficiency (FVII Padua)].
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
coagulation factor xa deficiency
"I have been refused to be treated by three dentists": Barriers to patient care.
A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X.
A case of factor X deficiency in a Chihuahua dog.
A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma.
A Compound Heterozygosis of Two Novel Mutations Causes Factor X Deficiency in a Chinese Pedigree.
A family with factor X deficiency from Argentina: a compound heterozygosis because of the combination of a new mutation (Gln138Arg) with an already known one (Glu350Lys).
A family with hereditary factor X deficiency with a point mutation Gla32 to Gln in the Gla domain (factor X Tokyo).
A functional factor X deficiency.
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A new family with classical factor X deficiency as demonstrated by electroimmunoassay.
A NlaIII polymorphism within the human factor VII gene.
A novel factor X gene mutation Val (GTC) 384Ala (GCC) in a Chinese family resulting in congenital factor X deficiency.
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
A possible new thromboplastin deficiency occurring in five siblings.
A Rare Cause of Coagulopathy in a Patient with Rapidly Progressive Renal Failure.
A rare cause of intracranial hemorrhage: factor X deficiency.
A Rare Cause of Isolated Prothrombin Time Prolongation: Congenital Factor X Deficiency.
A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency.
A rare presentation of homozygous factor X deficiency in a pregnant patient: A case report and review of the literature.
A tongue resection in macroglossia due to primary amyloidosis.
A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X.
Abscess in bilateral ovarian haematomas in a girl with factor X deficiency, necessitating oopherectomy.
Acquired and transient factor X deficiency associated with sodium valproate treatment.
Acquired circulating anticoagulants in systemic collagen disease; auto-immune thromboplastin deficiency.
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone.
Acquired factor X deficiency and amyloidosis.
Acquired factor X deficiency and disseminated intravascular coagulation in a case of metastasizing carcinoma of the stomach and its course under chemotherapy.
Acquired factor X deficiency associated with atypical AL-amyloidosis.
Acquired factor X deficiency associated with systematized amyloidosis--a report of a case.
Acquired factor X deficiency developed four years after autologous transplantation in a patient with multiple myeloma associated with systemic AL amyloidosis.
Acquired factor X deficiency in a Negro boy.
Acquired factor X deficiency in a patient with amyloidosis.
Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
Acquired factor x deficiency in light chain amyloidosis: a report of 2 korean cases.
Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis.
Acquired factor X deficiency in systemic amyloidosis.
Acquired factor X deficiency in systemic amyloidosis: management of two cases.
Acquired factor X deficiency with associated defects in platelet aggregation. A response to corticosteroid therapy.
Acquired factor X deficiency. Altered plasma antithrombin activity and association with amyloidosis.
Acquired factor X deficiency: an experience with multiple tooth extraction.
Acquired isolated factor X deficiency associated with systemic amyloidosis. Case report and review of literature.
Acquired selective factor X deficiency in acute nonlymphocytic leukemia.
Acquired, non-amyloid related factor X deficiency: review of the literature.
Acquired, transient factor X (Stuart factor) deficiency in patient with mycoplasma pneumonial infection.
Acquired-transient factor X deficiency associated with anticardiolipin antibodies in a child with extensive burns.
Acquired-transient factor X deficiency in a teenager with extensive burns.
Advances in treatment of bleeding disorders.
Amyloidosis and factor X deficiency.
Amyloidosis with factor X deficiency.
An analysis of 8 cases of factor X deficiency.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Angiodysplasia of upper gastrointestinal tract with coagulopathy.
Antenatally diagnosed subdural haemorrhage in congenital factor X deficiency.
Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody.
Atraumatic splenic rupture in amyloidosis.
Autoimmune Coagulation Factor X Deficiency as a Rare Acquired Hemorrhagic Disorder: A Literature Review.
Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Report of a new association and its possible relationship to endothelial cell injury.
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
Bilateral periorbital ecchymoses. An often missed sign of amyloid purpura.
Bleeding manifestations in 100 patients with amyloidosis.
Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice.
Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.
Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency.
Candida vertebra osteomyelitis in a girl with factor X deficiency.
Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
Characterization of amyloid deposits and P component from a patient with factor X deficiency reveals proteins derived from a lambda VI light chain.
Chronic peritoneal dialysis in a patient with primary amyloidosis, renal failure, and factor X deficiency.
Circumcision in Patients with Congenital Factor X Deficiency.
Classical factor X deficiency. Report of a further case.
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
Clinical audit of inherited bleeding disorders in a developing country.
Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy.
Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.
Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.
Complete remission in a bleeding patient with idiopathic autoimmune factor X deficiency caused by non-neutralizing anti-factor X autoantibody.
Complex history of the discovery and characterization of congenital factor X deficiency.
Congenital bleeding disorders of the vitamin K-dependent clotting factors.
Congenital coagulation factor X deficiency: Genetic analysis of five patients and functional characterization of mutant factor X proteins.
Congenital coagulopathies and pregnancy: report of four pregnancies in a factor X-deficient woman.
Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation.
Congenital factor X deficiency and incomplete transverse paralysis.
Congenital factor X deficiency in Japan.
Congenital Factor X deficiency in women: A systematic review of the literature.
Congenital factor X deficiency of coagulation revealed by epistaxis.
Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients.
Congenital haemorrhagic condition similar but not identical to factor X deficiency. A haemorrhagic state due to an abnormal factor X?
Corpus luteum hemorrhage: rare complication of congenital and acquired coagulation abnormalities.
Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
Danazol therapy in factor X deficiency.
Danazol therapy in factor X deficiency: more questions than answers.
Dental management of a patient with factor X deficiency.
Diagnosis and treatment of inherited factor X deficiency.
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency.
Diagnostic Error of a Patient with Combined Inherited Factor VII and Factor X Deficiency due to Accidental Ingestion of a Diphacinone Rodenticide.
Different genotypes are responsible for the normal Russell viper venom assays seen in some cases of congenital factor X deficiency.
Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran.
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency.
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency.
Ethnic Differences in Coagulation Factor Abnormalities After the Fontan Procedure.
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis.
Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery.
Factor VII and factor X deficiency in a child with a chromosome 13q duplication and deletion.
Factor X and its deficiency states.
Factor X assays using chromogenic substrate S-2222.
Factor X deficiency and hemophilia A : occurrence of two different coagulation defects in a family.
Factor X deficiency and intracranial bleeding: who is at risk?
Factor X deficiency and pregnancy: case report and counselling.
Factor X deficiency and pregnancy: preconception counselling and therapeutic options.
Factor X deficiency and systemic amyloidosis.
Factor X deficiency associated with compound heterozygosity involving a novel missense mutation at codon 38 from Val (GTC) to Leu (CTC) in exon 2.
Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib: A Case Report and Review of the Literature.
Factor X deficiency due to a compound heterozygosis between a new mutation (Gla72Asp) in exon 2 and an already known one (Gly154Arg) in exon 5: Factor X Mar del Plata 1).
Factor X deficiency during treatment of relapsed acute myeloid leukaemia with amsacrine.
Factor X deficiency in a cat.
Factor X deficiency in a Jack Russell terrier.
Factor X deficiency in North Pakistan.
Factor X deficiency in primary amyloidosis.
Factor X deficiency in primary amyloidosis: resolution after splenectomy.
Factor X deficiency in systemic amyloidosis.
Factor X deficiency in the neonatal period.
Factor X Deficiency Management for Elective Cesarean Delivery in a Pregnant Patient.
Factor X deficiency presenting as a pseudotumor. Case report.
Factor X deficiency presenting with bilateral chronic subdural hematoma.
Factor X Deficiency with Heterozygous Mutations of Novel p.G435S and Known p.G244R in a Patient Presenting with Severe Umbilical Hemorrhage.
Factor X deficiency--a rare disorder.
Factor X deficiency.
Factor X Deficiency: A Rare Cause of Puberty Menorrhagia.
Factor X deficiency: An uncommon presentation of AL amyloidosis.
Factor X deficiency: an unusual cause for spontaneous intracranial bleeding.
Factor x deficiency: an unusual cause of spontaneous intracranial bleeding.
Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene.
Factor X Frankfurt I: molecular and functional characterization of a hereditary factor X deficiency (Gla+25 to Lys).
Factor X inhibitor: a fulminant presentation and fatal course of a rare syndrome in a 59-year-old male.
Factor X level in coumarin treated patients and in factor X deficiency as assayed with different techniques.
Factor X Nagoya 1 and Nagoya 2: a CRM- factor X deficiency and a dysfunctional CRM+ factor X deficiency characterized by substitution of Arg306 by Cys and of Gly366 by Ser, respectively.
Factor XDebrecen: Gly204Arg mutation in factor X causes the synthesis of a non-secretable protein and severe factor X deficiency.
Factors X Nice I and II: two novel missense mutations (Met-40Val and Pro304Ser) in patient with coagulation factor X deficiency.
Femur fracture in a woman with severe factor X deficiency - an experience using factor X concentrate in surgery.
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
Frequencies of mild factor V, VII and X deficiencies in a Japanese population.
Frequency of inherited bleeding disorders in women with menorrhagia.
Frequency of the p.Gly262Asp mutation in congenital Factor X deficiency.
Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection.
Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency.
Genetic analysis of a compound heterozygous patient with congenital factor X deficiency and regular replacement therapy with a prothrombin complex concentrate.
Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry: in vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X.
Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency.
Genotyping of five Pakistani patients with severe inherited factor X deficiency: identification of two novel mutations.
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
Hemorrhage because of amyloid-related factor x deficiency after insertion of tenckhoff catheter.
Hemorrhagic diathesis caused by factor X deficiency in a child with thymic cyst.
Hemostatic abnormalities in multiple myeloma and related disorders.
Hereditary coagulation factor X deficiency--a clinico-haematological profile of 5 cases from Varanasi.
Hereditary coagulation factor X deficiency.
Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses.
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
Human coagulation factor X deficiency caused by a mutant signal peptide that blocks cleavage by signal peptidase but not targeting and translocation to the endoplasmic reticulum.
Identification of a novel factor X deletion in combination with a missense mutation in the gene - Genotype-phenotype correlation in a girl with severe factor X deficiency.
Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.
Impact of Rare Bleeding Disorders during Pregnancy on Maternal and Fetal Outcomes: Review of 29 Pregnancies at a Single Center.
Importance of pharmacokinetic studies in the management of acquired factor X deficiency.
Influence of glass and anticoagulant concentration on improvement of factor X deficiency tests.
Inherited bleeding disorders in Indian women with menorrhagia.
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Inherited factor X deficiency in two brothers.
Inherited factor X deficiency: molecular genetics and pathophysiology.
Inherited factor X deficiency: presentation of a case with etiologic and treatment considerations.
Inherited Moderate Factor X Deficiency Presenting as Cardiac Tamponade.
Intracerebral haemorrhage in an adult due to transient factor X deficiency.
Intracranial haemorrhage in patients with congenital haemostatic defects.
Intracranial Hemorrhage as the First Manifestation of Severe Congenital Factor X Deficiency in a 20-Month-Old Male: Case Report and Review of the Literature.
Isolated factor X deficiency in amyloidosis. Case report and review of the literature.
Kinetic analysis of the clotting system in the presence of heparin and depolymerized heparin.
Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis.
Life-threatening bleeding tendency provoked by an acquired isolated factor X deficiency associated with respiratory infection.
Liver transplantation for haemophiliacs with hepatitis C cirrhosis.
Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications.
Management of Factor X Deficiency for Vaginal Delivery in a Parturient: A Case Report.
Massive Upper and Lower GI Bleed from Simultaneous Primary (AL) Amyloidosis of the Stomach and Transverse Colon in a Patient with Multiple Myeloma.
Mechanism of factor X deficiency in systemic amyloidosis.
Membranoproliferative glomerulonephritis and a rare bleeding disorder: factor X deficiency.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Mode of inheritance of factor X deficiency.
Modulation of severity of clinical bleeding by co-inherited thrombophilia is also true for severe factor X deficiency.
Molecular analysis of patients with severe congenital factor X deficiency: First report from north and northwest of Iran.
Molecular analysis of the genotype-phenotype relationship in factor X deficiency.
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glu102Lys) in the second EGF-like domain.
Molecular basis of factor X deficiency cases from India.
Molecular characterization of factor X deficiency associated with borderline plasma factor X level.
Molecular characterization of human factor XSan Antonio.
Molecular characterization of two novel mutations causing factor X deficiency in a Chinese pedigree.
Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg").
Molecular dynamics characterization of five pathogenic Factor X mutants associated with decreased catalytic activity.
Molecular genetic analysis of factor X deficiency: gene deletion and germline mosaicism.
Near fatal spontaneous intraperitoneal bleeding: A rare manifestation in a congenital factor X deficiency carrier.
Neonatal congenital Factor X deficiency.
Neonatal congenital factor X deficiency.
Neonatal onset of congenital factor X deficiency: a description of two novel mutations with 6-year follow-up.
NORETHYNODREL IN THE TREATMENT OF FACTOR X DEFICIENCY.
Normalization of plasma factor X levels in amyloidosis after plasma exchange.
Novel factor X deficiency. Normal partial thromboplastin time and associated spindle cell thymoma.
Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency.
One missense mutation in the factor X gene causing factor X deficiency--factor X Kanazawa.
Partial gene deletion in a family with factor X deficiency.
Pharmacokinetics and prophylactic use of FEIBA(®) in a child with severe congenital factor X deficiency and recurrent spontaneous intracranial haemorrhage: a case report.
Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency.
Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency.
PheWAS uncovers a pathological role of coagulation Factor X during Acinetobacter baumannii infection.
Plasma exchange in a case of severe factor X deficiency in pregnancy: critical review of the literature.
Plasma-derived factor X concentrate compassionate use for hereditary factor X deficiency: Long-term safety and efficacy in a retrospective data-collection study.
Platelet aggregation and adhesiveness in classical factor X deficiency and in the abnormal factor X (factor X Friuli) coagulation disorder.
Poor recovery and short survival of infused factor X in a case of acquired factor X deficiency and amyloidosis.
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Posttraumatic lipoma in a patient with congenital factor X deficiency.
Pregnancy in a patient with severe factor X deficiency.
Prenatal diagnosis of factor X deficiency using a combination of direct mutation detection and linkage analysis with an intragenic single nucleotide polymorphism.
Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency.
Prevalence of bleeding manifestations in 128 heterozygotes for Factor X deficiency, mainly for FX Friuli, matched vs 128 unaffected family members, during a long sequential observation period (23.5 years).
Prevention of recurrent intracranial hemorrhage in a factor X-deficient infant.
Primary amyloidosis with severe nephrotic syndrome and acquired factor X deficiency.
Progressive systemic sclerosis with the nephrotic syndrome and acquired factor X deficiency.
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Prophylactic treatment of bleeding episodes in children <12 years with moderate to severe hereditary factor X deficiency (FXD): Efficacy and safety of a high-purity plasma-derived factor X (pdFX) concentrate.
Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrate.
Prophylaxis in rare coagulation disorders -- factor X deficiency.
Prophylaxis with prothrombin complex concentrate in four children with severe congenital factor X deficiency.
Prothrombin in factor X deficiency.
Rare case of combined factor V and factor X deficiency in pregnancy: presenting as secondary postpartum haemorrhage in first pregnancy and successful outcome in second pregnancy.
Rare inherited coagulation disorders in India.
Rare post-operative complications in a previously undiagnosed Congenital Factor X deficiency patient.
Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency.
Recurrent ovarian haemorrhage in a girl with congenital factor X deficiency.
Recurrent, isolated factor X deficiency in myeloma: repeated normalization of factor X levels after cytostatic chemotherapy followed by late treatment failure associated with the development of systemic amyloidosis.
Replacement therapy for congenital Factor X deficiency.
Report on a disease-adapted treatment in a patient with severe factor X deficiency resulting from a homozygous factor X gene mutation.
Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy.
Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.
Resolution of factor X deficiency in primary amyloidosis following splenectomy.
Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.
Retroperitoneal amyloidosis, factor IX and X deficiency,and gastrointestinal bleeding.
Routine preoperative coagulation screening detects a rare bleeding disorder.
Secondary severe factor X deficiency associated with antiphospholipid syndrome.
Severe congenital factor X deficiency in 5-month-old child.
Severe congenital factor X deficiency with intracranial bleeding in two siblings.
Severe congenital factor X deficiency with intracranial haemorrhage.
Severe factor X deficiency and successful pregnancy.
Severe factor X deficiency due to a homozygous mutation (Cys364Arg) that disrupts a disulphide bond in the catalytic domain.
Severe factor X deficiency in a pair of siblings: clinical presentation, phenotypic and genotypic features, prenatal diagnosis and treatment.
Severe factor X deficiency in a twin pregnancy.
Severe factor X deficiency in pregnancy: case report and review of the literature.
Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.
Severe Factor X Deficiency Presenting as Febrile Seizure in an Infant.
Severe factor X deficiency treated with heparin-added prothrombin complex concentrate.
Six novel missense mutations causing factor X deficiency and application of thrombin generation test.
Six novel mutations including triple heterozygosity for Phe31Ser, 514delT and 516T-->G factor X gene mutations are responsible for congenital factor X deficiency in patients of Nepali and Indian origin.
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
Splenectomy in an uraemic patient with acquired factor X deficiency due to AL amyloidosis.
Splenectomy in plasma cell dyscrasias: a review of the clinical practice.
Spontaneous epidural hematoma following a shunt in an infant with congenital factor X deficiency. Case report and literature review.
Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis.
Spontaneous perinephric hematoma due to acquired factor X deficiency in AL amyloidosis.
Spontaneous resolution of acquired factor X deficiency in amyloidosis.
Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
Spontaneous rupture of the spleen in AL amyloidosis.
Spontaneous spinal epidural hematoma in a patient with acquired Factor X deficiency secondary to systemic amyloid light-chain amyloidosis.
Staged Surgical Palliation for HLHS in a Girl with Severe Factor X Deficiency.
Steroid hormone-responsive secondary factor X deficiency.
Subclinical factor X deficiency may increase hemorrhage in women undergoing cesarean section.
Subgaleal hemorrhage in a neonate with factor X deficiency following a non-traumatic cesarean section.
Successful liver transplantation for a child with life-threatening recurrent bleeding episodes due to congenital factor X deficiency: a case report.
Successful perioperative management of factor X deficiency associated with primary amyloidosis.
Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis.
Successful pregnancy in a woman with severe factor X deficiency.
Successful treatment of a noninhibitory antibody-mediated acquired factor X deficiency in a patient with marginal-zone lymphoma.
Successful treatment of an acquired haemorrhagic diathesis due to factor X deficiency with chemotherapy.
Successful Treatment of Life-threatening Bleeding Caused by Acquired Factor X Deficiency Associated with Respiratory Infection.
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy.
Successful Use of Four Factor-Prothrombin Complex Concentrate for Congenital Factor X Deficiency in the Setting of Neurosurgery.
Surgical excision of a pseudotumour under the coverage of the plasma-derived factor X concentrate in a patient with severe factor X deficiency: A case report.
Surgical treatment for a paraplegic patient induced by congenital factor X deficiency.
Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X.
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.
Systemic amyloidosis associated with factor X deficiency.
The 13-year bleed: Exuberant amyloid angiopathies, angiodysplasias, and acquired coagulopathies of the gut.
The Clinical Findings and Prophylactic Treatment in Children with Factor X Deficiency.
The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency.
The impact of Glu102Lys on the factor X function in a patient with a doubly homozygous factor X deficiency (Gla14Lys and Glu102Lys).
THE INHERITANCE OF STUART DISEASE: INVESTIGATION OF A FAMILY WITH FACTOR X DEFICIENCY.
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
The perils of inhibiting deficient factors.
The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency.
Therapeutic approaches to factor X deficiency with emphasis on the use of a new clotting-factor concentrate (Konyne).
Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy.
Transient acquired factor X deficiency associated with pneumonia.
Transient acquired factor X deficiency: report of the use of activated clotting concentrate to control a life-threatening hemorrhage.
Transient selective factor X deficiency in a severely burned child.
Transient, selective factor X deficiency and acute liver failure following chest infection treated with erythromycin BP.
Treatment of amyloidosis associated factor X deficiency.
Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency.
Two novel factor X gene mutations in a Chinese family with factor X deficiency.
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study.
Use of plasma-derived factor X concentrate in neonates and infants with congenital factor X deficiency.
Use of prothrombin complex concentrate for prophylaxis of bleeding in acquired factor X deficiency associated with light-chain amyloidosis.
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis.
["NON-CORRECTABLE" THROMBOPLASTIN DEFICIENCY AND HEMORRHAGIC MANIFESTATIONS IN THROMBOPENIC HEMOBLASTOSIS.]
[3 families with a congenital factor X deficiency, one of them with an associated factor XII deficiency]
[A case of double valve substitution in a female patient carrier of a factor X deficiency]
[A case of factor X deficiency (author's transl)]
[A case of primary hepatic amyloidosis with factor X deficiency.]
[A case of retroperitoneal hemorrhage due to multiple myeloma complicated with factor X deficiency and amyloidosis]
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
[A new family with factor X deficiency]
[A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review]
[Acquired coagulation factor X deficiency: three cases report and literature review].
[Acquired factor X deficiency associated with A.L.type amyloidosis. A case report]
[Acquired factor X deficiency in a case of monoclonal gammopathy]
[ACQUIRED FACTOR X DEFICIENCY IN A PATIENT WITH PRIMARY AMYLOIDOSIS. INJECTION OF A B.S.C. FRACTION.]
[Acquired factor X deficiency in a patient with primary amyloidosis. Injection of a coagulating fraction (C.S.B)]
[Acquired factor X deficiency in primary amyloidosis]
[ACQUIRED HEMORRHAGIC DIATHESIS CAUSED BY ISOLATED FACTOR X DEFICIENCY.]
[Acquired isolated factor X deficiency in generalized amyloidosis]
[Analysis of seven cases of multiple myeloma with initial manifestation of bleeding].
[Blood clotting in an infant with factor X deficiency]
[Case of congenital Stuart factor deficiency in a 22-month-old child]
[Case of hemorrhagic diathesis following prothrombase deficiency.]
[Case of severe hemorrhagic disease due to combined antihemophilic globulin deficiency and plasma thromboplastin deficiency.]
[Cerebromeningeal hemorrhages and their sequelae in congenital deficiencies of plasma hemostasis factors. Apropos of a case of Stuart factor deficiency with early cerebromengeal hemorrhage leading to hydrocephalus with considerable psychomotor retardation]
[Clinical and coagulation studies in 3 cases of congenital factor X deficiency and review of reported cases in Japan (author's transl)]
[Clotting factor X deficiency resulted from an T 58-->G mutation within exon 1 of human factor X gene]
[Combined 2d-type TAR syndrome, factor X deficiency, immune deficiency and mitral valve prolapse]
[Congenital and familial Stuart factor deficiency. Apropos of 2 personal cases considered congenital hypoconvertinemia.]
[Congenital blood coagulation factor X deficiency. Successful result of the use prothrombin concentrated complex in the control of ++cesarean section hemorrhage in 2 pregnancies]
[Congenital factor X deficiency showing cross-reacting material negative (CRM-)]
[Congenital factor X deficiency, the Prower-Stuart deficiency]
[Congenital factor X deficiency. Case report and review of literature]
[CONGENITAL STUART FACTOR DEFICIENCY. UNCOMPLICATED DELIVERY FOLLOWING INJECTION OF CSB FRACTION.]
[Congenital stuart factor deficiency: 4 cases]
[Decreased Quick percentage, acquired factor X deficiency, hemarthrosis and ecchymosis: amyloidosis]
[Differential diagnosis of congenital Stuart factor deficiency.]
[Extensive subcutaneous hemorrhage complicating primary amyloidosis]
[Factor X deficiency and pregnancy]
[Factor X deficiency and systemic amylosis]
[Factor X deficiency associated with multiple myeloma.]
[Factor X deficiency in amyloidosis (author's transl)]
[Factor X deficiency in systemic amyloidosis. Presentation of a case]
[Factors VII, VIII, IX, and X: molecular genetics and gene diagnosis]
[Familial amyloidosis of AL type and factor X deficiency. The valve of long-term colchicine administration]
[Familial hemorrhagic diathesis caused by factor X deficiency]
[Gene analysis of a combined inherited factor VII and factor X deficiency pedigree].
[Hemarthrosis disclosing factor X deficiency in primary amyloidosis]
[Hemorrhage of delivery and during the sequelae of labor caused by Stuart factor deficiency.]
[Hemorrhagic syndrome due to isolated Stuart factor deficiency during Kahler's disease with amylosis]
[Homozygous missense mutation p.Val298Met of F10 gene causing hereditary coagulation factor X deficiency in a Chinese pedigree].
[How can factor X deficiency in nephropathy explained?]
[Inherited coagulation factor X deficiency caused by two novel mutations in factor X gene.]
[Isolated factor X deficiency in chronic myelomonocytic leukemia: Report of one case].
[New form of pseudohemophilia following prothrombinase deficiency.]
[Primary amyloidosis associated to severe factor X deficiency]
[Primary pseudotumoral pulmonary amyloidosis with Pierre-Marie syndrome]
[Probably inherited factor X deficiency. Report of a case (author's transl)]
[Recurrence of Waldenström macroglobulinemia accompanied by factor X deficiency].
[Successful long-term management of ovarian bleeding and menorrhagia with prothrombin complex concentrate in a patient with congenital factor X deficiency].
[Systemic light chain amyloidosis with acquired factor X deficiency: a case report].
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
coagulation factor xia deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Definition of the population at risk of bleeding due to factor XI deficiency in Ashkenazic Jews and the value of activated partial thromboplastin time in its detection.
Factor XI deficiency in an Ashkenazi Jewish child, causing severe postoperative hemorrhage.
Factor XI deficiency in Kerry Blue Terriers.
Factor XI deficiency-related spontaneous primary intraventricular hemorrhage.
Factor XI deficiency: detection and management during urological surgery.
Factor XI deficiency: implications for management of patients undergoing aesthetic surgery.
Failure of Routine Coagulation Screening Tests to Detect Heterozygous State of Bovine Factor XI Deficiency.
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
Intraneural hematoma after nerve stimulation-guided femoral block in a patient with factor XI deficiency: case report.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Normal aPTT in children with mild factor XI deficiency.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Perioperative management of factor XI deficiency in a patient undergoing hip arthroplasty.
Preoperative screening for coagulopathy using prothrombin time and partial thromboplastin time in patients requiring primary cranial vault remodeling.
Successful Peritoneal Dialysis Catheter Placement in a New End-Stage Renal Disease Patient with Combined Antiphospholipid Syndrome and Factor XI Deficiency.
The activated partial thromboplastin time and factor XI deficiency.
The factor of factor XI deficiency in thyroid neoplasia.
The rare inherited coagulation disorders.
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
[Thrombocyte dysfunction in children with albinism]
coagulation factor xiia deficiency
A female hemophilia A combined with hereditary coagulation factor XII deficiency: a case report.
Additional factor XII (Hageman factor) deficiency in hemophilia A and in von Willebrand syndrome.
Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis.
Factor XII (Hageman Factor) Deficiency: a rare harbinger of life threatening complications.
Factor XII deficiency and pregnancy.
Feline factor XII (Hageman) deficiency.
Implications for cardiac surgery in patients with factor XII deficiency.
Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients.
Inherited bleeding disorders in Indian women with menorrhagia.
Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects.
Periodic painful purpura: Fact or factitious?
Prolonged activated partial thromboplastin time secondary to factor XII deficiency in two surgical patients.
Rosai-Dorfman disease with factor XII deficiency.
[3 families with a congenital factor X deficiency, one of them with an associated factor XII deficiency]
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
[Successes and failures of the activated partial thromboplastin time in the preoperative evaluation]
Coinfection
Clinical and Laboratory Characteristics of Dengue-Orientia tsutsugamushi co-Infection from a Tertiary Care Center in South India.
Colic
Clinical relevance of monocyte procoagulant activity in horses with colic.
Hemostatic abnormalities in equine colic.
The coagulation system in horses with colic.
Colitis
Free colonic perforation without dilatation in ulcerative colitis.
Rivaroxaban Induces Mucosal Healing in a Rat Model of Trinitrobenzene Sulfonic Acid-Induced Colitis.
Thromboelastography in healthy horses and horses with inflammatory gastrointestinal disorders and suspected coagulopathies.
Colitis, Ulcerative
Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice.
Efficacy of oral colon-specific delivery capsule of low-molecular-weight heparin on ulcerative colitis.
Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Collagen Diseases
Acquired circulating anticoagulants in systemic collagen disease; auto-immune thromboplastin deficiency.
Immunologic abnormalities associated with primary anetoderma.
Colonic Neoplasms
Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: implications for coagulation regulation on tumor cells.
Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation.
Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation.
Successful resection of sigmoid colon cancer in a patient with factor XI deficiency.
Colorectal Neoplasms
Factor X-activating activity in patients with colorectal carcinoma.
Prediction of Poor Outcomes in Patients with Colorectal Cancer: Elevated Preoperative Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT).
Project for the National Program of Early Diagnosis of Endometrial Cancer Part I.
Tumor cell generation of thrombin via functional prothrombinase assembly.
[Prolonged prophylaxis of thromboembolic disease in patients with colorectal surgical resections for malignancy]
Colorectal Neoplasms, Hereditary Nonpolyposis
Project for the National Program of Early Diagnosis of Endometrial Cancer Part I.
Coma
A new prognostic scoring system for meningococcal septic shock in children. Comparison with three other scoring systems.
A Newly Established Severity Scoring System in Predicting the Prognosis of Patients with Severe Fever with Thrombocytopenia Syndrome.
An explainable machine learning algorithm for risk factor analysis of in-hospital mortality in sepsis survivors with ICU readmission.
Association of Platelets and White Blood Cells Subtypes with Trauma Patients' Mortality Outcome in the Intensive Care Unit.
Clinical characteristics and risk factors of male exertional heatstroke in patients with myocardial injury: an over 10-year retrospective cohort study.
Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery.
Coronavirus disease 2019 (COVID-19) can predispose young to Intracerebral hemorrhage: a retrospective observational study.
Development and internal validation of the multivariable CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate of Risk) clinical risk prediction model.
Development and validation of the revised injury severity classification score for severely injured patients.
Early coagulopathy and metabolic acidosis predict transfusion of packed red blood cells in pediatric trauma patients.
Early coagulopathy is an independent predictor of mortality in children after severe trauma.
Early hemorrhagic progression of traumatic brain contusions: frequency, correlation with coagulation disorders, and patient outcome: a prospective study.
Expanding traumatic intracerebral contusion/hematoma.
FDP/fibrinogen ratio reflects the requirement of packed red blood cell transfusion in patients with blunt trauma.
Fibrinolytic markers and neurologic outcome in traumatic brain injury.
Gastrointestinal failure score in children with traumatic brain injury.
Glasgow Coma Scale predicts coagulopathy in pediatric trauma patients.
Hematological factors predicting mortality in patients with traumatic epidural or subdural hematoma undergoing emergency surgical evacuation: A retrospective cohort study.
Hypernatremia and Coagulopathy May or May Not Be Useful Clinical Biomarkers in Dogs with Head Trauma: A Retrospective Study.
In vivo diagnosis of massive hepatic infarction by computed tomography.
Intracranial Hemorrhages Related with Warfarin Use and Comparison of Warfarin and Acetylsalicylic Acid.
Massive blood transfusion and outcome in 1062 polytrauma patients: a prospective study based on the Trauma Registry of the German Trauma Society.
Model for predicting the injury severity score.
Multivariate regression modeling for the prediction of inflammation, systemic pressure, and end-organ function in severe sepsis.
PIRO concept: staging of sepsis.
Polytrauma Defined by the New Berlin Definition: A Validation Test Based on Propensity-Score Matching Approach.
Potential applicability of recombinant factor VIIa for intracerebral hemorrhage.
The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial.
The exploration of risk factors of concurrent bacteraemia in patients critically ill with severe dengue.
The influence of hemocoagulation disorders on the development of posttraumatic cerebral infarction and outcome in patients with moderate or severe head trauma.
The influence of hemocoagulative disorders on the outcome of children with head injury.
Validating the incidence of coagulopathy and disseminated intravascular coagulation in patients with traumatic brain injury ? analysis of 242 cases.
[A new warning scoring system establishment for prediction of sepsis in patients with trauma in intensive care unit].
[Effect of long-term and short-term mild hypothermia in severe traumatic brain injury: a comparative study].
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
Communicable Diseases
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
[Blood coagulation studies in children. VIII. Thromboplastin formation in various infectious diseases in childhood.]
Compartment Syndromes
Enoxaparin-induced bleeding resulting in compartment syndrome of the thigh: A case report.
The Compartment Syndrome Associated with Deep Vein Thrombosis due to Rattlesnake Bite: A Case Report.
complement factor d deficiency
Deletion of plasma thromboplastin factor D deficiency.
Confusion
Severe Fever with Thrombocytopenia Syndrome in South Korea, 2013-2015.
Congenital Abnormalities
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
Congenital Disorders of Glycosylation
Coagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome: case report and review of the literature.
Connective Tissue Diseases
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.
Superior mesenteric vein thrombosis presented transient false positivity for lupus anticoagulant under heparin treatment.
The clinical significance of a shortened activated partial thromboplastin time in patients with connective tissue disease.
Coronary Artery Disease
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
Association of Platelets and White Blood Cells Subtypes with Trauma Patients' Mortality Outcome in the Intensive Care Unit.
Coronary Artery Disease Presentation and Its Association with Shortened Activated Partial Thromboplastin Time.
Correlation between the aPTT and clinical events in acute coronary syndromes treated with unfractionated heparin.
Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease.
Haemostatic function in coronary artery disease (CAD).
Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice.
Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.
Risk Factors for Major Amputation in Diabetic Foot Ulcer Patients.
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
SR-90107 (Sanofi-Synthélabo).
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
YM-150, a Factor Xa inhibitor for the prevention of venous thromboembolism and coronary artery disease.
Coronary Disease
Analysis of influencing factors related to elevated serum troponin I level for COVID-19 patients in Yichang, China.
Analysis of Risk Factors in Endoscopic Retrograde Cholangiopancreatography-Related Immediate and Delayed Hemorrhage.
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
[ASPECTS OF BLOOD COAGULATION IN CORONARY HEART DISEASE. HEMATIC THROMBOPLASTIN.]
Coronary Stenosis
Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
Coronary Thrombosis
Acute myocardial infarction and antiphospholipid antibody syndrome: a systematic review.
Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.
Coronavirus Infections
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.
Cough
A novel risk score to predict cardiovascular complications in patients with coronavirus disease 2019 (COVID-19): A retrospective, multicenter, observational study.
Acute respiratory failure in adult patients with dengue virus infection.
Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children.
The clinical differences between dengue and scrub typhus with acute respiratory failure in southern Taiwan.
COVID-19
A Case Series of Thromboelastography-Guided Anticoagulation in COVID-19 Patients with Inherited and Acquired Hypercoagulable States.
Characteristics of laboratory indexes in COVID-19 patients with non-severe symptoms in Hefei City, China: diagnostic value in organ injuries.
Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China.
Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.
Coagulation Panel in Patients with SARS-CoV2 Infection (COVID-19).
Coagulopathy in COVID-19.
Comparative analysis of clinical features of SARS-CoV-2 and adenovirus infection among children.
Comparison of clinical features on admission between coronavirus disease 2019 and influenza a among children: a retrospective study in China.
COVID-19 and acute coagulopathy in pregnancy.
COVID-19 and coagulation dysfunction in adults: A systematic review and meta-analysis.
COVID-19 and Hematology-What Do We Know So Far?
COVID-19 and its implications for thrombosis and anticoagulation.
COVID-19 versus HIT hypercoagulability.
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis.
Decreased CRRT Filter Lifespan in COVID-19 ICU Patients.
Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy.
FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant.
Hemostatic abnormalities in COVID-19: A guided review.
Hemostatic Changes in Patients with COVID-19: A Meta-Analysis with Meta-Regressions.
Higher admission activated partial thromboplastin time, neutrophil-lymphocyte ratio, serum sodium, and anticoagulant use predict in-hospital COVID-19 mortality in people with Diabetes: Findings from Two University Hospitals in the U.K.
Management of therapeutic unfractionated heparin in COVID-19 patients: A retrospective cohort study.
Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO.
Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen.
Phlegmasia cerulea dolens superimposed on disseminated intravascular coagulation in COVID-19.
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases.
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.
Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low- and Middle-Income Countries.
Prognostic Factors in COVID-19 Patients With New Neurological Manifestations: A Retrospective Cohort Study in a Romanian Neurology Department.
Prognostic Value of Fibrinogen among COVID-19 Patients Admitted to an Emergency Department: An Italian Cohort Study.
Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19.
Routine Hematological Parameters May Be Predictors of COVID-19 Severity.
Severe COVID-19 has a distinct phenotype from bacterial sepsis: a retrospective cohort study in deceased patients.
The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents.
The values of coagulation function in COVID-19 patients.
Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment.
Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19.
Unclear Issues Regarding COVID-19.
Venous thromboembolic events in patients with COVID-19: a systematic review and meta-analysis.
Viscoelastic Tests in the Evaluation of Haemostasis Disturbances in SARS-CoV2 Infection.
Craniocerebral Trauma
A retrospective and prospective study of cerebral tissue pulmonary embolism in severe head trauma.
Blunt brain injury activates the coagulation process.
Development and validation of the revised injury severity classification score for severely injured patients.
Effect of hypothermia on serum electrolyte, inflammation, coagulation, and nutritional parameters in patients with severe traumatic brain injury.
Glasgow Coma Scale predicts coagulopathy in pediatric trauma patients.
Haemostatic Abnormalities in Patients with Closed Head Injuries and their role in Predicting Early Mortality.
Hemophilia presenting with intracranial hemorrhage. An approach to the infant with intracranial bleeding and coagulopathy.
Hemostatic abnormalities in patients with closed head injuries and their role in predicting early mortality.
Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study.
Role of coagulopathy in patients with head trauma.
The incidence and significance of hemostatic abnormalities in patients with head injuries.
The influence of hemocoagulative disorders on the outcome of children with head injury.
Craniopharyngioma
Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: A Chinese single-center, retrospective study.
Craniosynostoses
Elevated prothrombin time on routine preoperative laboratory results in a healthy infant undergoing craniosynostosis repair: Diagnosis and perioperative management of congenital factor VII deficiency.
Crohn Disease
Hemostasis in Crohn's disease: low factor XIII levels in active disease.
Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Cross Infection
The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue.
Cryptococcosis
Cryptococcosis in patients with liver cirrhosis: Death risk factors and predictive value of prognostic models.
Disseminated intravascular coagulation associated with disseminated cryptococcosis in a patient with acquired immunodeficiency syndrome.
Cystic Fibrosis
Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin.
Crystal Structure of Isoform CBd of the Basic Phospholipase A2 Subunit of Crotoxin: Description of the Structural Framework of CB for Interaction with Protein Targets.
Exclusion of human chromosome 13q34 as the site of the cystic fibrosis mutation.
Cystitis
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Cysts
Cause of hematic cysts of the orbit: increased fibrinolysis and immunohistologic expression of tissue plasminogen activator.
Corpus luteum hemorrhage: rare complication of congenital and acquired coagulation abnormalities.
Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency.
Dehydration
The use of protein-DNA, chromatin immunoprecipitation, and transcriptome arrays to describe transcriptional circuits in the dehydrated male rat hypothalamus.
[Clinical characteristics and outcomes of cerebral venous sinus thrombosis during pregnancy and puerperium].
[Effects of dehydration and infusion of blood substitutes on the hemostasis system in an experiment with 21-hour bed rest]
Dementia
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Treatment with the direct oral anticoagulants (DOACs) apixaban and rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD).
Dengue
Acute kidney injury in dengue virus infection.
Acute respiratory failure in adult patients with dengue virus infection.
Assessment of aPTT-based clot waveform analysis for the detection of haemostatic changes in different types of infections.
Clinical and Laboratory Characteristics of Dengue-Orientia tsutsugamushi co-Infection from a Tertiary Care Center in South India.
Coagulation abnormalities in Dengue fever infection: A systematic review and meta-analysis.
Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome.
Determinants of mortality and prolonged hospital stay among dengue patients attending tertiary care hospital: a cross-sectional retrospective analysis.
Expression of NF-kB and COX-2 in Young Versus Older Patients with Sporadic Colorectal Cancer.
Prothrombin time and partial thromboplastin time as a predictor of bleeding in patients with dengue hemorrhagic fever.
Risk factors associated with development of dengue haemorrhagic fever or dengue shock syndrome in adults in Hospital Tengku Ampuan Afzan Kuantan.
The clinical differences between dengue and scrub typhus with acute respiratory failure in southern Taiwan.
The exploration of risk factors of concurrent bacteraemia in patients critically ill with severe dengue.
Trajectories of hepatic and coagulation dysfunctions related to a rapidly fatal outcome among hospitalized patients with dengue fever in Tainan, 2015.
Dermatitis
Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
Diabetes Complications
Evaluation of Coagulation Profile in Children with Type 1 Diabetes Mellitus Using Rotational Thromboelastometry.
Diabetes Mellitus
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus.
Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.
Coronavirus disease 2019 (COVID-19) can predispose young to Intracerebral hemorrhage: a retrospective observational study.
Deep Venous Thrombosis Recurrence and Its Predictors at Selected Tertiary Hospitals in Ethiopia: A Prospective Cohort Study.
Determination of risk factors affecting the in-hospital prognosis of patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention.
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values.
Does von Willebrand Factor Have an Effect on the Occurrence of the Diabetic Complications?
Factor VII hyperactivity in chronic dialysis patients.
Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients.
Prognosis of spontaneous intracerebral hemorrhage in hemodialysis patients.
Prothrombin time, activated partial thromboplastin time and platelet counts of type II diabetes mellitus: a comparative study.
Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus.
Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
Shortened Activated Partial Thromboplastin Time and Increased Superoxide Dismutase Levels Are Associated with Type 2 Diabetes Mellitus.
The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus.
The tissue thromboplastin inhibition test in diabetics without cerebro-cardiovascular diseases.
The use of dielectric blood coagulometry in the evaluation of coagulability in patients with peripheral arterial disease.
[Hemostatic studies in decompensated diabetes mellitus]
Diabetes Mellitus, Type 1
Enhanced anticoagulant response to activated protein C in patients with IDDM.
Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy.
Platelet prothrombinase activity, a final pathway platelet procoagulant activity, is overexpressed in type 1 diabetes: no relationship with mean platelet volume or background retinopathy.
Diabetes Mellitus, Type 2
Association of coagulation profile with microvascular complications and glycemic control in type 2 diabetes mellitus - a study at a tertiary care center in Delhi.
Expression and significance of fgl2 prothrombinase in cardiac microvascular endothelial cells of rats with type 2 diabetes.
Novel Risk Factors and the Prediction of Type 2 Diabetes in the Atherosclerosis Risk in Communities (ARIC) Study.
Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus.
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
Shortened Activated Partial Thromboplastin Time and Increased Superoxide Dismutase Levels Are Associated with Type 2 Diabetes Mellitus.
Diabetic Foot
Clinical Characteristics, Treatment, and Prognosis of Diabetic Foot Disease in Macao and Beijing: A Retrospective Study.
Diabetic Nephropathies
Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.
Protease-activated receptor 2 protects against VEGF inhibitor-induced glomerular endothelial and podocyte injury.
Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice.
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Diabetic Retinopathy
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture.
Diphtheria
Biologically active interleukin 2-ricin A chain fusion proteins may require intracellular proteolytic cleavage to exhibit a cytotoxic effect.
Disseminated Intravascular Coagulation
6,7-Dihydroxy-3-phenylcoumarin inhibits thromboplastin induced disseminated intravascular coagulation.
A comparative study of the disease in cattle caused by Theileria parva or T. lawrencei: II. Hematology, clinical chemistry, coagulation studies and complement.
A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.
ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats.
Acquired factor X deficiency and disseminated intravascular coagulation in a case of metastasizing carcinoma of the stomach and its course under chemotherapy.
Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders.
Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation.
Acute Promyelocytic Leukemia-Associated Thrombosis.
Acute renal failure after snakebite: a report of four cases.
Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels.
Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin.
Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.
Beneficial effect of JTV-803, a new synthetic inhibitor of activated factor X, against both lipopolysaccharide-induced and tissue factor-induced disseminated intravascular coagulation in rat models.
Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia.
Clinical significance of increased thromboplastin activity on the monocyte surface--a brief review.
Coagulopathy in the nephrotic syndrome.
Diagnostic efficacy of activated partial thromboplastin time waveform and procalcitonin analysis in pediatric meningococcal sepsis.
Diagnostic efficacy of six plasma proteins in evaluating consumptive coagulopathies. Use of receiver operating characteristic curves to compare antithrombin III, plasminogen, alpha 2-plasmin inhibitor, fibronectin, prothrombin, and protein C.
DIC Score: Statistical Relationship with PT, APTT, and Simplified Scoring Systems with Combinations of PT and APTT.
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Discreplasminin, a plasmin inhibitor isolated from Tityus discrepans scorpion venom.
Disseminated intravascular coagulation caused by moojenactivase, a procoagulant snake venom metalloprotease.
Disseminated intravascular coagulation in post-dysenteric haemolytic uraemic syndrome.
Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis.
Effect of a selective PAF antagonist SM-10661 ((+/-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC).
Effect of FR128998, a novel PAF receptor antagonist, on endotoxin-induced disseminated intravascular coagulation.
Effect of NOS Inhibitors and Anticoagulants on Nitric Oxide Production in a Tissue-factor Induced Rat DIC Model.
Effects of a highly selective synthetic inhibitor of plasma kallikrein on disseminated intravascular coagulation in rats.
Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats.
Effects of intravascular clotting on the activation of the complement system: The role of the platelet.
Effects of intravenous infusion of human prostate tissue substances in dogs.
Effects of prolonged poisoning by Russell's viper venom on blood coagulation, platelets and fibrinolysis.
Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock.
Extracorporeal CO2-removal with a heparin coated artificial lung.
Fibrin degradation products in renal diseases.
Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation.
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Haemostatic Abnormalities in Patients with Closed Head Injuries and their role in Predicting Early Mortality.
Hemorrhagic, Hemostatic, and Thromboelastometric Disorders in 35 Dogs with a Clinical Diagnosis of Leptospirosis: A Prospective Study.
Hemostatic abnormalities in dogs with hemangiosarcoma.
Hemostatic abnormalities in patients with closed head injuries and their role in predicting early mortality.
Hemostatic disorders in cats: a retrospective study and review of the literature.
Hirudin in disseminated intravascular coagulation.
Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation.
Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis.
Induction of disseminated intravascular coagulation in the factor XII-deficient fowl. Morphological effects of liquoid, bacterial endotoxin and tissue thromboplastin in the normal and anticoagulated fowl.
Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats.
Involvement of the heparanase procoagulant domain in bleeding and wound healing.
Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.
Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases.
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Mononuclear phagocyte thromboplastin, bacterial counts and endotoxin levels in experimental endogenous gram-negative sepsis.
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock.
Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation.
Oral Route Driven Acute Trypanosoma cruzi Infection Unravels an IL-6 Dependent Hemostatic Derangement.
Outcome and risk factors of patients with acute fatty liver of pregnancy: a multicentre retrospective study.
Pathogenesis of thrombocytopenia in cyanotic congenital heart disease.
Pig kidney transplantation in baboons: anti-Gal(alpha)1-3Gal IgM alone is associated with acute humoral xenograft rejection and disseminated intravascular coagulation.
Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988.
Post-traumatic thrombotic microangiopathy following pelvic fracture treated with transcatheter arterial embolization: a case report.
Postoperative bleeding in a patient with normal screening coagulation tests.
Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass.
Prognostic significance of abnormal hematological parameters in severe traumatic brain injury requiring decompressive craniectomy.
Progression of plasma D-dimer concentration and coagulopathies during hospitalization in horses with colic.
Prolonged prothrombin time and partial thromboplastin time in disseminated intravascular coagulation not due to deficiency of factors V and VIII.
Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats.
Retinal detachment in association with preeclampsia and abruptio placentae.
Serotonin Syndrome, Disseminated Intravascular Coagulation, and Hepatitis After a Single Ingestion of MDMA in an Asian Woman.
Severe coagulopathy in Merrem's hump-nosed pit viper (Hypnale hypnale) envenoming unresponsive to fresh frozen plasma: A case report.
Snakebite doesn't cause disseminated intravascular coagulation: coagulopathy and thrombotic microangiopathy in snake envenoming.
Sporadic cases of Legionnaires' disease: the expanding clinical spectrum.
Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation.
Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome successfully treated with cyclosporin A.
Successful treatment of uterine torsion in a cat with severe metabolic and haemostatic complications.
The glycosaminoglycan of recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced disseminated intravascular coagulation.
The incidence and significance of hemostatic abnormalities in patients with head injuries.
The pathophysiologic role of fat in dysbaric osteonecrosis.
The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin. An assay for detection of endotoxin.
The role of cellular cooperation in thromboplastin synthesis.
The role of the E2F1 transcription factor in the innate immune response to systemic LPS.
The value of variables of disseminated intravascular coagulation in the diagnosis of adult respiratory distress syndrome.
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.
Tissue thromboplastin induced reversible DIC and heparin-enhanced inhibitors in dogs.
Transmittance waveform of routine coagulation tests is a sensitive and specific method for diagnosing non-overt disseminated intravascular coagulation.
Treatment of adult patients with sepsis-induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (Ceprotin).
Unclear Issues Regarding COVID-19.
Unusual metastatic behavior and clinicopathologic findings in eight cats with cutaneous or visceral hemangiosarcoma.
Update on hemostasis: neurosurgery.
Update on the Clot Waveform Analysis.
Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit.
Vascular liver calcification in infants. A case report with some pathogenetic considerations.
[Diagnostic therapeutic problems of defibrination syndrome in shock, sepsis, and neonatal hypoxia (author's transl)]
[Disseminated intravascular coagulation masking neonatal hemophilia]
[Experimental therapy of disseminated intravascular coagulation by streptokinase administration]
[Inhibitory effect of heparin in dogs with acute disseminated intravascular coagulation induced by tissue thromboplastin]
[Prevention of endotoxin-induced disseminated intravascular coagulation, and inhibition of endotoxin-induced release of thromboplastin activity from leukocytes by a protease-inhibitor, urinastatin]
[Proceedings: Consumption coagulopathy in the newborn infant caused by inwashing of tissue thromboplastin]
[Purpura fulminans in the newborn. Report of two cases successfully treated with heparin and antithrombin III]
[Reasons for fresh frozen plasma transfusion in a general hospital]
[Secondary blood coagulation disturbances after severe head injuries (author's transl)]
[Significance of fibrinopeptide A as an indicator for coagulative analysis in thrombotic diseases]
[Use of partial thromboplastin time and thrombin time in the diagnosis of disseminated intravascular coagulation]
Down Syndrome
Attributable fraction for cardiac malformations.
Drug-Related Side Effects and Adverse Reactions
Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation.
Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia.
The efficacy and safety of low-molecular-weight heparin calcium combined with Xueshuantong injections in the treatment of elderly acute deep venous thrombosis patients.
Duodenal Ulcer
Mononuclear phagocyte thromboplastin and endotoxin in patients with secondary bacterial peritonitis.
Dyslipidemias
Selected Blood Inflammatory and Metabolic Parameters Predicted Successive Bilateral Sudden Sensorineural Hearing Loss.
Dyspnea
Acute respiratory failure in adult patients with dengue virus infection.
Pulmonary hemorrhage after intracoronary stent placement.
Surgical treatment of early acute thrombosis of mechanical mitral prosthesis.
Ecchymosis
Acquired factor VIII inhibitor syndrome: A rare cause of hematuria.
Acquired hemophilia A in a patient associated with community-acquired pneumonia.
Coagulopathy induced by aortoiliac aneurysms.
Comparison of curative effect between different anticoagulation regimens in continuous renal replacement therapy after cardiac valve replacement.
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Factor VIII inhibitors. Laboratory diagnosis of inhibitors.
Neonatal congenital Factor X deficiency.
Propylthiouracil-related hemorrhagic diathesis: a case report and review of the literature.
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
[Clinical study on the application of covered vacuum sealing drainage technology to the bite of venomous snakes of Trimeresurus stejnegeri in Guangxi].
[Decreased Quick percentage, acquired factor X deficiency, hemarthrosis and ecchymosis: amyloidosis]
[Refractory kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: clinical analysis of 10 cases].
Eclampsia
Eclampsia II. Clinical significance of laboratory findings.
Ehlers-Danlos Syndrome
Plasma thromboplastin component deficiency in the Ehlers-Danlos syndrome.
Embolic Stroke
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial.
Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design.
Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source.
Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial.
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial.
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Reduced Smoke-like Echo and Resolved Thrombus in the Left Atrium with Rivaroxaban Therapy in an Acute Cardioembolic Stroke Patient.
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.
Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
Embolism
A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial.
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial.
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients with Atrial Fibrillation.
Arterial thromboembolism and associated antithrombin III deficiency.
Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source.
Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Cholesterol Crystal Embolism Induced by Direct Factor Xa inhibitor: A First Case Report.
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Coagulation abnormalities associated with acute Angiostrongylus vasorum infection in dogs.
Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.
Correction to: Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Direct oral factor Xa inhibitors for the prevention of non-central nervous systemic embolism patients with non-valvular atrial fibrillation - a systematic review and meta-analysis.
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Disseminated intravascular coagulation.
Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.
Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor.
Early anticoagulation after large cerebral embolic infarction: a safety study.
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-Valvular Atrial Fibrillation and Venous Thromboembolism.
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Factors Associated With Major Bleeding Events: Insights From the ROCKET AF Trial (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial.
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.
Indications for antithrombotic therapy after myocardial infarction.
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks.
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.
New anticoagulants in atrial fibrillation.
New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials.
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Novel oral anticoagulant management issues for the stroke clinician.
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
Oral anticoagulants for Asian patients with atrial fibrillation.
Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects.
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.
Practical management of patients on apixaban: a consensus guide.
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Preclinical and clinical data for factor Xa and "universal" reversal agents.
Preliminary Observations on the Antihypertension Action of Dabigatran Etexilate in Patients With Nonvalvular Atrial Fibrillation: A Prospective Multicenter Single-Arm Interventional Study.
Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.
Pulmonary embolism in congenital bleeding disorders: intriguing discrepancies among different clotting factors deficiencies.
Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.
Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban.
Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.
Rivaroxaban in atrial fibrillation.
Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study.
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation.
Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
Safety and efficacy of apixaban in the treatment of atrial fibrillation.
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.
Spontaneous Arterial Dissection.
Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
Stroke Prevention in Atrial Fibrillation: Impact of Novel Oral Anticoagulants.
Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy.
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.
Transitions of care in anticoagulated patients.
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
[Anticoagulation with low molecular-weight heparin in patients with prosthetic heart valve replacements]
[Clinical treatment and therapy for dissected cervicocerebral artery]
[Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
[Hemodynamic and respiratory changes during hip and knee arthroplasty. An echocardiographic study]
[Pharmacology of the new oral anticoagulants].
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
Embolism, Amniotic Fluid
Disseminated intravascular coagulation.
Embolism, Fat
The pathophysiologic role of fat in dysbaric osteonecrosis.
Encephalitis
Antithrombin activity of an algal polysaccharide.
Encephalomyelitis
Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
Encephalopathy, Bovine Spongiform
Antithrombin activity of an algal polysaccharide.
Endocarditis
Changes in hemostasis parameters in nonfatal methicillin-sensitive Staphylococcus aureus bacteremia complicated by endocarditis or thromboembolic events: a prospective gender-age adjusted cohort study.
Endocarditis, Bacterial
Enhancement of generation of monocyte tissue thromboplastin by bacterial phagocytosis: possible pathway for fibrin formation on infected vegetations in bacterial endocarditis.
The role of bacterial adherence in the pathogenesis of infective endocarditis.
Endometrial Neoplasms
Co-localization of Coagulation Factor X and its Inhibitory System, PZ/ZPI, in Human Endometrial Cancer Tissue.
Endometriosis
Assessment of Coagulation Parameters in Women Affected by Endometriosis: Validation Study and Systematic Review of the Literature.
Coagulation Status in Women With Endometriosis.
Noninvasive evaluation of ovarian endometriosis: a single-center experience.
Endometritis
New approach to the risk variables for administration of fibrinogen in patients with postpartum hemorrhage by using cluster analysis.
Endotoxemia
Antithrombin-III treatment limits disseminated intravascular coagulation in endotoxemia.
Beneficial effect of cod liver oil in murine endotoxemia.
Endotoxemia in horses: protection provided by antiserum to core lipopolysaccharide.
Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats.
Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats.
Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat.
Eosinophilia
Acquired Factor V Inhibitors in a Patient with End-stage Renal Disease.
Eosinophilia and first-line coagulation testing.
Epilepsy, Tonic-Clonic
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Epiretinal Membrane
Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition.
Epistaxis
A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X.
Acquired Hemophilia A: A Potentially Fatal Bleeding Disorder.
Congenital factor X deficiency of coagulation revealed by epistaxis.
Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Hemorrhage in a cat caused by inhibition of factor XI (plasma thromboplastin antecedent).
In response to Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.
Propylthiouracil-related hemorrhagic diathesis: a case report and review of the literature.
Rare coagulation disorders.
Regarding epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.
Replacement therapy for congenital Factor X deficiency.
Report of the fifth homozygous patient with factor VII Padua defect.
Risk factors for epistaxis in patients followed in general practices in Germany.
Superwarfarin Exposure: An Important Uncommon Cause of Painless Bleeding.
von Willebrand factor activity and activated partial thromboplastin time as proxy biomarkers for coagulopathies in women with menorrhagia in Zambia: a case-control study.
[Acquired factor V inhibitors in a polytraumatized patient]
[Clinical and epidemiological characteristic of dengue]
[The determination of activated partial thromboplastin time, coagulate time and thrombin time in patients with epistaxis of indeterminate cause]
Epstein-Barr Virus Infections
Transient lupus anticoagulant and prolonged activated partial thromboplastin time secondary to Epstein-Barr virus infection.
Esophageal and Gastric Varices
Survival in alcoholic liver cirrhosis: prognostic value of portal pressure, size of esophageal varices and biochemical data. Comparison with Child classification.
Essential Hypertension
Coagulation and the hypertensive diseases of pregnancy.
Increased sensitivity to thromboplastin synthesis in blood monocytes from pre-eclamptic patients.
Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension.
Exanthema
Diagnostic Pitfalls in a Man with Systemic Lupus Erythematous.
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue.
Exotropia
Neurological Involvement and Hepatocellular Injury Caused by a Snake With Hematotoxin Envenomation.
Eye Diseases
Platelet coagulant activities in arterial occlusive disease of the eye.
Factor V Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A novel compensating mechanism for homozygous coagulation factor V deficiency suggested by enhanced activated partial thromboplastin time after reconstitution with normal factor V.
Abnormal formation of the prothrombinase complex: factor V deficiency and related disorders.
Acquired Factor V Deficiency Associated with CFPM Administration.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
Clinical audit of inherited bleeding disorders in a developing country.
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Intracranial haemorrhage due to factor V deficiency.
Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis.
Observations on hemophilia, parahemophilia, and coexistent hemophilia and parahemophilia; alterations in the platelets and the thromboplastin generation test.
Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets.
Rare inherited coagulation disorders in India.
Snake Venoms in Diagnostic Hemostasis and Thrombosis.
Splenectomy and proximal lieno-renal shunt in a factor five deficient patient with extra-hepatic portal vein obstruction.
Successful Management of Life-threatening Pelvic Hemorrhage From Acquired Factor V Deficiency With immunosuppressive Therapy.
Factor VII Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A NlaIII polymorphism within the human factor VII gene.
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Another patient with a congenital hemorrhagic disorder intermediate between factor X and factor VII deficiency.
Asymptomatic factor VII deficiency: gene analysis and structure-function relationships.
Clinical audit of inherited bleeding disorders in a developing country.
Combined mild PTC (plasma thromboplastin component) and factor VII deficiencies.
Determinants of coagulation activation in humans.
Determinants of plasma factor VIIa levels in humans.
Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds.
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Factor VII deficiency detected in pregnancy: a case report.
Factor VII deficiency with intracranial hemorrhage: a case report.
Factor VII Deficiency: A Rare Case Report.
Fatal intracranial hemorrhage in a newborn with factor VII deficiency.
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
Inherited bleeding disorders in Indian women with menorrhagia.
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Multiple intracranial hemorrhages at the time of a transiently prolonged activated partial thromboplastin time in an infant with congenital factor VII deficiency.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Paracetamol poisoning unmasking factor VII deficiency.
Rare inherited coagulation disorders in India.
Sensitivity of different thromboplastin reagents to factor VII deficiency in the blood of beagle dogs.
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
[Congenital factor VII deficiency: about two family cases].
[Significant decrease in factor VII activity by tissue thromboplastin derived from rabbit brain in a patient with congenital factor VII deficiency (FVII Padua)].
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
Factor X Deficiency
"I have been refused to be treated by three dentists": Barriers to patient care.
A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X.
A case of factor X deficiency in a Chihuahua dog.
A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma.
A Compound Heterozygosis of Two Novel Mutations Causes Factor X Deficiency in a Chinese Pedigree.
A family with factor X deficiency from Argentina: a compound heterozygosis because of the combination of a new mutation (Gln138Arg) with an already known one (Glu350Lys).
A family with hereditary factor X deficiency with a point mutation Gla32 to Gln in the Gla domain (factor X Tokyo).
A functional factor X deficiency.
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A new family with classical factor X deficiency as demonstrated by electroimmunoassay.
A NlaIII polymorphism within the human factor VII gene.
A novel factor X gene mutation Val (GTC) 384Ala (GCC) in a Chinese family resulting in congenital factor X deficiency.
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
A Rare Cause of Coagulopathy in a Patient with Rapidly Progressive Renal Failure.
A rare cause of intracranial hemorrhage: factor X deficiency.
A Rare Cause of Isolated Prothrombin Time Prolongation: Congenital Factor X Deficiency.
A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency.
A rare presentation of homozygous factor X deficiency in a pregnant patient: A case report and review of the literature.
A tongue resection in macroglossia due to primary amyloidosis.
A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X.
Abscess in bilateral ovarian haematomas in a girl with factor X deficiency, necessitating oopherectomy.
Acquired and transient factor X deficiency associated with sodium valproate treatment.
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone.
Acquired factor X deficiency and amyloidosis.
Acquired factor X deficiency and disseminated intravascular coagulation in a case of metastasizing carcinoma of the stomach and its course under chemotherapy.
Acquired factor X deficiency associated with atypical AL-amyloidosis.
Acquired factor X deficiency associated with systematized amyloidosis--a report of a case.
Acquired factor X deficiency developed four years after autologous transplantation in a patient with multiple myeloma associated with systemic AL amyloidosis.
Acquired factor X deficiency in a Negro boy.
Acquired factor X deficiency in a patient with amyloidosis.
Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
Acquired factor x deficiency in light chain amyloidosis: a report of 2 korean cases.
Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis.
Acquired factor X deficiency in systemic amyloidosis.
Acquired factor X deficiency in systemic amyloidosis: management of two cases.
Acquired factor X deficiency with associated defects in platelet aggregation. A response to corticosteroid therapy.
Acquired factor X deficiency. Altered plasma antithrombin activity and association with amyloidosis.
Acquired factor X deficiency: an experience with multiple tooth extraction.
Acquired isolated factor X deficiency associated with systemic amyloidosis. Case report and review of literature.
Acquired selective factor X deficiency in acute nonlymphocytic leukemia.
Acquired, non-amyloid related factor X deficiency: review of the literature.
Acquired, transient factor X (Stuart factor) deficiency in patient with mycoplasma pneumonial infection.
Acquired-transient factor X deficiency associated with anticardiolipin antibodies in a child with extensive burns.
Acquired-transient factor X deficiency in a teenager with extensive burns.
Advances in treatment of bleeding disorders.
Amyloidosis and factor X deficiency.
Amyloidosis with factor X deficiency.
An analysis of 8 cases of factor X deficiency.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Angiodysplasia of upper gastrointestinal tract with coagulopathy.
Antenatally diagnosed subdural haemorrhage in congenital factor X deficiency.
Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody.
Atraumatic splenic rupture in amyloidosis.
Autoimmune Coagulation Factor X Deficiency as a Rare Acquired Hemorrhagic Disorder: A Literature Review.
Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Report of a new association and its possible relationship to endothelial cell injury.
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
Bilateral periorbital ecchymoses. An often missed sign of amyloid purpura.
Bleeding manifestations in 100 patients with amyloidosis.
Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice.
Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.
Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency.
Candida vertebra osteomyelitis in a girl with factor X deficiency.
Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
Characterization of amyloid deposits and P component from a patient with factor X deficiency reveals proteins derived from a lambda VI light chain.
Chronic peritoneal dialysis in a patient with primary amyloidosis, renal failure, and factor X deficiency.
Circumcision in Patients with Congenital Factor X Deficiency.
Classical factor X deficiency. Report of a further case.
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
Clinical audit of inherited bleeding disorders in a developing country.
Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy.
Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.
Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.
Complete remission in a bleeding patient with idiopathic autoimmune factor X deficiency caused by non-neutralizing anti-factor X autoantibody.
Complex history of the discovery and characterization of congenital factor X deficiency.
Congenital bleeding disorders of the vitamin K-dependent clotting factors.
Congenital coagulation factor X deficiency: Genetic analysis of five patients and functional characterization of mutant factor X proteins.
Congenital coagulopathies and pregnancy: report of four pregnancies in a factor X-deficient woman.
Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation.
Congenital factor X deficiency and incomplete transverse paralysis.
Congenital factor X deficiency in Japan.
Congenital Factor X deficiency in women: A systematic review of the literature.
Congenital factor X deficiency of coagulation revealed by epistaxis.
Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients.
Congenital haemorrhagic condition similar but not identical to factor X deficiency. A haemorrhagic state due to an abnormal factor X?
Corpus luteum hemorrhage: rare complication of congenital and acquired coagulation abnormalities.
Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
Danazol therapy in factor X deficiency.
Danazol therapy in factor X deficiency: more questions than answers.
Dental management of a patient with factor X deficiency.
Diagnosis and treatment of inherited factor X deficiency.
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency.
Diagnostic Error of a Patient with Combined Inherited Factor VII and Factor X Deficiency due to Accidental Ingestion of a Diphacinone Rodenticide.
Different genotypes are responsible for the normal Russell viper venom assays seen in some cases of congenital factor X deficiency.
Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran.
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency.
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency.
Ethnic Differences in Coagulation Factor Abnormalities After the Fontan Procedure.
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis.
Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery.
Factor VII and factor X deficiency in a child with a chromosome 13q duplication and deletion.
Factor X and its deficiency states.
Factor X assays using chromogenic substrate S-2222.
Factor X deficiency and hemophilia A : occurrence of two different coagulation defects in a family.
Factor X deficiency and intracranial bleeding: who is at risk?
Factor X deficiency and pregnancy: case report and counselling.
Factor X deficiency and pregnancy: preconception counselling and therapeutic options.
Factor X deficiency and systemic amyloidosis.
Factor X deficiency associated with compound heterozygosity involving a novel missense mutation at codon 38 from Val (GTC) to Leu (CTC) in exon 2.
Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib: A Case Report and Review of the Literature.
Factor X deficiency due to a compound heterozygosis between a new mutation (Gla72Asp) in exon 2 and an already known one (Gly154Arg) in exon 5: Factor X Mar del Plata 1).
Factor X deficiency during treatment of relapsed acute myeloid leukaemia with amsacrine.
Factor X deficiency in a cat.
Factor X deficiency in a Jack Russell terrier.
Factor X deficiency in North Pakistan.
Factor X deficiency in primary amyloidosis.
Factor X deficiency in primary amyloidosis: resolution after splenectomy.
Factor X deficiency in systemic amyloidosis.
Factor X deficiency in the neonatal period.
Factor X Deficiency Management for Elective Cesarean Delivery in a Pregnant Patient.
Factor X deficiency presenting as a pseudotumor. Case report.
Factor X deficiency presenting with bilateral chronic subdural hematoma.
Factor X Deficiency with Heterozygous Mutations of Novel p.G435S and Known p.G244R in a Patient Presenting with Severe Umbilical Hemorrhage.
Factor X deficiency--a rare disorder.
Factor X deficiency.
Factor X Deficiency: A Rare Cause of Puberty Menorrhagia.
Factor X deficiency: An uncommon presentation of AL amyloidosis.
Factor X deficiency: an unusual cause for spontaneous intracranial bleeding.
Factor x deficiency: an unusual cause of spontaneous intracranial bleeding.
Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene.
Factor X Frankfurt I: molecular and functional characterization of a hereditary factor X deficiency (Gla+25 to Lys).
Factor X inhibitor: a fulminant presentation and fatal course of a rare syndrome in a 59-year-old male.
Factor X level in coumarin treated patients and in factor X deficiency as assayed with different techniques.
Factor X Nagoya 1 and Nagoya 2: a CRM- factor X deficiency and a dysfunctional CRM+ factor X deficiency characterized by substitution of Arg306 by Cys and of Gly366 by Ser, respectively.
Factor XDebrecen: Gly204Arg mutation in factor X causes the synthesis of a non-secretable protein and severe factor X deficiency.
Factors X Nice I and II: two novel missense mutations (Met-40Val and Pro304Ser) in patient with coagulation factor X deficiency.
Femur fracture in a woman with severe factor X deficiency - an experience using factor X concentrate in surgery.
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
Frequencies of mild factor V, VII and X deficiencies in a Japanese population.
Frequency of inherited bleeding disorders in women with menorrhagia.
Frequency of the p.Gly262Asp mutation in congenital Factor X deficiency.
Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection.
Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency.
Genetic analysis of a compound heterozygous patient with congenital factor X deficiency and regular replacement therapy with a prothrombin complex concentrate.
Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry: in vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X.
Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency.
Genotyping of five Pakistani patients with severe inherited factor X deficiency: identification of two novel mutations.
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
Hemorrhage because of amyloid-related factor x deficiency after insertion of tenckhoff catheter.
Hemorrhagic diathesis caused by factor X deficiency in a child with thymic cyst.
Hemostatic abnormalities in multiple myeloma and related disorders.
Hereditary coagulation factor X deficiency--a clinico-haematological profile of 5 cases from Varanasi.
Hereditary coagulation factor X deficiency.
Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses.
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
Human coagulation factor X deficiency caused by a mutant signal peptide that blocks cleavage by signal peptidase but not targeting and translocation to the endoplasmic reticulum.
Identification of a novel factor X deletion in combination with a missense mutation in the gene - Genotype-phenotype correlation in a girl with severe factor X deficiency.
Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.
Impact of Rare Bleeding Disorders during Pregnancy on Maternal and Fetal Outcomes: Review of 29 Pregnancies at a Single Center.
Importance of pharmacokinetic studies in the management of acquired factor X deficiency.
Influence of glass and anticoagulant concentration on improvement of factor X deficiency tests.
Inherited bleeding disorders in Indian women with menorrhagia.
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Inherited factor X deficiency in two brothers.
Inherited factor X deficiency: molecular genetics and pathophysiology.
Inherited factor X deficiency: presentation of a case with etiologic and treatment considerations.
Inherited Moderate Factor X Deficiency Presenting as Cardiac Tamponade.
Intracerebral haemorrhage in an adult due to transient factor X deficiency.
Intracranial haemorrhage in patients with congenital haemostatic defects.
Intracranial Hemorrhage as the First Manifestation of Severe Congenital Factor X Deficiency in a 20-Month-Old Male: Case Report and Review of the Literature.
Isolated factor X deficiency in amyloidosis. Case report and review of the literature.
Kinetic analysis of the clotting system in the presence of heparin and depolymerized heparin.
Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis.
Life-threatening bleeding tendency provoked by an acquired isolated factor X deficiency associated with respiratory infection.
Liver transplantation for haemophiliacs with hepatitis C cirrhosis.
Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications.
Management of Factor X Deficiency for Vaginal Delivery in a Parturient: A Case Report.
Massive Upper and Lower GI Bleed from Simultaneous Primary (AL) Amyloidosis of the Stomach and Transverse Colon in a Patient with Multiple Myeloma.
Mechanism of factor X deficiency in systemic amyloidosis.
Membranoproliferative glomerulonephritis and a rare bleeding disorder: factor X deficiency.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Mode of inheritance of factor X deficiency.
Modulation of severity of clinical bleeding by co-inherited thrombophilia is also true for severe factor X deficiency.
Molecular analysis of patients with severe congenital factor X deficiency: First report from north and northwest of Iran.
Molecular analysis of the genotype-phenotype relationship in factor X deficiency.
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glu102Lys) in the second EGF-like domain.
Molecular basis of factor X deficiency cases from India.
Molecular characterization of factor X deficiency associated with borderline plasma factor X level.
Molecular characterization of human factor XSan Antonio.
Molecular characterization of two novel mutations causing factor X deficiency in a Chinese pedigree.
Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg").
Molecular genetic analysis of factor X deficiency: gene deletion and germline mosaicism.
Near fatal spontaneous intraperitoneal bleeding: A rare manifestation in a congenital factor X deficiency carrier.
Neonatal congenital Factor X deficiency.
Neonatal congenital factor X deficiency.
Neonatal onset of congenital factor X deficiency: a description of two novel mutations with 6-year follow-up.
NORETHYNODREL IN THE TREATMENT OF FACTOR X DEFICIENCY.
Normalization of plasma factor X levels in amyloidosis after plasma exchange.
Novel factor X deficiency. Normal partial thromboplastin time and associated spindle cell thymoma.
Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency.
One missense mutation in the factor X gene causing factor X deficiency--factor X Kanazawa.
Partial gene deletion in a family with factor X deficiency.
Pharmacokinetics and prophylactic use of FEIBA(®) in a child with severe congenital factor X deficiency and recurrent spontaneous intracranial haemorrhage: a case report.
Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency.
Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency.
PheWAS uncovers a pathological role of coagulation Factor X during Acinetobacter baumannii infection.
Plasma exchange in a case of severe factor X deficiency in pregnancy: critical review of the literature.
Plasma-derived factor X concentrate compassionate use for hereditary factor X deficiency: Long-term safety and efficacy in a retrospective data-collection study.
Platelet aggregation and adhesiveness in classical factor X deficiency and in the abnormal factor X (factor X Friuli) coagulation disorder.
Poor recovery and short survival of infused factor X in a case of acquired factor X deficiency and amyloidosis.
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Posttraumatic lipoma in a patient with congenital factor X deficiency.
Pregnancy in a patient with severe factor X deficiency.
Prenatal diagnosis of factor X deficiency using a combination of direct mutation detection and linkage analysis with an intragenic single nucleotide polymorphism.
Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency.
Prevalence of bleeding manifestations in 128 heterozygotes for Factor X deficiency, mainly for FX Friuli, matched vs 128 unaffected family members, during a long sequential observation period (23.5 years).
Prevention of recurrent intracranial hemorrhage in a factor X-deficient infant.
Primary amyloidosis with severe nephrotic syndrome and acquired factor X deficiency.
Progressive systemic sclerosis with the nephrotic syndrome and acquired factor X deficiency.
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Prophylactic treatment of bleeding episodes in children <12 years with moderate to severe hereditary factor X deficiency (FXD): Efficacy and safety of a high-purity plasma-derived factor X (pdFX) concentrate.
Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrate.
Prophylaxis in rare coagulation disorders -- factor X deficiency.
Prophylaxis with prothrombin complex concentrate in four children with severe congenital factor X deficiency.
Prothrombin in factor X deficiency.
Rare case of combined factor V and factor X deficiency in pregnancy: presenting as secondary postpartum haemorrhage in first pregnancy and successful outcome in second pregnancy.
Rare inherited coagulation disorders in India.
Rare post-operative complications in a previously undiagnosed Congenital Factor X deficiency patient.
Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency.
Recurrent ovarian haemorrhage in a girl with congenital factor X deficiency.
Recurrent, isolated factor X deficiency in myeloma: repeated normalization of factor X levels after cytostatic chemotherapy followed by late treatment failure associated with the development of systemic amyloidosis.
Replacement therapy for congenital Factor X deficiency.
Report on a disease-adapted treatment in a patient with severe factor X deficiency resulting from a homozygous factor X gene mutation.
Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy.
Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.
Resolution of factor X deficiency in primary amyloidosis following splenectomy.
Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.
Retroperitoneal amyloidosis, factor IX and X deficiency,and gastrointestinal bleeding.
Routine preoperative coagulation screening detects a rare bleeding disorder.
Secondary severe factor X deficiency associated with antiphospholipid syndrome.
Severe congenital factor X deficiency in 5-month-old child.
Severe congenital factor X deficiency with intracranial bleeding in two siblings.
Severe congenital factor X deficiency with intracranial haemorrhage.
Severe factor X deficiency and successful pregnancy.
Severe factor X deficiency due to a homozygous mutation (Cys364Arg) that disrupts a disulphide bond in the catalytic domain.
Severe factor X deficiency in a pair of siblings: clinical presentation, phenotypic and genotypic features, prenatal diagnosis and treatment.
Severe factor X deficiency in a twin pregnancy.
Severe factor X deficiency in pregnancy: case report and review of the literature.
Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.
Severe Factor X Deficiency Presenting as Febrile Seizure in an Infant.
Severe factor X deficiency treated with heparin-added prothrombin complex concentrate.
Six novel missense mutations causing factor X deficiency and application of thrombin generation test.
Six novel mutations including triple heterozygosity for Phe31Ser, 514delT and 516T-->G factor X gene mutations are responsible for congenital factor X deficiency in patients of Nepali and Indian origin.
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
Splenectomy in an uraemic patient with acquired factor X deficiency due to AL amyloidosis.
Splenectomy in plasma cell dyscrasias: a review of the clinical practice.
Spontaneous epidural hematoma following a shunt in an infant with congenital factor X deficiency. Case report and literature review.
Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis.
Spontaneous perinephric hematoma due to acquired factor X deficiency in AL amyloidosis.
Spontaneous resolution of acquired factor X deficiency in amyloidosis.
Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
Spontaneous rupture of the spleen in AL amyloidosis.
Spontaneous spinal epidural hematoma in a patient with acquired Factor X deficiency secondary to systemic amyloid light-chain amyloidosis.
Staged Surgical Palliation for HLHS in a Girl with Severe Factor X Deficiency.
Steroid hormone-responsive secondary factor X deficiency.
Subclinical factor X deficiency may increase hemorrhage in women undergoing cesarean section.
Subgaleal hemorrhage in a neonate with factor X deficiency following a non-traumatic cesarean section.
Successful liver transplantation for a child with life-threatening recurrent bleeding episodes due to congenital factor X deficiency: a case report.
Successful perioperative management of factor X deficiency associated with primary amyloidosis.
Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis.
Successful pregnancy in a woman with severe factor X deficiency.
Successful treatment of a noninhibitory antibody-mediated acquired factor X deficiency in a patient with marginal-zone lymphoma.
Successful treatment of an acquired haemorrhagic diathesis due to factor X deficiency with chemotherapy.
Successful Treatment of Life-threatening Bleeding Caused by Acquired Factor X Deficiency Associated with Respiratory Infection.
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy.
Successful Use of Four Factor-Prothrombin Complex Concentrate for Congenital Factor X Deficiency in the Setting of Neurosurgery.
Surgical excision of a pseudotumour under the coverage of the plasma-derived factor X concentrate in a patient with severe factor X deficiency: A case report.
Surgical treatment for a paraplegic patient induced by congenital factor X deficiency.
Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X.
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.
Systemic amyloidosis associated with factor X deficiency.
The 13-year bleed: Exuberant amyloid angiopathies, angiodysplasias, and acquired coagulopathies of the gut.
The Clinical Findings and Prophylactic Treatment in Children with Factor X Deficiency.
The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency.
The impact of Glu102Lys on the factor X function in a patient with a doubly homozygous factor X deficiency (Gla14Lys and Glu102Lys).
THE INHERITANCE OF STUART DISEASE: INVESTIGATION OF A FAMILY WITH FACTOR X DEFICIENCY.
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
The perils of inhibiting deficient factors.
The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency.
Therapeutic approaches to factor X deficiency with emphasis on the use of a new clotting-factor concentrate (Konyne).
Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy.
Transient acquired factor X deficiency associated with pneumonia.
Transient acquired factor X deficiency: report of the use of activated clotting concentrate to control a life-threatening hemorrhage.
Transient selective factor X deficiency in a severely burned child.
Transient, selective factor X deficiency and acute liver failure following chest infection treated with erythromycin BP.
Treatment of amyloidosis associated factor X deficiency.
Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency.
Two novel factor X gene mutations in a Chinese family with factor X deficiency.
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study.
Use of plasma-derived factor X concentrate in neonates and infants with congenital factor X deficiency.
Use of prothrombin complex concentrate for prophylaxis of bleeding in acquired factor X deficiency associated with light-chain amyloidosis.
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis.
[3 families with a congenital factor X deficiency, one of them with an associated factor XII deficiency]
[A case of double valve substitution in a female patient carrier of a factor X deficiency]
[A case of factor X deficiency (author's transl)]
[A case of primary hepatic amyloidosis with factor X deficiency.]
[A case of retroperitoneal hemorrhage due to multiple myeloma complicated with factor X deficiency and amyloidosis]
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
[A new family with factor X deficiency]
[A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review]
[Acquired coagulation factor X deficiency: three cases report and literature review].
[Acquired factor X deficiency associated with A.L.type amyloidosis. A case report]
[Acquired factor X deficiency in a case of monoclonal gammopathy]
[ACQUIRED FACTOR X DEFICIENCY IN A PATIENT WITH PRIMARY AMYLOIDOSIS. INJECTION OF A B.S.C. FRACTION.]
[Acquired factor X deficiency in a patient with primary amyloidosis. Injection of a coagulating fraction (C.S.B)]
[Acquired factor X deficiency in primary amyloidosis]
[ACQUIRED HEMORRHAGIC DIATHESIS CAUSED BY ISOLATED FACTOR X DEFICIENCY.]
[Acquired isolated factor X deficiency in generalized amyloidosis]
[Analysis of seven cases of multiple myeloma with initial manifestation of bleeding].
[Blood clotting in an infant with factor X deficiency]
[Blood coagulation disorder in a 7-year-old child with a partial factor X or Stuart-Prower factor deficiency]
[Clinical and coagulation studies in 3 cases of congenital factor X deficiency and review of reported cases in Japan (author's transl)]
[Clotting factor X deficiency resulted from an T 58-->G mutation within exon 1 of human factor X gene]
[Combined 2d-type TAR syndrome, factor X deficiency, immune deficiency and mitral valve prolapse]
[Congenital blood coagulation factor X deficiency. Successful result of the use prothrombin concentrated complex in the control of ++cesarean section hemorrhage in 2 pregnancies]
[Congenital factor X deficiency showing cross-reacting material negative (CRM-)]
[Congenital factor X deficiency, the Prower-Stuart deficiency]
[Congenital factor X deficiency. Case report and review of literature]
[Decreased Quick percentage, acquired factor X deficiency, hemarthrosis and ecchymosis: amyloidosis]
[Extensive subcutaneous hemorrhage complicating primary amyloidosis]
[Factor X deficiency and pregnancy]
[Factor X deficiency and systemic amylosis]
[Factor X deficiency associated with multiple myeloma.]
[Factor X deficiency in amyloidosis (author's transl)]
[Factor X deficiency in systemic amyloidosis. Presentation of a case]
[Factors VII, VIII, IX, and X: molecular genetics and gene diagnosis]
[Familial amyloidosis of AL type and factor X deficiency. The valve of long-term colchicine administration]
[Familial hemorrhagic diathesis caused by factor X deficiency]
[Gene analysis of a combined inherited factor VII and factor X deficiency pedigree].
[Hemarthrosis disclosing factor X deficiency in primary amyloidosis]
[Homozygous missense mutation p.Val298Met of F10 gene causing hereditary coagulation factor X deficiency in a Chinese pedigree].
[How can factor X deficiency in nephropathy explained?]
[Inherited coagulation factor X deficiency caused by two novel mutations in factor X gene.]
[Isolated factor X deficiency in chronic myelomonocytic leukemia: Report of one case].
[Primary amyloidosis associated to severe factor X deficiency]
[Primary pseudotumoral pulmonary amyloidosis with Pierre-Marie syndrome]
[Probably inherited factor X deficiency. Report of a case (author's transl)]
[Recurrence of Waldenström macroglobulinemia accompanied by factor X deficiency].
[Successful long-term management of ovarian bleeding and menorrhagia with prothrombin complex concentrate in a patient with congenital factor X deficiency].
[Systemic light chain amyloidosis with acquired factor X deficiency: a case report].
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
Factor XI Deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Definition of the population at risk of bleeding due to factor XI deficiency in Ashkenazic Jews and the value of activated partial thromboplastin time in its detection.
Factor XI deficiency in an Ashkenazi Jewish child, causing severe postoperative hemorrhage.
Factor XI deficiency in Kerry Blue Terriers.
Factor XI deficiency-related spontaneous primary intraventricular hemorrhage.
Factor XI deficiency: detection and management during urological surgery.
Factor XI deficiency: implications for management of patients undergoing aesthetic surgery.
Failure of Routine Coagulation Screening Tests to Detect Heterozygous State of Bovine Factor XI Deficiency.
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
Intraneural hematoma after nerve stimulation-guided femoral block in a patient with factor XI deficiency: case report.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Normal aPTT in children with mild factor XI deficiency.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Perioperative management of factor XI deficiency in a patient undergoing hip arthroplasty.
Preoperative screening for coagulopathy using prothrombin time and partial thromboplastin time in patients requiring primary cranial vault remodeling.
Successful Peritoneal Dialysis Catheter Placement in a New End-Stage Renal Disease Patient with Combined Antiphospholipid Syndrome and Factor XI Deficiency.
The activated partial thromboplastin time and factor XI deficiency.
The factor of factor XI deficiency in thyroid neoplasia.
The rare inherited coagulation disorders.
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
[Thrombocyte dysfunction in children with albinism]
Factor XII Deficiency
A female hemophilia A combined with hereditary coagulation factor XII deficiency: a case report.
A new family with congenital factor XII deficiency.
Additional factor XII (Hageman factor) deficiency in hemophilia A and in von Willebrand syndrome.
Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis.
Factor XII (Hageman Factor) Deficiency: a rare harbinger of life threatening complications.
Factor XII deficiency and pregnancy.
Feline factor XII (Hageman) deficiency.
Implications for cardiac surgery in patients with factor XII deficiency.
Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients.
Inherited bleeding disorders in Indian women with menorrhagia.
Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects.
Periodic painful purpura: Fact or factitious?
Prolonged activated partial thromboplastin time secondary to factor XII deficiency in two surgical patients.
Rosai-Dorfman disease with factor XII deficiency.
[3 families with a congenital factor X deficiency, one of them with an associated factor XII deficiency]
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
[Successes and failures of the activated partial thromboplastin time in the preoperative evaluation]
Factor XIII Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease.
Clinical audit of inherited bleeding disorders in a developing country.
De Novo Precursor B-Lymphoblastic Leukemia/Lymphoma With Double-Hit Gene Rearrangements (MYC/BCL-2) Presented With Spinal Cord Compression and Acquired Factor XIII Deficiency.
Hemorrhagic Shock after Neonatal Circumcision: Severe Congenital Factor XIII Deficiency.
Inherited bleeding disorders in Indian women with menorrhagia.
Intracranial haemorrhage in patients with congenital haemostatic defects.
Lobar Hemorrhage Induced by Acquired Factor XIII Deficiency in a Patient with Cerebral Amyloid Angiopathy.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Rare bleeding disorders in children: identification and primary care management.
Rare inherited coagulation disorders in India.
The rare inherited coagulation disorders.
Familial Primary Pulmonary Hypertension
The FGL2 prothrombinase contributes to the pathological process of experimental pulmonary hypertension.
Fasciitis, Necrotizing
Contact activation in shock caused by invasive group A Streptococcus pyogenes.
Erysipelas and necrotizing fasciitis.
Fatty Liver
Hemostatic alterations in fatty liver disease.
Fetal Death
Antibody to cardiolipin, lupus anticoagulant, and fetal death.
Autoimmune hepatitis associated with the antiphospholipid syndrome.
Hypercoagulability. Should every patient with venous thrombosis be tested?
Outcome and risk factors of patients with acute fatty liver of pregnancy: a multicentre retrospective study.
Fetal Growth Retardation
Impact of Rare Bleeding Disorders during Pregnancy on Maternal and Fetal Outcomes: Review of 29 Pregnancies at a Single Center.
Fetal Resorption
Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin.
Animal models for antiphospholipid syndrome in pregnancy.
Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome.
Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome.
Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice.
Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation.
Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome.
Oxidized low-density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS).
The pathogenic role of anti-phosphatidylserine antibodies: active immunization with the antibodies leads to the induction of antiphospholipid syndrome.
Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell.
Fibromyalgia
Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome.
Fibrosarcoma
The production of a factor X activator by a methylcholanthrene-induced rat fibrosarcoma.
Thromboplastin release, but not content, correlates with spontaneous metastasis of cancer cells.
Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host.
Foot Diseases
Clinical Characteristics, Treatment, and Prognosis of Diabetic Foot Disease in Macao and Beijing: A Retrospective Study.
Foramen Ovale, Patent
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Gaucher Disease
Coexistence of factor XI (plasma thromboplastin antecedent) deficiency and Gaucher's disease.
[Gaucher's disease type I, anticoagulant factor and pregnancy]
Glaucoma
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Risk Factors for Decompression Retinopathy After Glaucoma Surgery.
Glioblastoma
Coagulation Factor X Regulated by CASC2c Recruited Macrophages and Induced M2 Polarization in Glioblastoma Multiforme.
Corrigendum: Coagulation Factor X Regulated by CASC2c Recruited Macrophages and Induced M2 Polarization in Glioblastoma Multiforme.
Routine Blood Tests Do Not Predict Survival in Patients with Glioblastoma-Multivariable Analysis of 497 Patients.
Targeting FGL2, a molecular drug target for glioblastoma, with natural compounds through virtual screening method.
Glioma
F10 gene hypomethylation, a putative biomarker for glioma prognosis.
Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: A Chinese single-center, retrospective study.
Glomerulonephritis
Effects of membrane plasma exchange on the hemostatic system and on thyroid hormones in critically ill patients.
Enhanced glomerular procoagulant activity and fibrin deposition in rats with mercuric chloride-induced autoimmune nephritis.
Further investigations on the significance of a plasma coagulation-accelerating factor in glomerular disease.
Glomerular coagulation system in renal diseases.
Hypercoagulation in glomerulonephritis.
Lipopolysaccharide-triggered acute aggravation of mesangioproliferative glomerulonephritis through activation of coagulation in a high IgA strain of ddY mice.
Roles of coagulation pathway and factor Xa in rat mesangioproliferative glomerulonephritis.
Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice.
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Glomerulonephritis, IGA
Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation.
Glomerulonephritis, Membranoproliferative
Membranoproliferative glomerulonephritis and a rare bleeding disorder: factor X deficiency.
Glucose Intolerance
Comparison of the hypoglycemic and antithrombotic (anticoagulant) actions of whole bovine and camel milk in streptozotocin-induced diabetes mellitus in rats.
Gonorrhea
Contemporary Concepts in Managing Menorrhagia.
Granulosa Cell Tumor
Androgenic adult granulosa cell tumour with prolongation of the activated partial thromboplastin time in a 29 year old woman.
Gray Platelet Syndrome
Platelet prothrombin converting activity in hereditary disorders of platelet function.
Hashimoto Disease
Anti-Factor V inhibitor in patients with autoimmune diseases: case report and literature review.
Study on an antibody against F1F2 fragment of human factor V in a patient with Hashimoto's disease and bullous pemphigoid.
Head and Neck Neoplasms
Systemic effects of subcutaneous heparin use in otolaryngology patients.
Head Injuries, Closed
Coagulopathy in acute head injury--a study of its role as a prognostic indicator.
Hearing Loss, Sudden
[The correlation analysis of coagulation detection and blood routine parameters of sudden hearing loss].
Heart Arrest
Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation.
Development and validation of the revised injury severity classification score for severely injured patients.
Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters.
Prolonged Activated Partial Thromboplastin Time after Successful Resuscitation from Cardiac Arrest is Associated with Unfavorable Neurologic Outcome.
Heart Defects, Congenital
Pediatric patients with congenital heart disease: thrombin generation measured by calibrated automated thrombography.
Usefulness of high-concentration calcium chloride solution for correction of activated partial thromboplastin time (APTT) in patients with high-hematocrit value.
Heart Diseases
A novel risk score to predict cardiovascular complications in patients with coronavirus disease 2019 (COVID-19): A retrospective, multicenter, observational study.
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital.
Experience with heparin dosing at Christchurch Hospital.
Risk factors for increased postoperative drainage of calcaneal fractures after open reduction and internal fixation: An observational study.
Thromboembolism and resistance to activated protein C in children with underlying cardiac disease.
Heart Failure
Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
Correction to: Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.
Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients.
Hemostatic Markers in Congestive Heart Failure Dogs with Mitral Valve Disease.
Levels of vitamin K-dependent procoagulant and anticoagulant proteins in over-anticoagulated patients.
Patients' self-evaluation of symptoms, signs and compliance to therapy for heart failure surveillance: A pilot study on identification of worsening heart failure.
Procoagulant activity of purified protein derivative-stimulated pleural effusion mononuclear cells in tuberculous pleurisy.
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
Successful COMPASS, disappointing COMMANDER HF, what have we learned from these two trials?
The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
Thromboembolic Risk in the Patient with Heart Failure.
Whole blood hypercoagulability despite anticoagulation during mechanical cardiac assist.
Heart Septal Defects, Atrial
Attributable fraction for cardiac malformations.
Heart Septal Defects, Ventricular
Attributable fraction for cardiac malformations.
HELLP Syndrome
Disseminated intravascular coagulation complicating HELLP syndrome: perioperative management.
Hemangioma
Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal.
Hemangioma of the radius associated with Kasabach-Merritt syndrome: case report and literature review.
[Peculiar features of the coagulation, fibrinolytic, and anticoagulation systems of blood in the patients presenting with vascular ENT tumours].
[Refractory kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: clinical analysis of 10 cases].
Hemangiosarcoma
Platelet function in dogs treated for lymphoma and hemangiosarcoma and supplemented with dietary n-3 fatty acids.
Hemarthrosis
Acquired Factor VIII Inhibitors: Three Cases.
Rare coagulation disorders.
Replacement therapy for congenital Factor X deficiency.
[Decreased Quick percentage, acquired factor X deficiency, hemarthrosis and ecchymosis: amyloidosis]
[Hemarthrosis disclosing factor X deficiency in primary amyloidosis]
Hematologic Diseases
Clinical factors and biomarkers predicting outcome in patients with immune-mediated thrombotic thrombocytopenic purpura.
Viscoelastic testing in oncology patients (including for the diagnosis of fibrinolysis): Review of existing evidence, technology comparison, and clinical utility.
[Behavior of the Biggs-Douglas thromboplastin generation test in various blood diseases in children.]
[Hemorrhagic diathesis in patients with malignant neoplasms (author's transl)]
Hematologic Neoplasms
[Correlation of coagulation indicators with inflammatory markers for sepsis in the patients with hematological malignancies].
Hematoma, Subdural
Chronic peritoneal dialysis in a patient with primary amyloidosis, renal failure, and factor X deficiency.
Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban): a challenging management.
Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis.
Predictors of 30-Day Mortality in Traumatic Brain-Injured Patients after Primary Decompressive Craniectomy.
Spontaneous thoracic spinal subdural hematoma associated with apixaban therapy.
[The relationship between coagulation time and bilateral occurrence in chronic subdural hematoma]
Hematoma, Subdural, Chronic
Factor X deficiency presenting with bilateral chronic subdural hematoma.
Hematoma, Subdural, Intracranial
Spontaneous thoracic spinal subdural hematoma associated with apixaban therapy.
Hematuria
A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X.
Acquired Hemophilia A: A Potentially Fatal Bleeding Disorder.
Brodifacoum-Laced Synthetic Marijuana Toxicity: A Fight Against Time.
Convulsive status epilepticus as the initial presentation of superwarfarin poisoning: a case report.
Development of cephradine-induced acquired factor v inhibitors: a case report.
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Prekallikrein deficiency in a dog.
Rare coagulation disorders.
Renal hemorrhage caused by acquired inhibitors to coagulation factors VIII and V in a hemodialysis patient.
[Crimean-Congo hemorrhagic fever]
Hemoglobinuria
Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.
[Presence of lupus-type anticoagulant, in systemic lupus erythematosus and other clinical entities]
[Thromboplastin formation characteristics in paroxysmal nocturnal hemoglobinuria]
Hemoglobinuria, Paroxysmal
Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.
[Presence of lupus-type anticoagulant, in systemic lupus erythematosus and other clinical entities]
[Thromboplastin formation characteristics in paroxysmal nocturnal hemoglobinuria]
Hemoperitoneum
Corpus luteum hemorrhage: rare complication of congenital and acquired coagulation abnormalities.
Replacement therapy for congenital Factor X deficiency.
Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency.
Hemophilia A
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
A cell-based model of coagulation and the role of factor VIIa.
A diagnosis of mild hemophilia A made by massive intraabdominal bleeding in a 13-year-old boy.
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A.
A perioperative uncontrollable bleeding in an elderly patient with acquired hemophilia A: a case report.
A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.
A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.
A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.
Acquired haemophilia A in a patient with breast cancer and lung carcinoma: a case report and literature review.
Acquired Haemophilia A in Association with Influenza A and Urinary Tract Infection.
Acquired haemophilia complicated with gastrointestinal bleeding and spontaneous iliopsoas muscle haematoma in a woman with chronic C hepatitis under treatment with pegylated IFN alpha 2a and ribavirin.
Acquired haemophilia syndrome: pathophysiology and therapy.
Acquired hemophilia A associated with therapeutic cupping.
Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment.
Acquired Hemophilia A.
Acquired hemophilia A.
Acquired Hemophilia A.
Acquired Hemophilia A: A Rare but Potentially Fatal Bleeding Disorder.
Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.
Activated partial thromboplastin time. A multicenter evaluation of 11 reagents in the screening of mild haemophilia A.
Activated ppsb in the treatment of a patient with haemophilia and antibodies to factor VIII.
Acute onset dysphagia associated with an intramural oesophageal haematoma in acquired haemophilia.
An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform.
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant.
Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.
Barriers to effective diagnosis and management of a bleeding patient with undiagnosed bleeding disorder across multiple specialties: results of a quantitative case-based survey.
Bedside measurement of factor VIII:C activity in individuals with hemophilia A.
Bioengineered factor Xa as a potential new strategy for hemophilia therapy.
Bioengineering factor Xa to treat bleeding.
Bone haemophilic pseudotumour of the ulna: A rare complication of haemophilia in a dog.
Bullous pemphigoid associated with acquired hemophilia a: a rare association of autoimmune disease.
Characteristics and thrombogenicity of factor IX concentrate.
Christmas disease: diagnosis and management of a haemorrhagic diathesis following dentofacial trauma.
Clinical audit of inherited bleeding disorders in a developing country.
Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - Phase I trial.
Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
Clotting defect in hemophilia; deficiency in a plasma factor required for thromboplastin liberation from platelets.
Combined congenital deficiency of factor V and factor VIII. Report of a further case with some considerations on the hetereditary transmission of this disorder.
Combined deficiency of factor V and factor VIII. A report of another case.
Comparing Safety and Efficacy of Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Hemophiliacs with Non-Valvular Atrial Fibrillation.
Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources.
Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.
Congenital hemophilia A diagnosed with postoperative hemorrhage after thyroidectomy for papillary thyroid carcinoma: a case report.
Current laboratory practices in the diagnosis and management of haemophilia: a global assessment.
Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.
Determination of normal values using an automated coagulation timer for activated coagulation time and its application in dogs with hemophilia.
Development of a World Federation of Hemophilia External Quality Assessment Scheme: results of a pilot study.
Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis.
Dr Leandro Tocantins's inhibitor theory of hemophilia and factor X: reply.
Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.
Efficacy of therapeutic plasma exchange in a patient with coagulation inhibitors (acquired haemophilia A) - A case report.
Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery.
Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII.
Factor VII and haemostasis.
Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: Mode of its action.
Factor VIII inhibitors. Laboratory diagnosis of inhibitors.
Factor X deficiency and hemophilia A : occurrence of two different coagulation defects in a family.
FEIBA: mode of action.
FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
Genetic variants of haemophilia B detected by immunoradiometric assay: implications for prenatal diagnosis.
Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex.
Haemophilia A: molecular insights.
Haemophilia B: from molecular diagnosis to gene therapy.
Hemophilia and hemophilia-like diseases caused by deficiencies in plasma thromboplastin factors: anti-hemophilic globulin (AHG), plasma thromboplastin component (PTC) and plasma thromboplastin antecedent (PTA).
Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor.
Hemophilia BM in a female.
Hemophilia presenting as recurrent ocular hemorrhage.
Hemophilia presenting with intracranial hemorrhage. An approach to the infant with intracranial bleeding and coagulopathy.
Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia.
Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent.
Identification of de novo deletion in the factor VIII gene by MLPA technique in two girls with isolated factor VIII deficiency.
Identification of patients with congenital hemophilia in a large electronic health record database.
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
In vitro detection of mild inhibitors to factor VIII in hemophilia.
In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia.
Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma.
Intracranial haemorrhage in patients with congenital haemostatic defects.
Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges.
Laboratory diagnosis of hereditary bleeding disorders: external quality assessment.
Laboratory performance of haemophilia centres in developing countries: 3 years' experience of the World Federation of Hemophilia External Quality Assessment Scheme.
Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Mild Hemophilia A Diagnosed in a 55-year-old Patient after Pancreatoduodenectomy for Carcinoma of the Papilla of Vater.
Mild hemophilia A presaged by recurrent postoperative hemorrhagic complications in an elderly patient.
Myelofibrosis and acquired hemophilia A: a case report.
Next Generation Antibody Therapeutics Using Bispecific Antibody Technology.
Normalization of the haemostatic plugs of dogs with haemophilia A (factor VIII deficiency) following the infusion of a combination of factor Xa and phosphatidylcholine/phosphatidylserine vesicles.
Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.
Observations on hemophilia, parahemophilia, and coexistent hemophilia and parahemophilia; alterations in the platelets and the thromboplastin generation test.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate).
Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.
PARTIAL THROMBOPLASTIN TIME TEST WITH KAOLIN. NORMAL RANGE AND MODIFICATIONS FOR THE DIAGNOSIS OF HAEMOPHILIA AND CHRISTMAS DISEASE.
Partial thromboplastin time test with kaolin: diagnosis of haemophilia and Christmas disease without natural reference plasmas.
Partial thromboplastin time test--proposed performance guidelines. ICSH Panel on the PTT.
Performance guidelines for the partial thromboplastin time test.
Pharmacokinetics, distribution, and excretion of (125)I-labeled human plasma-derived-FVIIa and -FX with MC710 (FVIIa/FX mixture) in rats.
Plasma thromboplastin component (PTC) deficiency; a new disease resembling hemophilia.
PLASMA THROMBOPLASTIN GENERATION BLOCKING ANTICOAGULANT IN HEMOPHILIA. CLINICOPATHOLOGIC STUDY OF A REFRACTORY CASE.
Problems involved in grading the severity of hemophilia by test results.
Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant.
Rapid decrease in high titer of factor VIII inhibitors upon immunosuppressive treatment in severe postpartum acquired hemophilia A.
Recombinant Factor VIIa.
Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre.
Reversible acylation of factor Xa as a potential therapy for hemophilia.
Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies: comment.
Screening and diagnosis of coagulation disorders.
Simultaneous deep venous thrombosis and acquired factor VIII inhibitor.
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
Structure and function of factor IX: defects in haemophilia B.
Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Surface-dependent reactions of the vitamin K-dependent enzyme complexes.
The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
The diagnosis of mild haemophilia by the partial thromboplastin time test. WFH/ICTH study of the Manchester method.
The ICTH/WFH study of the partial thromboplastin time in mild haemophilia.
The kaolin partial thromboplastin time (PTT) test: the normal value in 150 healthy chinese and the usefulness in the diagnosis and management of coagulopathies especially hemophilia.
The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
THE PTT TEST: PARTIAL THROMBOPLASTIN TIME. II. ITS USEFULNESS IN THE LABORATORY CONTROL OF PLASMA THERAPY IN HEMOPHILIA.
The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).
Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII.
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas.
Thromboplastin generation with particular reference to haemophilia.
Thromboplastin in hemophilia.
Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.
Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients.
Treatment for abdominal aortic aneurysm in a patient with hemophilia A: a case report and review of the literature.
Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review.
Unusual Initial Manifestation of Acquired Hemophilia A: A Normal Activated Partial Thromboplastin Time, Intramuscular Hematoma and Cerebral Hemorrhage.
Use of purified prothrombin in the study of hemophilia and plasma thromboplastin component (PTC) deficiency.
Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk.
Verification of the guidelines for lupus anticoagulant detection: usefulness of index for circulating anticoagulant in APTT mixing test.
[A Pediatric Case of Acquired Hemophilia A: The Usefulness of the Activated Partial Thromboplastin Time (APTT) Cross-Mixing Test for Early Diagnosis].
[A surgical case of subdural hematoma with hemophilia A]
[Acquired hemophilia A associated with chronic myelomonocytic leukemia successfully treated by rituximab and azacitidine].
[Acquired hemophilia A complicated by dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid].
[Attempted retarded therapy with subcutaneous implantation of thromboplastin in a case of sporadic hemophilia.]
[Case of hemophilia caused by deficiency of plasma thromboplastin component, or hemophilia B.]
[Case of sporadic hemophilia caused by deficiency of plasma thromboplastin antecedent and plasma thromboplastin component.]
[Cerebromeningeal hemorrhages and their sequelae in congenital deficiencies of plasma hemostasis factors. Apropos of a case of Stuart factor deficiency with early cerebromengeal hemorrhage leading to hydrocephalus with considerable psychomotor retardation]
[Clinical analysis and laboratory findings in a patient with acquired hemophilia a.]
[Clinical efficacy of desmopressin in the treatment of mild hemophilia A in children].
[Coagulopathy with autoantibodies to blood-clotting factors: overview and laboratory diagnosis]
[Detection of carriers of hemophilia B]
[Diagnostic value of the thromboplastin generation test in hemophilia; clinical observations.]
[Hemophilia B in a mixed breed male dog: treatment of a hemorrhagic crisis with fresh frozen plasma]
[Hemophilia.]
[Individualization of a third plasmatic factor of thromboplastin (plasma thromboplastin antecedent) the deficiency of which causes a hemorrhagic disease similar to hemophilia.]
[Infective morbidity of replacement therapy in congenital coagulation deficiencies and its effects on demand of coagulation factors]
[Ischemic colitis following the treatment of acute hemorrhage in a patient with acquired hemophilia A]
[Mixing test for prolonged clotting time: clinical availability and problems]
[Newly developed method by the use of factor Y assay for the detection of the lupus anticoagulant]
[Partial thromboplastin time in the diagnosis and therapeutic control of hemophilia]
[Primary myelofibrosis complicated by acquired hemophilia A and subsequent development of acute myeloid leukemia].
[Problem of hemophilia from the standpoint of tissue thrombokinase.]
[Radical prostatectomy in a patient with hemophilia B]
[Studies on a new hemorrhagic diseases similar to hemophilia; plasma thromboplastin component deficiency.]
[The antiphospholipid syndrome during chronic lymphatic leukemia. An association with anti-factor VIII antibodies]
[The effect of factor VIII:C activity on the activated partial thromboplastin time (aPTT) in the dog. Adaptation of the aPTT as a screening test for canine hemophilia A?]
[Trial therapy of sporadic hemophilia by implant of thromboplastin tablets.]
Hemophilia B
A Candidate Activation Pathway for Coagulation Factor VII.
A diagnostic challenge: mild hemophilia B with normal activated partial thromboplastin time.
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
Advances in gene therapy using factor VIIa in hemophilia.
Aminoglycoside suppression of nonsense mutations in severe hemophilia.
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Christmas disease: diagnosis and management of a haemorrhagic diathesis following dentofacial trauma.
Christmas disease; report of a case of severe bleeding disease showing a failure to form intrinsic thromboplastin.
Clinical audit of inherited bleeding disorders in a developing country.
Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high-expressing human factor IX plasmid.
Current laboratory practices in the diagnosis and management of haemophilia: a global assessment.
Deuterohemophilia: plasma thromboplastin factor B deficiency: plasma thromboplastin component (PTC) deficiency, Christmas disease, hemophilia B.
Fatal case of congenital plasma thromboplastin component deficiency: failure of response to therapy in Christmas disease.
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX.
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.
Mild haemophilia B from a novel missense mutation Ser350Ala of the F9 gene.
Missense mutations and evolutionary conservation of amino acids: evidence that many of the amino acids in factor IX function as "spacer" elements.
No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
Normal activated partial thromboplastin time in Chinese patients with mild hemophilia B.
Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.
PARTIAL THROMBOPLASTIN TIME TEST WITH KAOLIN. NORMAL RANGE AND MODIFICATIONS FOR THE DIAGNOSIS OF HAEMOPHILIA AND CHRISTMAS DISEASE.
Partial thromboplastin time test with kaolin: diagnosis of haemophilia and Christmas disease without natural reference plasmas.
Plasma thromboplastin component deficiency --Christmas disease: a report of 3 cases.
Plasma thromboplastin component deficiency in the Ehlers-Danlos syndrome.
Plasma thromboplastin component deficiency. I. Studies on its inheritance and therapy.
Prevalence of HIV infection in a cohort of patients with congenital coagulation defects of the prothrombin complex factors.
Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report.
Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Repeated Diffuse Alveolar Hemorrhage in a Patient with Hemophilia B.
Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.
Spontaneous thoracolumbar hematomyelia secondary to hemophilia B in a cat.
Variable manifestations of plasma thromboplastin component deficiency.
[Case of Christmas disease; plasma thromboplastin component deficiency, deuterohemophilia.]
[Case of hemophilia caused by deficiency of plasma thromboplastin component, or hemophilia B.]
[Detection of carriers of hemophilia B]
[Detection of Factor IX gene Mutation in Paitients with Hemophilia B by DNA Sequencing.]
[Infective morbidity of replacement therapy in congenital coagulation deficiencies and its effects on demand of coagulation factors]
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
[Studies on a new hemorrhagic diseases similar to hemophilia; plasma thromboplastin component deficiency.]
[Studies on hemorrhagic disease due to plasma thromboplastin component deficiency.]
Hemoptysis
Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome.
Pulmonary hemorrhage after intracoronary stent placement.
[Acquired factor V inhibitors in a polytraumatized patient]
Hemorrhagic Disorders
Another patient with a congenital hemorrhagic disorder intermediate between factor X and factor VII deficiency.
Autoimmune Coagulation Factor X Deficiency as a Rare Acquired Hemorrhagic Disorder: A Literature Review.
Evaluation of thromboelastography in two factor XII-deficient cats.
Hemorrhagic diathesis caused by factor X deficiency in a child with thymic cyst.
Hemorrhagic diathesis due to PTC (plasma thromboplastin component) deficiency.
Hemorrhagic, Hemostatic, and Thromboelastometric Disorders in 35 Dogs with a Clinical Diagnosis of Leptospirosis: A Prospective Study.
Prothrombin level and activity in the abnormal factor X (factor X Friuli) hemorrhagic disorder.
Simultaneous deep venous thrombosis and acquired factor VIII inhibitor.
[ACQUIRED HEMORRHAGIC DIATHESIS CAUSED BY ISOLATED FACTOR X DEFICIENCY.]
[Case of hemorrhagic diathesis following prothrombase deficiency.]
[Clinical studies on platelet function. II. Thromboplastin generation activity of the platelets in various hemorrhagic diathesis and blood disorders.]
[Coagulation and fibrinolysis associated with contact phase in plasma with high molecular weight kininogen deficiency]
[Congenital blood coagulation factor X deficiency. Successful result of the use prothrombin concentrated complex in the control of ++cesarean section hemorrhage in 2 pregnancies]
[Familial hemorrhagic diathesis caused by factor X deficiency]
[Grave transitory hemorrhagic diathesis in pregnancy; thrombokinase intoxication caused by premature detachment of the placenta in familial purpura simplex.]
[Hemato-oncological diseases.]
[Hemorrhagic diathesis due to anticoagulant inhibiting the formation or action of thromboplastin; concerning a personal case observed during chronic evolutive polyarthritis.]
[Remission of a non-haemophilic patient with acquired factor VIII inhibitor treated with infusion of factor VIII and corticosteroid]
[The significance of thrombokinase in the pathogenesis, diagnosis and therapy of hemorrhagic diatheses.]
Hemorrhagic Stroke
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long?term prevention of thromboembolic complications in patients with atrial fibrillation?
Apolipoprotein E genotype, coagulation, and survival following acute stroke.
Imaging of Hemorrhagic Stroke.
Licorice Root Associated With Intracranial Hemorrhagic Stroke and Cerebral Microbleeds.
Post-stroke seizure-Do the locations, types and managements of stroke matter?
Rat models of cardiometabolic diseases: baseline clinical chemistries, and rationale for their use in examining air pollution health effects.
Hemostatic Disorders
Designing a point-of-care program for coagulation testing.
Factor XI deficiency in an Ashkenazi Jewish child, causing severe postoperative hemorrhage.
Indications for plasma in massive transfusion.
Peripherally inserted central catheter placement in patients with coagulation disorders: A retrospective analysis.
Platelet dysfunction and coagulopathy in intraventricular hemorrhage in the premature infant.
Relative value of diagnostic studies for von Willebrand disease.
Hemothorax
An apparent case of brodifacoum toxicosis in a whelping dog.
Hepatic Encephalopathy
Derivation and validation of prognostic models for predicting survival outcomes in Acute-on-chronic liver failure (ACLF) patients.
Hepatic Infarction
In vivo diagnosis of massive hepatic infarction by computed tomography.
Hepatitis
Acquired haemophilia complicated with gastrointestinal bleeding and spontaneous iliopsoas muscle haematoma in a woman with chronic C hepatitis under treatment with pegylated IFN alpha 2a and ribavirin.
Association of mouse fibrinogen-like protein with murine hepatitis virus-induced prothrombinase activity.
Circulating anticoagulant associated with chronic active hepatitis.
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis.
Does Hepatitis B Virus Affect the Coagulation Parameters for HBV-Related Decompensated Cirrhosis?
Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection.
Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B.
Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase.
Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha.
Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity.
Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis.
Mouse hepatitis virus-3 induced prothrombinase (Fgl2) maps to proximal chromosome 5.
Murine hepatitis virus strain 3 induces the macrophage prothrombinase fgl-2 through p38 mitogen-activated protein kinase activation.
Peliosis hepatis mimicking hepatic malignancy: A case report.
Reactive oxygen intermediates and serum antioxidative system in patients with chronic C hepatitis treated with IFN-alpha and thymus factor X.
Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response.
The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis.
The nucleocapsid protein of murine hepatitis virus type 3 induces transcription of the novel fgl2 prothrombinase gene.
Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
[Anaesthesia for cesarean section in a patient with acute viral hepatitis (author's transl)]
[Establishment of pig acute liver failure model and the role of pig fibrinogen-like protein 2.]
[Hemostatic changes in the course of different chronic hepatopathies]
[Predictors of massive blood transfusion in liver transplantation for patients with benign end-stage liver disease]
[The diagnostic value of wedged hepatic vein pressure in chronic hepatitis and liver cirrhosis (author's transl)]
Hepatitis A
Dual interference of novel gene mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice.
Homogeneous hepatitis A virus particles. Proteolytic release of the assembly signal 2A from procapsids by factor Xa.
Novel mfgl2 Antisense Plasmid Inhibits Murine fgl2 Expression and Ameliorates Murine Hepatitis Virus Type 3-Induced Fulminant Hepatitis in BALB/cJ Mice.
Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice.
Hepatitis B
A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer.
Peliosis hepatis mimicking hepatic malignancy: A case report.
Post-Operative Hemorrhage After Liver Transplantation: Risk Factors and Long-Term Outcome.
Procoagulant versus anticoagulant factors in cirrhotic patients.
Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection.
Treatment with thymic extract TFX for chronic active hepatitis B.
Hepatitis B, Chronic
Thymic factor X treatment of chronic hepatitis B.
Hepatitis C
Impact of sustained virus elimination on natural anticoagulant activity in patients with chronic viral hepatitis C.
Procoagulant versus anticoagulant factors in cirrhotic patients.
Searching for discrimination rules in protease proteolytic cleavage activity using genetic programming with a min-max scoring function.
Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy.
Hepatitis E
Activities of Thrombin and Factor Xa Are Essential for Replication of Hepatitis E Virus and Are Possibly Implicated in ORF1 Polyprotein Processing.
Hepatitis, Autoimmune
Autoimmune hepatitis associated with the antiphospholipid syndrome.
Hepatitis, Chronic
Circulating anticoagulant associated with chronic active hepatitis.
Coagulation disorders in dogs with hepatic disease.
Treatment with thymic extract TFX for chronic active hepatitis B.
[The diagnostic value of wedged hepatic vein pressure in chronic hepatitis and liver cirrhosis (author's transl)]
Hepatitis, Viral, Human
The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis.
Hepatomegaly
Acquired isolated factor X deficiency associated with systemic amyloidosis. Case report and review of literature.
Non-alcoholic fatty liver disease in the Philippines: comparable with other nations?
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue.
[Contribution to the aetiology of "reversible hepatic dysfunction" (Stauffer's syndrome) associated with renal tumours]
[Crimean-Congo hemorrhagic fever]
Hernias, Diaphragmatic, Congenital
Development of the Pediatric Extracorporeal Membrane Oxygenation Prediction Model for Risk-Adjusting Mortality.
Herpes Simplex
Effects of viral activation of the vessel wall on inflammation and thrombosis.
Herpes simplex virus type 1-encoded glycoprotein C enhances coagulation factor VIIa activity on the virus.
Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression.
Peptidomimetic design.
Structurally homologous ligand binding of integrin Mac-1 and viral glycoprotein C receptors.
Herpes Zoster
Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity.
Histiocytoma, Benign Fibrous
Multiple eruptive dermatofibromas with CD34+ cells in a patient with hypertriglyceridemia.
HIV Infections
Hemostatic alterations during human immunodeficiency virus infection: a review.
Identification of two different coagulation phenotypes in people living with HIV with undetectable viral replication.
Hodgkin Disease
A Prolonged Activated Partial Thromboplastin Time in a Child With Hodgkin Lymphoma.
Protease receptors in Hodgkin's disease: expression of the factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells.
Hydatidiform Mole
Coagulation and fibrinolysis in intact hydatidiform molar pregnancy.
Effect of hydatidiform molar vesicular fluid on blood coagulation.
Hydrocephalus
Coronavirus disease 2019 (COVID-19) can predispose young to Intracerebral hemorrhage: a retrospective observational study.
Hunter syndrome complicated by hydrocephalus and an endogenous anticoagulant.
[Cerebromeningeal hemorrhages and their sequelae in congenital deficiencies of plasma hemostasis factors. Apropos of a case of Stuart factor deficiency with early cerebromengeal hemorrhage leading to hydrocephalus with considerable psychomotor retardation]
Hypercholesterolemia
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Hemostatic effects of simvastatin in subjects with impaired glucose tolerance.
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
Hypercholesteremia and pulmonary arterial lesions produced by thromboplastin.
Inhibition of thrombin attenuates stenosis after arterial injury in minipigs.
Hyperemia
Macrophage stimulation and the inflammatory response to asbestos.
[Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review]
Hypergammaglobulinemia
Reactive plasmacytosis mimicking multiple myeloma associated with SFTS virus infection: a report of two cases and literature review.
[Abdominal inflammatory pseudotumor (plasma cell granuloma) with anemia and hypergammaglobulinemia]
Hyperglycemia
Assessment of acute moderate hyperglycemia on traditional and thromboelastometry coagulation parameters in healthy adult horses.
Comparison of the hypoglycemic and antithrombotic (anticoagulant) actions of whole bovine and camel milk in streptozotocin-induced diabetes mellitus in rats.
Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
Malignant histiocytosis in a cat.
Pyogenic liver abscess. An audit of experience over the past decade.
Why are acute ischemic stroke patients not receiving thrombolysis in a telestroke network?
Hyperhomocysteinemia
[A case report of syphilitic uveitis and deafness.]
Hyperinsulinism
Hyperglycemia-induced hyperinsulinemia decreases maternal and fetal plasma protein C concentration during ovine gestation.
Hyperkalemia
[Heatstroke in dogs in southern Germany. A retrospective study over a 5.5-year period].
Hyperlactatemia
Pulsus alternans in a critically ill dog hospitalized for xylitol toxicity.
Hyperlipidemias
Hyperlipidemia, hypercoagulability, and accelerated thrombosis: studies in congenitally hyperlipidemic rats and in rats and monkeys with induced hyperlipidemia.
Impaired and exhausted platelets in modified generalized Shwartzman reaction: an analogue of hemolytic uremic syndrome associated with endotoxemia.
[Clinical characteristics and outcomes of cerebral venous sinus thrombosis during pregnancy and puerperium].
[Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy]
[Hemostatic changes during pregnancy in reference to hyperlipidemia]
Hyperlipoproteinemia Type II
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
Hypersensitivity
A risk-benefit assessment of aprotinin in cardiac surgical procedures.
Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.
Hypersensitivity reaction after administration of rivaroxaban (Xarelto).
Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs.
Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report.
Hypertension
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Association of Platelets and White Blood Cells Subtypes with Trauma Patients' Mortality Outcome in the Intensive Care Unit.
Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients.
Cardioprotective and antihypertensive effects of Enicostemma littorale Blume extract in fructose-fed rats.
Clinical Characteristics and Abnormal Parameters Evolution in Patients With Novel Coronavirus Infection: A Case Series of 272 Cases in Guangzhou.
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.
Evaluation of prothrombin time and activated partial thromboplastin time in hypertensive patients attending a tertiary hospital in calabar, Nigeria.
Hematological and Inflammatory Parameters to Predict the Prognosis in COVID-19.
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: association with cardiovascular events.
Intracerebral hemorrhage after liver transplantation.
Maternal serum nitric oxide levels associated with biochemical and clinical parameters in hypertension in pregnancy.
Perioperative Hidden Blood Loss in Elderly Cervical Spondylosis Patients With Anterior Cervical Discectomy Fusion and Influencing Factors.
Peripheral vascular disease in patients with systemic lupus erythematosus.
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.
Prognosis of spontaneous intracerebral hemorrhage in hemodialysis patients.
Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy.
Risk Factors for Decompression Retinopathy After Glaucoma Surgery.
Risk factors for increased postoperative drainage of calcaneal fractures after open reduction and internal fixation: An observational study.
Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
Selected Blood Inflammatory and Metabolic Parameters Predicted Successive Bilateral Sudden Sensorineural Hearing Loss.
The FGL2 prothrombinase contributes to the pathological process of experimental pulmonary hypertension.
[Cerebral hemorrhage complicating early anticoagulant treatment of transient ischemic attacks]
[Risk factors of deep venous thrombosis associated with peripherally inserted central venous catheter in upper extremity in ICU].
Hypertension, Portal
Andexanet Alfa Use for Small Bowel Obstruction Patient With History of Sugiura Procedure.
Disordered hemostasis in extrahepatic portal hypertension.
Machine Learning for the Prediction of Red Blood Cell Transfusion in Patients During or After Liver Transplantation Surgery.
Portal hypertension and gastric lesions in the rat.
Hypertension, Pulmonary
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
Effect of heparin and warfarin on chronic hypoxic pulmonary hypertension and vascular remodeling in the guinea pig.
Perioperative anticoagulation management in antiphospholipid syndrome.
The FGL2 prothrombinase contributes to the pathological process of experimental pulmonary hypertension.
Hyperthyroidism
Acute myocardial infarction and subclinical hyperthyroidism without significant coronary stenoses.
Atrial fibrillation and acute myocardial infarction without significant coronary stenoses associated with subclinical hyperthyroidism and erythrocytosis.
Atrial fibrillation associated with exogenous subclinical hyperthyroidism, changing axis deviation, troponin-I positive and without acute coronary syndrome.
Atrial fibrillation associated with exogenous subclinical hyperthyroidism.
Atrial fibrillation associated with subclinical hyperthyroidism.
Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Changing axis deviation and paroxysmal atrial flutter associated with subclinical hyperthyroidism.
Coagulation parameters in hyperthyroid cats before and after radioiodine treatment compared with healthy controls.
Coagulation profiles in hypothyroid and hyperthyroid female patients in Sudan.
Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study.
Hashitoxicosis with pericardial effusion.
New Interfaces of Thyroid Hormone Actions With Blood Coagulation and Thrombosis.
Paroxysmal atrial fibrillation during acute myocardial infarction associated with subclinical hyperthyroidism, severe three vessels coronary artery disease and elevation of prostate-specific antigen after TURP.
Paroxysmal ventricular tachycardia and paroxysmal atrial fibrillation associated with subclinical hyperthyroidism, chronic renal failure and elevation of prostate-specific antigen during acute myocardial infarction.
Pericardial effusion associated with subclinical hypothyroidism.
Prothrombin, activated partial thromboplastin, and proteins induced by vitamin K absence or antagonists clotting times in 20 hyperthyroid cats before and after methimazole treatment.
Recurrent acute pulmonary embolism and paroxysmal atrial fibrillation associated with subclinical hyperthyroidism.
["Lupus anticoagulant" in immune hyperthyroidism]
Hypertriglyceridemia
Cardioprotective and antihypertensive effects of Enicostemma littorale Blume extract in fructose-fed rats.
Hypoalbuminemia
Accidental fatal aflatoxicosis due to contaminated commercial diet in 50 dogs.
Acute fatty liver of pregnancy: an experience in diagnosis and management of eight cases.
Acute fatty liver of pregnancy: diagnosis and management of 8 cases.
Celiac disease with diffuse cutaneous vitamin K-deficiency bleeding.
Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience.
Profile of dengue patients admitted to a tertiary care hospital in Mumbai.
Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection.
[Acute fatty liver in pregnancy: a clinicopathologic study]
Hypocalcemia
Association between hypocalcemia and rivaroxaban in coagulation disorders: a case report.
Hypocalcemia in trauma patients receiving massive transfusion.
Hypoglycemia
Adrenal insufficiency complicated with antiphospholipid syndrome (APS).
Antithrombin-III treatment limits disseminated intravascular coagulation in endotoxemia.
Heatstroke: clinical signs, diagnosis, treatment, and prognosis.
Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia.
Mortality rate and prognostic factors for dogs with severe anaphylaxis: 67 cases (2016-2018).
Hypogonadism
Blood coagulation and fibrinolysis in male patients with hypogonadotropic hypogonadism: plasma factor V and factor X activities increase in hypogonadotropic hypogonadism.
Hypokalemia
Evaluation of prognostic factors in the surgical treatment of adrenal gland tumors in dogs: 41 cases (1999-2005).
Incidence and risk of adverse perioperative events among surgical patients taking traditional Chinese herbal medicines.
Prognostic indicators for canine monocytic ehrlichiosis.
[Analysis of clinical characteristics of the 12 cases of neonatal dengue fever in Guangzhou in 2014 and literatures review].
Hyponatremia
Adrenal insufficiency complicated with antiphospholipid syndrome (APS).
Analysis of clinical features and early warning indicators of death from severe fever with thrombocytopenia syndrome.
Complications and 30-day Outcomes Associated With Venous Thromboembolism in the Pediatric Orthopaedic Surgical Population.
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults.
Profile of dengue patients admitted to a tertiary care hospital in Mumbai.
Hypoproteinemia
Deficiency of the contact phase of intrinsic coagulation in a horse.
Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
Hypoprothrombinemias
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Lupus anticoagulant hypoprothrombinemia syndrome associated with bilateral adrenal haemorrhage in a child: early diagnosis and intervention.
Lupus anticoagulant-hypoprothrombinemia syndrome and immunoglobulin-A vasculitis: a report of Japanese sibling cases and review of the literature.
Pulmonary hemorrhage in pediatric lupus anticoagulant hypoprothrombinemia syndrome.
Rare coagulation disorders.
Thrombotic and hemorrhagic complications in children with the lupus anticoagulant.
Hypotension
A new prognostic scoring system for meningococcal septic shock in children. Comparison with three other scoring systems.
Acquired factor VIII deficiency presenting with compartment syndrome.
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Disseminated intravascular coagulation.
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Factor Xa-evoked relaxation in rat aorta: involvement of PAR-2.
Factors associated with the severity of hypertriglyceridemia induced acute pancreatitis.
Human umbilical cord blood-derived CD34+ cells cause attenuation of multiorgan dysfunction during experimental heatstroke.
Hyperbaric oxygen improves survival in heatstroke rats by reducing multiorgan dysfunction and brain oxidative stress.
Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling.
Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters.
Predictors of 30-Day Mortality in Traumatic Brain-Injured Patients after Primary Decompressive Craniectomy.
Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide.
Studies of the coagulation system and blood pressure during experimental Bolivian hemorrhagic fever in rhesus monkeys.
Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
[Crimean-Congo hemorrhagic fever]
Hypothyroidism
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Coagulation and fibrinolysis in thyroid disease.
Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study.
Evaluation of the respective influence of thyroid hormones and TSH on blood coagulation parameters after total thyroidectomy.
Idiopathic Pulmonary Fibrosis
Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity.
Pirfenidone inhibits p38-mediated generation of procoagulant microparticles by human alveolar epithelial cells.
Ileus
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
In vivo diagnosis of massive hepatic infarction by computed tomography.
Immunoglobulin Light-chain Amyloidosis
Acquired combined factor X and XII deficiency with isolated bleeding complications in a patient with AL amyloidosis.
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
Acquired factor X deficiency developed four years after autologous transplantation in a patient with multiple myeloma associated with systemic AL amyloidosis.
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis.
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency.
Characterization of amyloid deposits and P component from a patient with factor X deficiency reveals proteins derived from a lambda VI light chain.
Chronic peritoneal dialysis in a patient with primary amyloidosis, renal failure, and factor X deficiency.
Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy.
Factor X deficiency in primary amyloidosis.
Factor X deficiency in primary amyloidosis: resolution after splenectomy.
Factor X deficiency: An uncommon presentation of AL amyloidosis.
Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses.
Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.
Importance of pharmacokinetic studies in the management of acquired factor X deficiency.
Primary amyloidosis with severe nephrotic syndrome and acquired factor X deficiency.
Resolution of factor X deficiency in primary amyloidosis following splenectomy.
Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.
Splenectomy in an uraemic patient with acquired factor X deficiency due to AL amyloidosis.
Splenectomy in plasma cell dyscrasias: a review of the clinical practice.
Spontaneous perinephric hematoma due to acquired factor X deficiency in AL amyloidosis.
Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
Spontaneous rupture of the spleen in AL amyloidosis.
Successful perioperative management of factor X deficiency associated with primary amyloidosis.
Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X.
Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Treatment of amyloidosis associated factor X deficiency.
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
[A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review]
[ACQUIRED FACTOR X DEFICIENCY IN A PATIENT WITH PRIMARY AMYLOIDOSIS. INJECTION OF A B.S.C. FRACTION.]
[Acquired factor X deficiency in a patient with primary amyloidosis. Injection of a coagulating fraction (C.S.B)]
[Acquired factor X deficiency in primary amyloidosis]
[Extensive subcutaneous hemorrhage complicating primary amyloidosis]
[Hemarthrosis disclosing factor X deficiency in primary amyloidosis]
[Primary amyloidosis associated to severe factor X deficiency]
[Recurrence of Waldenström macroglobulinemia accompanied by factor X deficiency].
Infarction, Middle Cerebral Artery
Early initiation of a factor Xa inhibitor can attenuate tissue repair and neurorestoration after middle cerebral artery occlusion.
Infections
A comparison of two techniques of care for indwelling arterial introducers after coronary angioplasty.
Abnormal coagulation tests obtained in the emergency department are associated with mortality in patients with suspected infection.
Acquired, transient factor X (Stuart factor) deficiency in patient with mycoplasma pneumonial infection.
Adrenal gland infection by serotype 5 adenovirus requires coagulation factors.
An analysis of potential predictors of tunneled hemodialysis catheter infection or dysfunction.
Analysis of Bacterial and Fungal Infections after Cytoreduction Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Observational Single-Centre Study.
Analysis of clinical features and early warning indicators of death from severe fever with thrombocytopenia syndrome.
Analysis of the relationship between serum amyloid protein A, procalcitonin, C-reactive protein, and peripherally inserted central catheter infection in patients with malignant tumor.
Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection.
Association of mouse fibrinogen-like protein with murine hepatitis virus-induced prothrombinase activity.
Attributable fraction for cardiac malformations.
Coagulation defect in experimental trypanosomial infection.
Coagulation factor IX mediates serotype-specific binding of species A adenoviruses to host cells.
Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components.
Comparative analysis of clinical features of SARS-CoV-2 and adenovirus infection among children.
Cutaneous histopathologic findings in 'antiphospholipid syndrome'. Correlation with disease, including human immunodeficiency virus disease.
Development of cephradine-induced acquired factor v inhibitors: a case report.
Development of the Pediatric Extracorporeal Membrane Oxygenation Prediction Model for Risk-Adjusting Mortality.
DIAGNOSING DISSEMINATED INTRAVASCULAR COAGULATION IN ACUTE INFECTION : CAN WE DO WITHOUT FDP & D-DIMER.
Diagnosis and stage-related treatment of disseminated intravascular coagulation in meningococcal infections.
Does Hepatitis B Virus Affect the Coagulation Parameters for HBV-Related Decompensated Cirrhosis?
Effect of a Quality Improvement Program to Improve Guideline Adherence and Attainment of Clinical Standards in Dialysis Care: Report of Outcomes in Year 1.
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Effects of viral activation of the vessel wall on inflammation and thrombosis.
Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium.
Evaluating the safety and efficacy of argatroban locking solution in the prevention of the dysfunction of haemodialysis central venous catheters: a study protocol for a randomized controlled trial.
Expression of factor X and its significance for the determination of paramyxovirus tropism in the chick embryo.
Factor X and its deficiency states.
Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase.
FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant.
Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection.
Hematological and coagulation profiles in dogs experimentally infected with Angiostrongylus vasorum (Baillet, 1866).
HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement.
Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism.
Hypocoagulation induced by broad-spectrum antibiotics in extensive burn patients.
Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis.
Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha.
Inhibition of Herpes Simplex Virus Type 1 Attachment and Infection by Sulfated Polyglycerols with Different Architectures.
Life-threatening bleeding tendency provoked by an acquired isolated factor X deficiency associated with respiratory infection.
Longer aPTT values in healthy children than in adults: no single cause.
Lupus Anticoagulant Positivity in Pediatric Patients With Prolonged Activated Partial Thromboplastin Time: A Single-Center Experience and Review of Literature.
Masking of retroviral envelope functions by oligomerizing polypeptide adaptors.
Modification of retroviral tropism by display of IGF-I.
Monoclonal antibody analysis of a unique macrophage procoagulant activity induced by murine hepatitis virus strain 3 infection.
Multiple roles of the coagulation protease cascade during virus infection.
Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen.
Oral Route Driven Acute Trypanosoma cruzi Infection Unravels an IL-6 Dependent Hemostatic Derangement.
PheWAS uncovers a pathological role of coagulation Factor X during Acinetobacter baumannii infection.
Plasmodium berghei: pulmonary oedema and changes in clotting and fibrinolysis during infection in mice.
Reduced CD3/TCR complex expression leads to immunosuppression during Plasmodium falciparum malaria.
Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.
Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection.
Risk factors associated with development of dengue haemorrhagic fever or dengue shock syndrome in adults in Hospital Tengku Ampuan Afzan Kuantan.
Safety of surgical tracheostomy under continued antithrombotic therapy: a retrospective cohort study.
Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
Successful Treatment of Life-threatening Bleeding Caused by Acquired Factor X Deficiency Associated with Respiratory Infection.
Systemic cancer therapy with engineered adenovirus that evades innate immunity.
Targeting host cell proteases to prevent SARS-CoV-2 invasion.
The epidemiology of acute kidney injury in critically ill patients in the Gansu Province: The EACG study.
The exploration of risk factors of concurrent bacteraemia in patients critically ill with severe dengue.
The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis.
The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis.
The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?
The phosphoproteomic responses of duck (Cairna moschata) to classical/novel duck reovirus infections in the spleen tissue.
The procoagulant envelope virus surface: contribution to enhanced infection.
Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease activated receptor 2 cofactors that enhance infection.
Trajectories of hepatic and coagulation dysfunctions related to a rapidly fatal outcome among hospitalized patients with dengue fever in Tainan, 2015.
Transient, selective factor X deficiency and acute liver failure following chest infection treated with erythromycin BP.
[Analysis of risk factors and prognosis for bleeding in very old male patients with stage 5 chronic kidney disease].
[Biological diagnosis of postoperative thrombopenia]
[Clinical significance of detection of thrombus precursor protein in severe sepsis.]
[Clinical Value Evaluation of Perioperative Prophylactic Anticoagulation Therapy for Lung Cancer Patients].
[Effect of long-term and short-term mild hypothermia in severe traumatic brain injury: a comparative study].
[Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients]
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
[Risk factors of deep venous thrombosis associated with peripherally inserted central venous catheter in upper extremity in ICU].
Infectious Mononucleosis
Transient lupus anticoagulant with a prolonged activated partial thromboplastin time secondary to cytomegalovirus-related infectious mononucleosis.
Infertility
An ex vivo evaluation of efficacy of refrigerated canine plasma.
Inflammatory Bowel Diseases
Fibrinogen-like protein 2 prothrombinase may contribute to the progression of inflammatory bowel disease by mediating immune coagulation.
Influenza, Human
A peptide-based approach to evaluate the adaptability of influenza A virus to humans based on its hemagglutinin proteolytic cleavage site.
Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China.
Expression of Factor X in BHK-21 Cells Promotes Low Pathogenic Influenza Viruses Replication.
Human influenza A viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells.
Kallikrein-related peptidases in lung diseases.
Lack of effect of influenza vaccine on warfarin anticoagulation in the elderly.
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases.
Replication of influenza B virus in chicken embryos is suppressed by exogenous aprotinin.
TGF-? Blood Levels Distinguish Between Influenza A (H1N1)pdm09 Virus Sepsis and Sepsis due to Other Forms of Community-Acquired Pneumonia.
Venous Thromboembolism Events Following Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Syndrome Coronavirus 2 Based on CT Scans.
Insulin Resistance
Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.
Is There a Tendency for Thrombosis in Gestational Diabetes Mellitus?
Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans.
Swimming, but not vitamin E, ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease.
Insulinoma
Immunohistochemical localization of factor X-like antigen in pancreatic islets and their tumours.
Intestinal Diseases
[Decrease of antithrombin III and factor Xa inhibitor as the cause of thromboembolism complications in chronic inflammatory intestinal disease]
Intestinal Volvulus
Anticoagulant activity in salivary gland extracts of black flies (Diptera: Simuliidae).
Intracranial Embolism
Hypercoagulability in acute ischemic stroke: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method.
Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation.
Preliminary Observations on the Antihypertension Action of Dabigatran Etexilate in Patients With Nonvalvular Atrial Fibrillation: A Prospective Multicenter Single-Arm Interventional Study.
Intracranial Hemorrhage, Traumatic
Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage.
Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Intracranial Hemorrhages
A new regimen for heparin use in acute coronary syndromes.
A rare cause of intracranial hemorrhage: factor X deficiency.
Acquired hemophilia first manifesting as life-threatening intracranial hemorrhage: case report.
Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
Anticoagulation therapy for atrial fibrillation.
Comparison of outcomes in patients with intracranial hemorrhage on factor Xa inhibitors versus vitamin K antagonists treated with 4-factor prothrombin complex concentrate.
Dental management of a patient with factor X deficiency.
Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices.
Genotype and phenotype correlation in intracranial hemorrhage in neonatal factor VII deficiency among Thai children.
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage : A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.
Hemorrhagic Shock after Neonatal Circumcision: Severe Congenital Factor XIII Deficiency.
Homozygous Factor X gene mutations Gly380Arg and Tyr163delAT are associated with perinatal intracranial hemorrhage.
Indirect antiplatelet effects of rivaroxaban in a patient with intracranial hemorrhage: An underappreciated coagulopathy of factor Xa inhibitors?
Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis.
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Intracranial hemorrhage and circulating coagulation inhibitor in beta-thalassemia major.
Intracranial Hemorrhage as the First Manifestation of Severe Congenital Factor X Deficiency in a 20-Month-Old Male: Case Report and Review of the Literature.
Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage.
Multiple intracranial hemorrhages at the time of a transiently prolonged activated partial thromboplastin time in an infant with congenital factor VII deficiency.
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Novel oral anticoagulant management issues for the stroke clinician.
Prevention of recurrent intracranial hemorrhage in a factor X-deficient infant.
Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis.
Prothrombin Complex Concentrates for Intracranial Hemorrhage on Factor Xa Inhibitors.
Relationship between abnormalities of coagulation and fibrinolysis and postoperative intracranial hemorrhage in head injury.
Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors.
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.
[Difference in examination of coagulation function in heparin anticoagulant therapy between point of care tests and automatic coagulation analyzer]
[Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
Intracranial Hypertension
Human umbilical cord blood-derived CD34+ cells cause attenuation of multiorgan dysfunction during experimental heatstroke.
Hyperbaric oxygen improves survival in heatstroke rats by reducing multiorgan dysfunction and brain oxidative stress.
Intracranial Thrombosis
A case of cerebral infarction associated with positive antiphospholipid antibody in a systemic lupus patient.
Development of argatroban as an anticoagulant and antithrombin agent in Japan.
Hypercoagulability in acute ischemic stroke: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method.
Ischemic Attack, Transient
Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.
Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus.
Optimal Dosing of Intravenous Unfractionated Heparin Bolus in Transient Ischemic Attack or Stroke.
Use of rivaroxaban in patients with stroke.
Ischemic Stroke
Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation.
Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.
Antiphospholipid antibody syndrome: an unusual cause of stroke in a 22-year-old female.
Apixaban decreases brain thrombin activity in a male mouse model of acute ischemic stroke.
Apixaban Inhibits Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in Rabbits.
Apolipoprotein E genotype, coagulation, and survival following acute stroke.
Association between Coagulation Function and Cerebral Microbleeds in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease.
Direct oral factor Xa inhibitors for the prevention of non-central nervous systemic embolism patients with non-valvular atrial fibrillation - a systematic review and meta-analysis.
Efficacy and Safety of Direct Factor Xa Inhibitors Versus Warfarin in Prevention of Primary and Secondary Ischemic Strokes in Non-Valvular Atrial Fibrillation: A Literature Review.
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.
Endovascular treatment in acute ischemic stroke patient on factor Xa inhibitor.
Hemostatic risk factors in ischemic stroke.
Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study.
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation.
Ischemic stroke as initial manifestation of systemic lupus erythematosus: A case report and review of the literature.
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
New thrombin and factor Xa inhibitors for primary and secondary prevention of ischaemic stroke.
Novel oral anticoagulant management issues for the stroke clinician.
Novel Oral Anticoagulants as Treatment for Vertebral Artery Dissection: Case Report.
Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.
Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH.
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
Shortened Activated Partial Thromboplastin Time Is Associated With Acute Ischemic Stroke, Stroke Severity, and Neurological Worsening.
Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
The effects of heatwaves and cold spells on patients admitted with acute ischemic stroke.
The frequency of phospholipid antibodies in an unselected stroke population.
The influence of immunoglobulin class G from blood plasma of patients with stroke on the activity of some parameters of hemostasis system.
Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism.
Why are acute ischemic stroke patients not receiving thrombolysis in a telestroke network?
Joint Diseases
[1st studies on the problem of rectal resorption of MPS in the treatment of arthroses]
Kasabach-Merritt Syndrome
Hemangioma of the radius associated with Kasabach-Merritt syndrome: case report and literature review.
Kasabach-Merritt syndrome complicating treatment of a closed femoral fracture.
Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging.
Ketosis
Haemostatic changes in diabetic coma.
Kidney Calculi
[Experience of integrated traditional Chinese and Western medicine in first case of imported Zika virus disease in China].
Kidney Diseases
Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity.
Kidney Failure, Chronic
Association of Platelets and White Blood Cells Subtypes with Trauma Patients' Mortality Outcome in the Intensive Care Unit.
Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?
CD62P and P10 as predictive markers for assessing the efficacy of hemodialysis in treating end-stage renal disease.
Effect of heparin and prostacyclin-heparin infusion on blood coagulation in haemodialysed patients.
Reversible Neurological Adverse Reaction to Apixaban.
Kidney Neoplasms
Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
[The problem of hepatic dysfunction of the diagnosis of hypernephroid kidney carcinomas (Stauffer syndrome)]
Laryngeal Neoplasms
Risk factors for acute unplanned tracheostomy during panendoscopy in HNSCC patients.
Legg-Calve-Perthes Disease
[Congenital disorders of hemostasis in children with Perthes disease]
Leishmaniasis
Evaluation of secondary haemostasis in canine leishmaniasis.
Leishmaniasis, Visceral
Hemostatic assessment of dogs associated with hepatic parasite load of Leishmania infantum chagasi.
Leprosy
An unusual factor-X inhibitor in leprosy.
Leptospirosis
Activation of the coagulation cascade in patients with leptospirosis.
Coagulation studies in leptospirosis.
Leptospira Infection Interferes with the Prothrombinase Complex Assembly during Experimental Leptospirosis.
Lethargy
Evaluation of prognostic factors in the surgical treatment of adrenal gland tumors in dogs: 41 cases (1999-2005).
The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue.
Leukemia
Acquired selective factor X deficiency in acute nonlymphocytic leukemia.
Acute Promyelocytic Leukemia-Associated Thrombosis.
Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation.
Cancer procoagulant in acute lymphoblastic leukemia.
Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemia.
Expression of the murine leukemia virus protease in fusion with maltose-binding protein in Escherichia coli.
Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII.
Latest advances from basic and clinical research in hematology.
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis?
The use of protein-DNA, chromatin immunoprecipitation, and transcriptome arrays to describe transcriptional circuits in the dehydrated male rat hypothalamus.
[Abnormality of blood coagulation indexes in patients with de novo acute leukemia and its clinical significance].
[Changes in the thromboplastin generation tests in a case of acute leukemia.]
[Isolated factor X deficiency in chronic myelomonocytic leukemia: Report of one case].
[On the presence of thromboplastin inhibitors in the blood in leukemia and their significance.]
[Thromboplastin formation at different periods of acute leukemia in children]
[Unusual pathogenetic aspects of a hemorrhagic syndrome in chronic leukemia myelosis: plasma thromboplastin component (factor IX) defect & increased fibrinolysis; 2 clinical case reports.]
Leukemia, B-Cell
[The antiphospholipid syndrome during chronic lymphatic leukemia. An association with anti-factor VIII antibodies]
Leukemia, Lymphocytic, Chronic, B-Cell
[The antiphospholipid syndrome during chronic lymphatic leukemia. An association with anti-factor VIII antibodies]
Leukemia, Myeloid, Acute
Acquired selective factor X deficiency in acute nonlymphocytic leukemia.
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
The clinical and biological correlates of coagulopathy in children with acute leukemia.
Leukemia, Myelomonocytic, Chronic
[Isolated factor X deficiency in chronic myelomonocytic leukemia: Report of one case].
Leukemia, Promyelocytic, Acute
Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation.
Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemia.
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells.
Leukocytosis
Brodifacoum-Laced Synthetic Marijuana Toxicity: A Fight Against Time.
Clinical manifestations, laboratory findings, treatment and outcome of acute organophosphate or carbamate intoxication in 102 dogs: A retrospective study.
Epidemiological and clinical differences of snake bites among children and adults in south western Saudi Arabia.
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults.
Impaired and exhausted platelets in modified generalized Shwartzman reaction: an analogue of hemolytic uremic syndrome associated with endotoxemia.
Inhibition of leukocyte-endothelial cell interactions and inflammation by peptides from a bacterial adhesin which mimic coagulation factor X.
Investigating the impact of silymarin on liver oxidative injury.
Severe adenovirus infection in children.
Toxicity with intravenous injection of crude marijuana extract.
[Crimean-Congo hemorrhagic fever]
[Spontaneous bilateral extradural hematomas: a case report]
Leukopenia
Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation.
Adenoviral pneumonia in children.
Clinical features and dynamic ordinary laboratory tests differentiating dengue fever from other febrile illnesses in children.
Crimean-Congo hemorrhagic fever.
Evaluation of factors predictive of the prognosis in Crimean-Congo hemorrhagic fever: new suggestions.
Experimental Sarcocystis suicanis infections: disease in growing pigs.
Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes.
Hematologic manifestation of childhood celiac disease.
Laboratory findings in patients with avian-origin influenza A (H7N9) virus infections.
Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience.
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
The effects of indomethacin on the generalized shwartzman reaction.
The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue.
limulus clotting factor b deficiency
Deuterohemophilia: plasma thromboplastin factor B deficiency: plasma thromboplastin component (PTC) deficiency, Christmas disease, hemophilia B.
Lipoma
A novel missense mutation Asp506Gly in Exon 13 of the F11 gene in an asymptomatic Korean woman with mild factor XI deficiency.
Posttraumatic lipoma in a patient with congenital factor X deficiency.
[Diagnosis and treatment of posttraumatic pseudolipomas. A retrospective analysis]
Livedoid Vasculopathy
Successful Treatment of Painful Cutaneous Vasculopathy With Rivaroxaban in a Patient With Systemic Lupus Erythematosus.
Liver Cirrhosis
Deciphering the coagulation profile through the dynamics of thrombin activity.
Haemostasis unbalance in Pugh-scored liver cirrhosis: characteristic changes of plasma levels of protein C versus protein S.
Hyponatremia and Its Correlation With Hepatic Encephalopathy and Severity of Liver Disease.
Inhibition of activated factor X; a new pathway in ameliorating carbon tetrachloride-induced liver fibrosis in rats.
Multicenter retrospective study of transcatheter arterial embolisation for life-threatening haemorrhage in patients with uncorrected bleeding diathesis.
Rotational thromboelastometry can detect factor XIII deficiency and bleeding diathesis in patients with liver cirrhosis.
Thrombin and factor Xa link the coagulation system with liver fibrosis.
Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet for reinforcing qi and resolving stasis.
[Biological diagnosis of postoperative thrombopenia]
[Effect of intraperitoneal injection of topical thrombin on the coagulation and fibrinolysis of rabbits with experimental liver damages]
[Epidural hematoma associated with epidural catheterization in a cirrhotic patient]
[Rational hemostatic screening]
[Spectrum and bleeding complications of sonographically guided interventions of the liver and pancreas]
[The diagnostic value of wedged hepatic vein pressure in chronic hepatitis and liver cirrhosis (author's transl)]
[The therapeutic effects of natural vitamin K1, in decreasing the potential of serumsteady thrombokinase factors in cases of obstructive jaundice and of liver cirrhosis.]
[Thrombokinase inhibitors and alpha 1-antitrypsin deficiency in liver cirrhosis as a cause for hemorrhage in ascites shunt]
Liver Cirrhosis, Alcoholic
Deceptive prothrombin and activated partial thromboplastin times in alcoholic cirrhosis.
Liver Cirrhosis, Biliary
Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography.
Liver Diseases
A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy.
A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology.
A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.
A Retrospective Cohort Analysis of Pharmacologic VTE Prophylaxis and Padua Prediction Score in Hospitalized Patients With Chronic Liver Disease.
Activated partial thromboplastin time abnormality in patients with cholangiocarcinoma.
AGA Clinical Practice Update: Coagulation in Cirrhosis.
Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April).
An International Sensitivity Index (ISI) derived from patients with abnormal liver function improves agreement between INRs determined with different reagents.
Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.
Bleeding and clotting disorders in pediatric liver disease.
Bloodless living donor liver transplantation: Risk factors, outcomes, and diagnostic predictors.
Coagulation abnormalities in 22 cats with naturally occurring liver disease.
Coagulation Profile and its Correlation with Severity of Liver Dysfunction and Gastrointestinal Bleed in Alcoholic Liver Disease Patients.
Coagulopathy in the nephrotic syndrome.
Comparison of a chromogenic prothrombin time with clotting prothrombin time in the assessment of clinical coagulation deficiencies.
Comparison of human and rabbit brain thromboplastin in evaluation of haemostatic defect of liver disease.
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis.
Comparison of two automated coagulometers and the manual tilt-tube method for the determination of prothrombin time.
Cryptococcosis in patients with liver cirrhosis: Death risk factors and predictive value of prognostic models.
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Diagnosis and therapy of coagulopathies in patients with liver disease.
Effect of liver damage on the level of coagulation factor II, X and VII in human and bovine plasma.
Effects of DDAVP administrated subcutaneously in dogs with aspirin-induced platelet dysfunction and hemostatic impairment due to chronic liver diseases.
Erythrocyte protoporphyrins in hepatitis C viral infection.
Factor VII as a marker of hepatocellular synthetic function in liver disease.
Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.
Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.
Impact of an Institutional Change in Prothrombin Time Methodology on INR and MELD Scores in Liver Transplant Evaluations.
Implications of use of low international sensitivity index thromboplastins in prothrombin time testing.
Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors.
Interpretation of the international normalised ratio in patients with liver disease.
Long-term postoperative bleeding after dentoalveolar surgery in the pretransplant liver failure patient.
Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis.
Platelet Function and Other Indices of Hemostasis in Chronic Liver Disease.
Post-Operative Hemorrhage After Liver Transplantation: Risk Factors and Long-Term Outcome.
Radioimmunoassays for protein C and factor X. Plasma antigen levels in abnormal hemostatic states.
Recombinant human factor VIIa-induced alterations in tissue factor and thrombomodulin in patients with advanced liver cirrhosis.
Relation of simple clotting tests to clotting factor levels in liver disease.
Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease.
S protein/vitronectin in chronic liver diseases: correlations with serum cholinesterase, coagulation factor X and complement component C3.
Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis.
Solvent-detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies.
The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease.
The effect of hepatectomy on coagulation: an evaluation by thromboelastography.
Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis.
Usefulness and accuracy of the international normalized ratio and activity percent of prothrombin time in patients with liver disease.
[A new system of analysis for partial thromboplastin time. Comparison with other blood coagulation tests in liver diseases]
[Aspects of blood platelet function in liver diseases; adhesiveness and thromboplastin activity.]
[Comparative multicenter study of a rabbit high-sensitivity thromboplastin and a recombinant thromboplastin with synthetic phospholipids]
[Platelet function in liver diseases. II. Agglutinability & its plasmatic factor; platelet formula; thromboplastin generation test.]
[The diagnostic value of the aminophenazone breath test in chronic liver diseases]
[THEORIES CONCERNING FACTOR X (STUART-PROWER) IN LIVER DISEASES AND IN TREATMENT WITH INDIRECT ANTICOAGULANTS.]
[Thromboplastin generation test in liver disease.]
[Unexpected hemorrhage in surgery]
Liver Failure
Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders.
Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?
Liver Failure, Acute
Acute respiratory failure in adult patients with dengue virus infection.
Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase.
Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha.
Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?
Transient, selective factor X deficiency and acute liver failure following chest infection treated with erythromycin BP.
[Establishment of pig acute liver failure model and the role of pig fibrinogen-like protein 2.]
Lung Diseases
Activated clotting factor X mediates mitochondrial alterations and inflammatory responses via protease-activated receptor signaling in alveolar epithelial cells.
Lung Diseases, Interstitial
Evaluation on blood coagulation and C-reactive protein level among children with mycoplasma pneumoniae pneumonia by different chest imaging findings.
Lung Injury
Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity.
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury.
Procoagulant, tissue factor-bearing microparticles in bronchoalveolar lavage of interstitial lung disease patients: an observational study.
The effect of heparin administration in animal models of sepsis: A prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies*
[Meta-analysis of the impact of continuous anticoagulation therapy with low-dose heparin or low molecular weight heparin on the prognosis of patients with acute respiratory distress syndrome].
Lung Neoplasms
Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients.
Haemostatic abnormalities in lung cancer: prognostic implications.
Perioperative Bypassing Agent Therapy for Pulmonary Pleomorphic Carcinoma with Acquired Hemophilia.
Prognostic significance of blood coagulation tests in carcinoma of the lung and colon.
Prognostic significance of blood coagulation tests in lung cancer.
[Association between hemostasis/coagulation-system parameters and clinicopathological factors in patients with primary lung cancer].
[Prothrombin time and its standardization]
Lupus Erythematosus, Systemic
A case of Budd-Chiari syndrome with high antiphospholipid antibody in a patient with systemic lupus erythematosus.
A unique precipitating autoantibody against plasma thromboplastin antecedent associated with multiple apparent plasma clotting factor deficiencies in a patient with systemic lupus erythematosus.
Acquired factor XIII inhibitor: clinical features, treatment, fibrin structure and epitope determination.
Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays.
Antibodies to thromboplastin in systemic lupus erythematosus: isotype distribution and clinical significance in a series of 92 patients.
Antibody to cardiolipin, lupus anticoagulant, and fetal death.
Assays for lupus anticoagulant: the sensitivity of different assays.
Association of lupus anticoagulant and anticardiolipin antibodies with thrombosis in patients with systemic lupus erythematosus, primary antiphospholipid syndrome and other disorders.
Evaluation of four coagulation tests to detect plasma lupus anticoagulants.
Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome.
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.
Microparticles as biomarkers in autoimmunity: from dust bin to center stage.
Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies.
Prolonged Activated Partial Thromboplastin Time in Systemic Lupus Erythematosus Overlap Syndrome: Fatal Bleeding Due to Factor VIII Inhibitor.
Studies on a circulating anticoagulant in procainamide-induced lupus erythematosus.
The activated seven lupus anticoagulant assay detects clinically significant antibodies.
The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level.
The lupus anticoagulant. High incidence of 'negative' mixing studies in a human immunodeficiency virus-positive population.
The tissue thromboplastin inhibition test in diabetics without cerebro-cardiovascular diseases.
[Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range].
[Hemorrhagic syndrome due to a heparin-like anticoagulant in a patient with systemic lupus erythematosus].
[Interference of factor VIII excess on the detection of lupus anticoagulants by the activated partial thromboplastin time]
[Presence of lupus-type anticoagulant, in systemic lupus erythematosus and other clinical entities]
[Regulation of coagulo-fibrinolytic activity and lupus anticoagulants in systemic lupus erythematosus]
Lupus Nephritis
Identification of a unique glomerular factor X activator in murine lupus nephritis.
Monocyte procoagulant activity in glomerulonephritis associated with systemic lupus erythematosus.
Lymphadenopathy
Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Lymphatic Metastasis
Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation.
Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients.
Lymphedema
A model to assess the risk of peripherally inserted central venous catheter-related thrombosis in patients with breast cancer: a retrospective cohort study.
Lymphocytosis
Lymphoplasmacytic lymphoma exposed by haemoptysis and acquired von Willebrand syndrome.
Lymphoma
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.
Alteration in the laboratory profile of a lupus anticoagulant in a patient with non-Hodgkin's lymphoma.
Approach to the treatment, characterization and diagnosis of an acquired auto-antibody directed against factors prothrombin, factor X and factor IX: a case report and review of the literature.
Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.
Direct Factor X sequestration by systemic amyloid light-chain amyloidosis.
Factor VIII inhibitors. Laboratory diagnosis of inhibitors.
Increased activity of cell membrane-associated prothrombinase, fibrinogen-like protein 2, in peripheral blood mononuclear cells of B-cell lymphoma patients.
Interference from lupus anticoagulant on von Willebrand factor measurement in splenic marginal zone lymphoma: a case report.
Platelet function in dogs treated for lymphoma and hemangiosarcoma and supplemented with dietary n-3 fatty acids.
Protease receptors in Hodgkin's disease: expression of the factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells.
Successful treatment of a noninhibitory antibody-mediated acquired factor X deficiency in a patient with marginal-zone lymphoma.
The 13-year bleed: Exuberant amyloid angiopathies, angiodysplasias, and acquired coagulopathies of the gut.
[Relationship between coagulation function and international prognostic index in lymphoma patients].
Lymphoma, B-Cell
Activation of the Endoplasmic Reticulum Stress-Associated Transcription Factor X Box-Binding Protein-1 Occurs in a Subset of Normal Germinal-Center B Cells and in Aggressive B-Cell Lymphomas with Prognostic Implications.
Increased activity of cell membrane-associated prothrombinase, fibrinogen-like protein 2, in peripheral blood mononuclear cells of B-cell lymphoma patients.
Prolonged Activated Partial Thromboplastin Time and False-Positive Results for Fibrinogen and Fibrin Degradation Products in a B-Cell Lymphoma Patient.
Lymphoma, Large-Cell, Anaplastic
Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.
Lymphoma, Non-Hodgkin
Alteration in the laboratory profile of a lupus anticoagulant in a patient with non-Hodgkin's lymphoma.
Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo.
Lymphoma, T-Cell
Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity.
Lymphopenia
A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1.
COVID-19 versus HIT hypercoagulability.
Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis.
Laboratory findings in patients with avian-origin influenza A (H7N9) virus infections.
Malignant histiocytosis in a cat.
Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.
Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection.
SARS: clinical features and diagnosis.
Severe acute respiratory syndrome in a doctor working at the Prince of Wales Hospital.
Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong.
[Catastrophic antiphospholipid syndrome and rituximab: a new report]
[Transverse myelopathy in a patient with systemic lupus erythematosus associated with positive anticardiolipin antibody--a case report]
Macular Degeneration
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture.
Malaria
Activated partial thromboplastin time of owl monkey (Aotus trivirgatus) plasma.
Activation of the coagulation cascade in falciparum malaria.
Coagulation Status and Platelet Functions in Children with Severe Falciparum Malaria and their Correlation of Outcome.
Effects of malaria parasitaemia on some haemostatic parameters among pregnant women of African descent in Specialist Hospital Sokoto, Nigeria.
[Treatment of fulminant falciparum malaria with erythrapheresis]
Malaria, Falciparum
Activated partial thromboplastin time of owl monkey (Aotus trivirgatus) plasma.
Malnutrition
Moxalactam in the therapy of serious infections.
Massive Hepatic Necrosis
The nucleocapsid protein of murine hepatitis virus type 3 induces transcription of the novel fgl2 prothrombinase gene.
Mastitis
Alterations in coagulation parameters in dairy cows affected with acute mastitis caused by E. coli and S. aureus pathogens.
Meconium Aspiration Syndrome
Development of the Pediatric Extracorporeal Membrane Oxygenation Prediction Model for Risk-Adjusting Mortality.
Mediastinal Cyst
Hemorrhagic diathesis caused by factor X deficiency in a child with thymic cyst.
Melanoma
Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro.
Assembly and regulation of prothrombinase complex on B16F10 melanoma cells.
Cellular localization of activated factor X by Xa-specific probes.
Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation.
Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice.
Effects of nutritional folate deficiency on the adhesive properties of murine melanoma cells.
Interaction of human tumor cells with human platelets and the coagulation system.
Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor.
Melena
Superwarfarin Exposure: An Important Uncommon Cause of Painless Bleeding.
Meniere Disease
Acute peripheral vertigo: involvement of the hemostatic system.
Meningitis, Bacterial
Thromboplastic activity of cerebrospinal fluid in neurological disease.
Meningitis, Viral
Thromboplastic activity of cerebrospinal fluid in neurological disease.
Meningococcal Infections
Diagnosis and stage-related treatment of disseminated intravascular coagulation in meningococcal infections.
Diagnostic efficacy of activated partial thromboplastin time waveform and procalcitonin analysis in pediatric meningococcal sepsis.
Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis.
Menorrhagia
Factor X Deficiency: A Rare Cause of Puberty Menorrhagia.
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study.
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Rare coagulation disorders.
Screening and diagnosis of coagulation disorders.
von Willebrand factor activity and activated partial thromboplastin time as proxy biomarkers for coagulopathies in women with menorrhagia in Zambia: a case-control study.
[Successful long-term management of ovarian bleeding and menorrhagia with prothrombin complex concentrate in a patient with congenital factor X deficiency].
Mesothelioma, Malignant
Abnormal activated partial thromboplastin time and malignancy.
Metabolic Syndrome
Factor xa inhibitor attenuates leukocyte adhesion and thrombus formation in an experimental mouse model of the metabolic syndrome.
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
Metrorrhagia
Signal detection for bleeding associated with the use of direct oral anticoagulants.
Migraine Disorders
A Case of Migraine With Aura Resolving on Warfarin But Not on Apixaban.
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Mitral Valve Prolapse
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
[Combined 2d-type TAR syndrome, factor X deficiency, immune deficiency and mitral valve prolapse]
Mixed Connective Tissue Disease
Prolonged Activated Partial Thromboplastin Time in Systemic Lupus Erythematosus Overlap Syndrome: Fatal Bleeding Due to Factor VIII Inhibitor.
Monoclonal Gammopathy of Undetermined Significance
Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma.
Mucopolysaccharidosis II
Hunter syndrome complicated by hydrocephalus and an endogenous anticoagulant.
Multiple Myeloma
A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma.
A Rare Case of Early Onset Multiple Myeloma in a 20-Year-Old Female With Factor X Inhibitor.
Acquired factor X deficiency developed four years after autologous transplantation in a patient with multiple myeloma associated with systemic AL amyloidosis.
Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
Anticoagulant activities of a monoclonal antibody that binds to exosite II of thrombin.
Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma.
Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib: A Case Report and Review of the Literature.
Light-chain paraproteins with lupus anticoagulant activity.
Monoclonal antibody light chain with prothrombinase activity.
The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.
The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma.
[A case of retroperitoneal hemorrhage due to multiple myeloma complicated with factor X deficiency and amyloidosis]
[Factor X deficiency associated with multiple myeloma.]
[Thromboplastin formation in Waldenström's macroglobulinemia and in multiple myeloma]
Multiple Sclerosis
Influence of human allergic encephalitogenic peptide on platelet aggregation in multiple sclerosis.
Prothrombin and factor X are elevated in multiple sclerosis patients.
Myalgia
Alkhumra (Alkhurma) virus outbreak in Najran, Saudi Arabia: Epidemiological, clinical, and Laboratory characteristics.
Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children.
Difference in clinical presentation between the first and second phases of Kyasanur Forest disease: an experience from a teaching hospital in South India.
Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.
[Crimean-Congo hemorrhagic fever]
Myasthenia Gravis
[High thrombokinase activity in a thymoma during myasthenia gravis]
Mycoplasma Infections
Acquired-transient factor X deficiency in a teenager with extensive burns.
Myeloproliferative Disorders
Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation.
Myocardial Infarction
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml.
Activated partial thromboplastin time (aPTT) monitoring to achieve therapeutic anticoagulation before and after introducing a nomogram for adjunctive heparin treatment with thrombolytic therapy for acute myocardial infarction.
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.
Activated partial thromboplastin time correlates with methoxyhydroxyphenylglycol in acute myocardial infarction patients: therapeutic implications for patients at cardiovascular risk.
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.
Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
Alteration of plasma antithrombin III levels in ischemic heart disease.
Alterations in prothrombin time and activated partial thromboplastin time in patients with acute myocardial infarction.
Association of recurrent myocardial infarction with hemostatic factors: a prospective study.
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.
Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial.
Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction.
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.
Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease.
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction.
Correction to: Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
Different clinical presentations of a lupus anticoagulant in the same family.
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.
Drug evaluation: the directly activated Factor Xa inhibitor otamixaban.
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapy.
Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.
Fluctuation of thrombin-antithrombin III complex in patients with acute myocardial infarction: influence of low-dose heparin administration.
Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients.
Haemostatic function in coronary artery disease (CAD).
Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction.
Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Indications for antithrombotic therapy after myocardial infarction.
Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin.
Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
Left atrial structure and function and the risk of death or heart failure in atrial fibrillation.
Low molecular weight heparin in acute stroke.
Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.
Myocardial infarctions and other acute coronary syndromes in rare congenital bleeding disorders: a critical analysis of all reported cases.
Natural inhibitors and fibrinogen/fibrin degradation products in patients with myocardial infarction.
New data in treatment of acute coronary syndromes.
Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition?
Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review.
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Pre-operative labs: Wasted dollars or predictors of post-operative cardiac and septic events in orthopaedic trauma patients?
Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
Prognosis of spontaneous intracerebral hemorrhage in hemodialysis patients.
Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI.
Promise of factor Xa inhibition in acute coronary syndromes.
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial.
Reliability of an intravenous intermittent access port (saline lock) for obtaining blood samples for coagulation studies.
Rivaroxaban in acute coronary syndromes--is it prime time?
Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1.
Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.
Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)
Spotlight on fondaparinux sodium in acute coronary syndromes.
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions.
Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time.
Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streptokinase in patients with acute myocardial infarction.
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
The "Dual-Pathway" Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial.
The activated partial thromboplastin time in early diagnosis of myocardial infarction.
The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction.
The medical management of acute coronary syndromes and potential roles for new antithrombotic agents.
The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy.
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention.
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
[Assessment of hemostasis in patients with myocardial infarction complicated by deep venous thrombosis]
[Deviation of activated partial thromboplastin time from optimal level after 12 hours of intravenous infusion of unfractionated heparin -- an independent predictor of recurrence and unfavorable 30-day prognosis in patients with myocardial infarction]
[Difference in examination of coagulation function in heparin anticoagulant therapy between point of care tests and automatic coagulation analyzer]
[Factor Xa-inhibition in interventional cardiology]
[Fibrinolysis and hemorrhage after streptokinase in acute myocardial infarct]
[Fondaparinux: The present and the future.]
[Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction]
Myocardial Ischemia
Alteration of plasma antithrombin III levels in ischemic heart disease.
Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease.
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Factor VII and haemostasis.
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Rare variants lowering the levels of coagulation factor X are protective against ischemic heart disease.
Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice.
[THE TEST OF GENERATION OF THROMBIN IN DYNAMICS IN PATIENTS AFTER TRANSCUTANEOUS CORONARY INTERVENTION].
Myocarditis
Inhibition of coagulation factor Xa improves myocardial function during CVB3-induced myocarditis.
[EFFECT OF CORCHOROZIDE ON THE THROMBOPLASTIN AND HEPARIN TIME IN RABBITS UNDER NORMAL CONDITIONS AND IN EXPERIMENTAL MYOCARDITIS.]
Myoma
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
Myxoma
Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways.
Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets.
Nasal Polyps
Thrombin and activated coagulation factor X stimulate the release of cytokines and fibronectin from nasal polyp fibroblasts via protease-activated receptors.
Nasopharyngeal Carcinoma
Routine coagulation molecules predict nasopharyngeal carcinoma and associated metastases.
[The role of EPR-1 in proliferation and apoptosis in nasopharyngeal carcinoma]
Neoplasm Metastasis
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro.
Cancer and thrombosis in women - molecular mechanisms.
Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation.
Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity.
Factor X-activating activity from Guerin epithelioma.
Failure to warfarin to affect the tissue factor activity and the metastatic potential of murine fibrosarcoma cells.
Involvement of the heparanase procoagulant domain in bleeding and wound healing.
Is EPCR a multi-ligand receptor? Pros and cons.
Loss of metastatic and primary tumor factor X activator capabilities by Lewis lung carcinoma cells cultured in vitamin K-dependent protein deficient serum.
Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients.
Mechanisms of cancer-induced thrombosis in cancer.
Risk factors for brain metastases from non-small-cell lung cancer: A protocol for observational study.
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Thrombin is a selective inducer of heparanase release from platelets and granulocytes via protease-activated receptor-1.
Thromboplastin release, but not content, correlates with spontaneous metastasis of cancer cells.
Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells.
Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host.
[Contribution to the aetiology of "reversible hepatic dysfunction" (Stauffer's syndrome) associated with renal tumours]
Neoplasms
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
A discrepancy between prothrombin time and Normotest (Hepaplastintest) results is useful for diagnosis of acquired factor V inhibitors.
A factor X-activating cysteine protease from malignant tissue.
A Kunitz-type FXa inhibitor affects tumor progression, hypercoagulable state and triggers apoptosis.
A Novel Phenotype of Germline Pathogenic Variants in MAX: Concurrence of Pheochromocytoma and Ganglioneuroma in a Chinese Family and Literature Review.
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.
A retrospective analysis of plasma D-dimer dynamic variation in terminal stage cancer patients: implications for disease progression.
A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients.
A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
Abnormal activated partial thromboplastin time and malignancy.
Acquired factor IX inhibitor in a patient with adenocarcinoma of the colon.
Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from LPS-stimulated myeloid cells.
Activated protein c can be used as a prophylactic as well as a therapeutic agent for heat stroke in rodents.
Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation.
Activated protein C therapy in a rat heat stroke model.
Activated-protein-C resistance in cancer patients.
Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients.
Activation of coagulation after administration of tumor necrosis factor to normal subjects.
Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.
Activation of factor X and its regulation by tissue factor pathway inhibitor in small-diameter capillaries lined with human endothelial cells.
An assessment of monocyte procoagulant activity in patients with solid tumors.
An ultrastructural and immunohistochemical study of pigmented dermatofibrosarcoma protuberans (Bednar tumor).
An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis.
Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro.
Androgenic adult granulosa cell tumour with prolongation of the activated partial thromboplastin time in a 29 year old woman.
Antagonism by salvianolic acid B of lipopolysaccharide-induced disseminated intravascular coagulation in rabbits.
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
Antithrombin III and Factor VIII in patients with neoplasms.
Antithrombotic activities of wogonin and wogonoside via inhibiting platelet aggregation.
Apixaban for the treatment of cancer-associated venous thromboembolism and left atrial appendage thrombus refractory to optimal anticoagulation with warfarin: a case report.
Apixaban Suppresses the Release of TF-Positive Microvesicles and Restrains Cancer Cell Proliferation through Directly Inhibiting TF-fVIIa Activity.
Assembly and regulation of prothrombinase complex on B16F10 melanoma cells.
Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va.
Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes.
Brain cooling causes attenuation of cerebral oxidative stress, systemic inflammation, activated coagulation, and tissue ischemia/injury during heatstroke.
Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.
Cancer and thrombosis in women - molecular mechanisms.
Cancer cell procoagulants and their pharmacological modulation.
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro.
Cancer procoagulant A: a factor X activating procoagulant from malignant tissue.
Cancer procoagulant in acute lymphoblastic leukemia.
Cancer procoagulant in human tumor cells: evidence from melanoma patients.
Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue.
Cancer-associated thrombosis: investigating the role of new oral anticoagulants.
Case Report of a Prolactinoma in a Patient With a Novel
Cellular localization of activated factor X by Xa-specific probes.
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines.
Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients.
Circulating endothelial cells in cancer patients do not express tissue factor.
Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization.
Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients.
Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study.
Clinical significance of increased thromboplastin activity on the monocyte surface--a brief review.
Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I.
Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function.
Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: implications for coagulation regulation on tumor cells.
Coagulant and fibrinolytic activities of a metastasising and non-metastasising tumour line.
Coagulation and fibrinolysis in chronic venous insufficiency.
Coagulation and the expression of cell-mediated immunity.
Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation.
Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation.
Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation.
Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation.
Coagulation signaling and cancer immunotherapy.
Combining early coagulation and inflammatory status improves prediction of mortality in burned and nonburned trauma patients.
Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.
Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma.
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism.
Cutaneous histopathologic findings in 'antiphospholipid syndrome'. Correlation with disease, including human immunodeficiency virus disease.
Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Development of a novel mouse model for dengue virus infection.
Development of a Predictive Model of Difficult Hemostasis following Endobronchial Biopsy in Lung Cancer Patients.
Dexamethasone improves heat stroke-induced multiorgan dysfunction and damage in rats.
Direct analysis reveals an absence of gamma-carboxyglutamic acid in cancer procoagulant from human tissues.
Disseminated intravascular coagulopathy.
Dual functionalized chitosan based composite hydrogel for haemostatic efficacy and adhesive property.
Dual interference of novel gene mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice.
Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer.
Early response in septicemia in newborns and their mothers. Effect of Escherichia coli, Streptococcus agalactiae and tumor necrosis factor on lactoferrin release and the generation of tissue thromboplastin.
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
Effect of BsaA I genotyped intronic SNP of leptin gene on production and reproduction traits in Indian dairy cattle.
Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro.
Effect of FC43se on endotoxin-induced disseminated intravascular coagulation in rats.
Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice.
Effect of Serum Immunoglobulins on Routine Coagulation Tests: A Comparison of Coagulation Analyzers using Mechanical and Optical Clot Detection.
Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age.
Effects of bacterial translocation on hemodynamic and coagulation parameters during living-donor liver transplant.
Effects of curcumin on the gene expression profile of L-02 cells.
Effects of intravenous high doses of ketoprofen on blood clotting, bleeding time and platelet aggregation in man.
Effects of postoperative parenteral nutrition with different lipid emulsions in patients undergoing major abdominal surgery.
Efficacy of oral colon-specific delivery capsule of low-molecular-weight heparin on ulcerative colitis.
Elevated plasma levels of the factor Xa-TFPI complex in cancer patients.
Emergency Physicians Choose Wisely When Ordering Plain Radiographs for Low Back Pain Patients.
Endothelial dysfunction in experimental hyperhomocysteinemia.
Engineering of human coagulation factor x variants activated by prostate-specific antigen.
Enhanced induction of heme oxygenase-1 suppresses thrombus formation and affects the protein C system in sepsis.
Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.
Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia.
Evaluation of the Activity of Heparin Injected into the Fully Implantable Catheter for Chemotherapy (Portocath) between Two Moments of Use.
Evidence for a warfarin-sensitive serum factor that participates in factor X activation by Lewis lung tumor cells.
Evidence that cells from experimental tumours can activate coagulation factor X.
Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation.
F10 gene hypomethylation, a putative biomarker for glioma prognosis.
Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients.
Factor VIII inhibitors. Laboratory diagnosis of inhibitors.
Factor X-activating activity from Guerin epithelioma.
Factor Xa inhibits HMGB1-induced septic responses in human umbilical vein endothelial cells and in mice.
Factor Xa: at the crossroads between coagulation and signaling in physiology and disease.
Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.
Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma.
Fibrinolysis, thromboplastin activity and localization of radioiodinated fibrinogen in experimental tumors.
FVIIa Neutralization by a FXa Inhibitor: How It Could Dampen Tumorigenic Cancer Cell Phenotypes.
Heme oxygenase 1 modulates thrombomodulin and endothelial protein C receptor levels to attenuate septic kidney injury.
Hemostasis and cancer: tumor cells induce the expression of tissue factor-like procoagulant activity on endothelial cells.
Hemostasis and mechanism of action of selective antimetastatic drugs in mice bearing Lewis lung carcinoma.
Hemostasis following inoculation and during spreading of colon carcinoma in the rat.
Hemostasis in malignancy.
Hemostatic abnormalities associated with cancer and its therapy.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Hemostatic function in cancer patients.
High-dose antithrombin III treatment of severely injured patients: results of a prospective study.
Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.
Improved survival of patients presenting with acute variceal bleeding. Prognostic indicators of short- and long-term mortality.
In Vitro Screening of Synthetic Fluorogenic Substrates for Detection of Cancer Procoagulant Activity.
Inactivation of factor Va by activated protein C on selected human tumor cell lines.
Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.
Increased activity of cell membrane-associated prothrombinase, fibrinogen-like protein 2, in peripheral blood mononuclear cells of B-cell lymphoma patients.
Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin.
Inhibition of tissue factor signaling in breast tumour xenografts induces widespread changes in the microRNA expression profile.
Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model.
Interaction between Mouse Adenovirus Type 1 and Cell Surface Heparan Sulfate Proteoglycans.
INTRACELLULAR LOCATION OF TISSUE THROMBOPLASTIN AND POSSIBLE RELATION TO FIBRIN DEPOSITS IN HUMAN NEOPLASMS.
Intrinsic versus extrinsic coagulation. Kinetic considerations.
Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial.
Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue.
Lodgement and extravasation of tumour cells in blood-borne metastasis: an electron microscope study.
Loss of metastatic and primary tumor factor X activator capabilities by Lewis lung carcinoma cells cultured in vitamin K-dependent protein deficient serum.
Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients.
Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
Management of postoperative hemorrhage associated with factor VIII inhibitor: report of a case.
Markers of coagulation activation after hepatic resection for cancer: evidence of sustained upregulation of coagulation.
Mast cell-derived exosomes activate endothelial cells to secrete plasminogen activator inhibitor type 1.
Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo.
Mechanisms of cancer-induced thrombosis in cancer.
Myeloid cell-synthesized coagulation factor X dampens antitumor immunity.
New and old anticoagulants in cancer.
New antithrombotic drugs: potential for use in oncology.
New Bisabosquals from Stachybotrys sp. PH30583 Elicited on Solid Media.
Next Generation Antibody Therapeutics Using Bispecific Antibody Technology.
Noninvasive evaluation of ovarian endometriosis: a single-center experience.
Novel factor X deficiency. Normal partial thromboplastin time and associated spindle cell thymoma.
OC-03 - Modelisation of the procoagulant properties of cancer cells and their capacity to alter the antithrombotic efficiency of LMWHs and specific inhibitors of factor Xa.
Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung.
Opposing effects of HIF1? and HIF2? on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging.
Partial Thromboplastin Time: Accurate Measurement Through Evidence-Based Practice.
Pathophysiology of venous thromboembolism.
Peliosis hepatis mimicking hepatic malignancy: A case report.
Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues.
Plasma composition distribution in cancer: Discrimination by thrombin and factor Xa generation.
Platelets stimulate thromboplastin synthesis in human endothelial cells.
Platonin, a cyanine photosensitizing dye, causes attenuation of circulatory shock, hypercoagulable state, and tissue ischemia during heat stroke.
Platonin, a cyanine photosensitizing dye, is effective for attenuation of heatstroke in rats.
PO-23 - Expression of heparanase in cancer as biomarker of malignancies: overexpression in an aggressive, poor survival gastric cancer "gastric signet ring cell carcinoma" compared with that of other gastric cancers.
PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.
Pre-existing lipopolysaccharide may increase the risk of heatstroke in rats.
Prediction of gastrointestinal bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational cohort study (STROBE compliant).
Prediction of Poor Outcomes in Patients with Colorectal Cancer: Elevated Preoperative Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT).
Preoperative hematological assessment of pediatric patients with cerebral palsy.
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells.
Procoagulant activity of mouse and human cultured cells following various types of transformation.
Procoagulant activity of mouse transformed cells: different expression in freshly isolated or cultured cells.
Procoagulant properties of human MV3 melanoma cells.
Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population.
Promotion of metastasis by a specific complex of coagulation factors may be independent of fibrin formation.
Properties of proteins in cancer procoagulant preparations that are detected by anti-tissue factor antibodies.
Protease-activated receptor 2 (PAR2) blocking peptide counteracts endotoxin-induced inflammation and coagulation and ameliorates renal fibrin deposition in a rat model of acute renal failure.
Protective mechanism of Xuebijing injection against heat stroke in rats.
Protein Z/protein Z-dependent protease inhibitor system in human non-small-cell lung cancer tissue.
Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer.
Pulmonary Thromboembolism in COVID-19: Venous Thromboembolism or Arterial Thrombosis?
Pyogenic liver abscess. An audit of experience over the past decade.
Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X.
Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Recurrent Venous Thromboembolism in Two Patients With Cancer Taking Rivaroxaban.
Regulatory Factor X 7 and its Potential Link to Lymphoid Cancers.
Relation between coagulation/fibrinolysis and lactate in the course of human septic shock.
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Rhamnan sulfate extracted from Monostroma nitidum attenuates blood coagulation and inflammation of vascular endothelial cells.
Risk factors of early death in adult patients with secondary hemophagocytic lymphohistiocytosis: a single-institution study of 171 Chinese patients.
Rivaroxaban does not affect growth of human pancreatic tumors in mice.
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.
Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis.
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Role of Hypercoagulable State for Predictive Ovarian Malignancy in Women with a Pelvic Mass.
Role of phosphoinositide 3-kinase in adhesion of platelets to fibrinogen stimulated by cancer procoagulant.
Role of plasma, platelets, and endothelial cells in tumor metastasis.
Role of tissue factor in hepatocellular carcinoma genesis, invasion and metastasis.
Role of tumor thromboplastin in the mode of distribution of metastatic foci in the lung.
Roles of factor Xa beyond coagulation.
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics.
Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection.
Species D Adenoviruses as Oncolytic Viral Vectors.
Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE.
Stroke risk factor, pattern and outcome in patients with cancer.
Substrate optimization and clinical validation of reporter peptides for MS-based protease profiling in serum specimens: a new approach for diagnosis of malignant disease.
The action of Amblyomma cajennense tick saliva in compounds of the hemostatic system and cytotoxicity in tumor cell lines.
The C3H/St/Ha mammary tumor. I. Thromboplastin content.
The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development.
The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma.
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
The features comparison between patients in the ICU and general wards and between patients with different outcomes: a 2020 COVID-19 study.
The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.
The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention.
The production of tumour necrosis factor, tissue thromboplastin, lactoferrin and cathepsin C during lipopolysaccharide stimulation in whole blood.
The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options.
The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation.
The role of macrophage activation in chronic inflammation.
The site of activation of factor X by cancer procoagulant.
Therapy with interleukin-22 alleviates hepatic injury and hemostasis dysregulation in rat model of acute liver failure.
Thinking outside the box: mechanisms of environmental selective pressures on the outcome of the materno-fetal relationship.
Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant.
Thrombin stimulates arachidonate metabolism in murine tumor cells.
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
Thromboplastic and fibrinolytic activities of cultured human cancer cell lines.
Thromboplastin release, but not content, correlates with spontaneous metastasis of cancer cells.
Thrombosis and cancer.
Thrombosis in brain tumors.
Tissue Factor Pathway Inhibitor Attenuates the Progression of Malignant Pleural Mesothelioma in Nude Mice.
Tissue factor-like activity of the human monocytic tumor cell line U937.
Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.
Transcription factor RFX7 governs a tumor suppressor network in response to p53 and stress.
Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatment.
Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options.
Treatment of cancer with anticoagulants: rationale in the treatment of melanoma.
Treatment of venous thrombosis in the cancer patient.
Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
Trousseau's syndrome: cancer-associated thrombosis.
Tumor cell generation of thrombin via functional prothrombinase assembly.
Tumor cells augment the factor Xa-catalyzed conversion of prothrombin to thrombin.
Tumor cells induce platelet aggregation and intraplatelet calcium ion movements.
Tumor fluid thromboplastin activity.
Tumor volume estimation by the percentage carcinoma method in uterine cervix carcinoma.
Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models.
Use of Viscoelastography in Malignancy-Associated Coagulopathy and Thrombosis: A Review.
Venous Thromboembolism in Gynecological Malignancy.
XBP1 silencing decreases glioma cell viability and glycolysis possibly by inhibiting HK2 expression.
ZFX knockdown inhibits growth and migration of non-small cell lung carcinoma cell line H1299.
[A Meta-analysis of Qingre Jiedu and Liangxue Sanyu method in the treatment of sepsis].
[Advances in genes and molecular markers of pheochromocytoma].
[Anticoagulants: current topics].
[Assessment of variables relative to prethrombotic state after operation in patients with gynecological malignancies]
[Changes in the activity of blood thrombokinase in patients with malignant neoplasms under the influence of radiotherapy.]
[Effect of high-dose medroxyprogesterone acetate on coagulative and fibrinolytic factors in patients with gynecological cancers]
[Effect of the amount of portal blood stasis removal on endotoxemia and liver function after liver transplantation]
[Effectiveness of Xuebijing in treatment of multiple organ dysfunction syndrome: a Meta analysis].
[Establishment of a human lung squamous cell carcinoma cell line LK-17, and characterization of procoagulant, platelet aggregation and metastatic potential]
[Hemostasis system in lung cancer, benign tumors and chronic nonspecific pneumonias]
[Influence of thromboplastin on the development of experimental transplantable neoplasms]
[Meta-analysis of the impact of continuous anticoagulation therapy with low-dose heparin or low molecular weight heparin on the prognosis of patients with acute respiratory distress syndrome].
[Mixed corticomedullary tumor]
[On the relation of the tumor process to thrombokinase activity in the tumor tissue.]
[Paraneoplastic syndrome hematologic abnormalities]
[Refractory kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: clinical analysis of 10 cases].
[Studies on thromboplastin activity, fibrinolysis and uptake of radioactive iodine-labeled fibrinogen in various experimental tumors]
[Study on vascular endothelial injuries and inflammation related cytokines in patients with multiple organ dysfunction syndrome.]
[The phenomenon of relative resistance to heparin]
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
[Thrombokinase activity of the tissues in various endocrine disorders and tumor growths.]
[Thrombosis and embolism as paraneoplastic syndrome]
Neoplasms, Plasma Cell
Effect of Serum Immunoglobulins on Routine Coagulation Tests: A Comparison of Coagulation Analyzers using Mechanical and Optical Clot Detection.
Nephritis
Effect of antithrombin III on local hemostasis in the kidneys during experimental nephritis.
Plasma activity of contact coagulation factors in patients with IgA nephritis.
Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice.
Nephritis, Interstitial
Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis.
Nephrosis
Nonanticoagulant protective effect of heparin in chronic aminonucleoside nephrosis.
Nephrotic Syndrome
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
Acquired von Willebrand Syndrome Complicating Nephrotic Syndrome: A Case of a Patient With Membranous Nephropathy.
Changes of coagulation factors IX, VIII, VII, X, and V in nephrotic syndrome.
Effect of corticosteroids on coagulation factors in children with nephrotic syndrome.
Haemostatic parameters in childhood nephrotic syndrome. (Is there any difference in protein C levels between steroid sensitive and resistant groups?)
Nephrotic syndrome resulting in thromboembolic disease and disseminated intravascular coagulation in a dog.
Primary amyloidosis with severe nephrotic syndrome and acquired factor X deficiency.
Progressive systemic sclerosis with the nephrotic syndrome and acquired factor X deficiency.
Vasculas complications in nephrotic syndrome: relationship to steroid therapy and accelerated thromboplastin generation.
[Nephrotic syndrome and acquired deficiency of Stuart factor revealing the presence of amylosis and myeloma]
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
[Primary amyloidosis associated to severe factor X deficiency]
Neurilemmoma
Local Regulation of Thrombin Activity by Factor Xa in Peripheral Nerve Schwann Cells.
Neurofibromatoses
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Neurofibromatosis 1
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Neurogenic Inflammation
New mechanistic model for organic diisocyanate-induced respiratory disease.
Neuroinflammatory Diseases
Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
Neurologic Manifestations
Factors associated with stroke following the Fontan procedure.
Neuroma, Acoustic
Hypercoagulability in Vestibular Schwannoma Surgery.
Neuromyelitis Optica
Prothrombin and factor X are elevated in multiple sclerosis patients.
Neutropenia
Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
[Clinical and epidemiological characteristic of dengue]
Non-alcoholic Fatty Liver Disease
Hemostatic alterations in fatty liver disease.
Non-ST Elevated Myocardial Infarction
Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Noonan Syndrome
Hematological findings in Noonan syndrome.
Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Obesity
Activated partial thromboplastin time and risk of future venous thromboembolism.
Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.
Prevention of venous thromboembolism in obesity.
[On various aspects of blood coagulation in obesity. II. Studies on the aggregation ("clumping") of thrombocytes "in vitro" and on the thromboplastin formation]
Obesity, Morbid
Direct oral factor Xa inhibitors in patients with morbid obesity - Author's reply.
Direct oral factor Xa inhibitors in patients with morbid obesity.
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Prevention of venous thromboembolism in obesity.
Obstetric Labor, Premature
Expression of prothrombin and protease activated receptors in human myometrium during pregnancy and labor.
Oliguria
A new prognostic scoring system for meningococcal septic shock in children. Comparison with three other scoring systems.
Opportunistic Infections
Acquired circulating anticoagulants in children with acquired immunodeficiency syndrome.
Lupus anticoagulant in the acquired immunodeficiency syndrome.
Oral Ulcer
Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions.
Osteoarthritis
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Effect of nabumetone on hemostasis during arthroscopic knee surgery.
Effects of intravenous high doses of ketoprofen on blood clotting, bleeding time and platelet aggregation in man.
Effects on leukocyte function by arthroplasty. Thromboplastin activity and oxygen-derived free radicals studied in rheumatoid arthritis and arthrosis.
[Comparison of combined intravenous and topical use of tranexamic acid with different dosage in primary total knee arthroplasty].
Osteomyelitis
Candida vertebra osteomyelitis in a girl with factor X deficiency.
Osteoporosis
Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats.
Rivaroxaban significantly inhibits the stimulatory effects of bone-modulating hormones: In vitro study of primary female osteoblasts.
Osteosarcoma
Osteosarcoma cell-calcium signaling through tissue factor-factor VIIa complex and factor Xa.
Otitis
Antiphospholipids antibodies in a 12-month-old presenting with idiopathic thrombocytopenic purpura.
Ovarian Cysts
Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency.
Ovarian Neoplasms
Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment.
Overweight
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Pancreatic Neoplasms
Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study.
The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gene transfer in pancreatic cancer cells.
[Expression of RAD51 and MAX in pancreatic cancer rats.]
[Inhibitory effect of anti-platelet prostaglandin on liver metastasis of hamster pancreatic cancer]
Pancreatitis
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Influence of ischemic preconditioning on blood coagulation, fibrinolytic activity and pancreatic repair in the course of caerulein-induced acute pancreatitis in rats.
The effects upon blood coagulation in dogs of experimentally induced pancreatitis and the infusion of pancreatic juice.
The relationship of coagulation factors to clinical complications of acute pancreatitis.
[Biological diagnosis of postoperative thrombopenia]
[Hemostatic function and level of autoantibodies to trypsin and factor Xa in rats in experimental pancreatitis]
Pancreatitis, Acute Necrotizing
Factors associated with the severity of hypertriglyceridemia induced acute pancreatitis.
Pancytopenia
A Rare Case of Factor VII Inhibitor in a Patient Presenting with Primary Splenic Marginal Zone Lymphoma.
Diagnostic Pitfalls in a Man with Systemic Lupus Erythematous.
Pulmonary hemorrhage in pediatric lupus anticoagulant hypoprothrombinemia syndrome.
[Chronic hepatic encephalopathy in a patient with primary biliary cirrhosis].
Paraganglioma
A Novel, Likely Pathogenic MAX Germline Variant in a Patient With Unilateral Pheochromocytoma.
A patient with a germline SDHB mutation presenting with an isolated pituitary macroprolactinoma.
A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas.
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Opposing effects of HIF1? and HIF2? on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Somatic and germline mutations in the pathogenesis of pituitary adenomas.
Synchronous bilateral pheochromocytomas and paraganglioma with novel germline mutation in MAX: a case report.
Paralysis
Congenital factor X deficiency and incomplete transverse paralysis.
Inhibition of feline collateral vessel development following experimental thrombolic occlusion.
[Suspicious case of epidural hematoma due to coagulopathy caused by vitamin K deficiency associated with antibiotics]
Paraproteinemias
Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
Prolonged Activated Partial Thromboplastin Time and False-Positive Results for Fibrinogen and Fibrin Degradation Products in a B-Cell Lymphoma Patient.
Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.
The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma.
Waldenstrom's Macroglobulinemia and Peripheral Neuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes with a Bleeding Diathesis and Rash.
[Acquired factor X deficiency in a case of monoclonal gammopathy]
Parasitemia
Neither heparin nor acetylsalicylic acid influence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study.
Paratuberculosis
Antigenicity of recombinant maltose binding protein-Mycobacterium avium subsp. paratuberculosis fusion proteins with and without factor Xa cleaving.
Cloning and expression in Escherichia coli of DNA encoding a 60 kDa stress protein of Mycobacterium paratuberculosis, the causative agent of Johne's disease.
Paresis
Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability.
Parkinson Disease
[Electroacupuncture improved locomotor function by regulating expression of tyrosine hydroxylase and ?-synuclein proteins and transcription activating factor 6 and transcription factor X box binding protein 1 mRNAs in substantia nigra of rats with Parkinson's disease].
Pelvic Floor Disorders
The influence on coagulation of transdermal estrogen hormone replacement therapy as a preoperative preparation of the tissue before vaginal hysterectomy.
Pelvic Neoplasms
Establishment of a human renal pelvic cancer cell line producing tissue thromboplastin and plasminogen activator.
Pemphigoid, Bullous
Study on an antibody against F1F2 fragment of human factor V in a patient with Hashimoto's disease and bullous pemphigoid.
Peptic Ulcer
Prediction of gastrointestinal bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational cohort study (STROBE compliant).
Spontaneous antithrombin in a patient with benign paraprotein.
Pericardial Effusion
Management of Periprocedural and Early Pericardial Effusions with Tamponade Following Ablation of Atrial Fibrillation with Uninterrupted Factor Xa Inhibitors: A Case Series.
Periodontal Diseases
DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa.
Periodontitis
Activation of blood coagulation factor X by arginine-specific cysteine proteinases (gingipain-Rs) from Porphyromonas gingivalis.
Microvesicles, blood cells, and endothelial cells mediate phosphatidylserine-related prothrombotic state in patients with periodontitis.
Peripheral Arterial Disease
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Experimental model of lower limb ischemia in rats and the effect of YM466, an oral direct factor Xa inhibitor.
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Peripheral Vascular Diseases
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients.
Hypercoagulability in patients with peripheral vascular disease.
Peritoneal Fibrosis
Tissue factor and factor v involvement in rat peritoneal fibrosis.
Peritonitis
Experimental gram-negative peritonitis: decreased thromboplastin activity in organs with a simultaneous rise of thromboplastin in blood monocytes and peritoneal macrophages.
Macrophage matrix metalloproteinase-12 dampens inflammation and neutrophil influx in arthritis.
Mononuclear phagocyte thromboplastin and endotoxin in patients with secondary bacterial peritonitis.
Mononuclear phagocyte thromboplastin, bacterial counts and endotoxin levels in experimental endogenous gram-negative sepsis.
N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo.
Variables associated with outcome in dogs undergoing extrahepatic biliary surgery: 60 cases (1988-2002).
Peritonsillar Abscess
[Preoperative markers for risk of post-tonsillectomy bleeding in adults]
Persistent Infection
[Chronic pulmonary heart disease during ventriculo-atrial shunts in children]
Pharyngitis
[Crimean-Congo hemorrhagic fever]
Pheochromocytoma
18F-FDOPA PET/CT imaging of MAX-related pheochromocytoma.
A Novel Phenotype of Germline Pathogenic Variants in MAX: Concurrence of Pheochromocytoma and Ganglioneuroma in a Chinese Family and Literature Review.
A Novel, Likely Pathogenic MAX Germline Variant in a Patient With Unilateral Pheochromocytoma.
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Opposing effects of HIF1? and HIF2? on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Synchronous bilateral pheochromocytomas and paraganglioma with novel germline mutation in MAX: a case report.
[Advances in genes and molecular markers of pheochromocytoma].
[Mixed corticomedullary tumor]
Pituitary Neoplasms
A patient with a germline SDHB mutation presenting with an isolated pituitary macroprolactinoma.
Somatic and germline mutations in the pathogenesis of pituitary adenomas.
Placenta Diseases
The coagulation system in placental insufficiency: a study in the fetal circulation.
Placental Insufficiency
The coagulation system in placental insufficiency: a study in the fetal circulation.
plasma kallikrein deficiency
A Rare Cause of Isolated Prolonged Activated Partial Thromboplastin Time: An Overview of Prekallikrein Deficiency and the Contact System.
Fletcher factor deficiency, source of variations of the activated partial thromboplastin time test.
Isolated prolonged activated partial thromboplastin time in an asymptomatic patient: Fletcher factor deficiency.
Long-term safety outcomes of prekallikrein (Fletcher factor) deficiency: A systematic literature review of case reports.
Prekallikrein deficiency presenting as recurrent cerebrovascular accident: case report and review of the literature.
Prolonged Activated Clotting Time Immediately Prior to Open Cardiac Surgery.
Prolonged activated partial thromboplastin time due to plasma prekallikrein deficiency: a case study and literature review on its clinical significance.
Prolonged Partial Thromboplastin Time Without Bleeding History; Fletcher Factor Deficiency.
Severe prekallikrein deficiency due to a homozygous Trp499Stop nonsense mutation.
The effect of increased contact activation time on the activated partial thromboplastin time.
[Prekallikrein deficiency: a rare cause of a significant prolongation of the activated partial thromboplastin time. Apropos of a case]
Platelet Storage Pool Deficiency
Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity--a comparison with Scott syndrome.
Pleural Effusion
Heparan sulfate chains contribute to the anticoagulant milieu in malignant pleural effusion.
Procoagulant activity of purified protein derivative-stimulated pleural effusion mononuclear cells in tuberculous pleurisy.
Pneumonia
Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Phlegmasia cerulea dolens superimposed on disseminated intravascular coagulation in COVID-19.
TGF-? Blood Levels Distinguish Between Influenza A (H1N1)pdm09 Virus Sepsis and Sepsis due to Other Forms of Community-Acquired Pneumonia.
The role of hypothermia in the management of severe brain injury: a meta-analysis.
Transient acquired factor X deficiency associated with pneumonia.
Transient presence of lupus anticoagulant associated with mycoplasma pneumonia.
Venous Thromboembolism Events Following Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Syndrome Coronavirus 2 Based on CT Scans.
[Coagulopathy correlates with outcomes in patients with community- acquired pneumonia].
[Comparison of relevant indicators of coagulation and fibrinolysis in patients with varying severity of community-acquired pneumonia].
[Hemostasis system in lung cancer, benign tumors and chronic nonspecific pneumonias]
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
Pneumonia, Aspiration
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
Pneumoperitoneum
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Laparoscopic Sleeve Gastrectomy Affects Coagulation System of Obese Patients.
Pneumothorax
Internal jugular versus subclavian vein catheterization for central venous catheterization in orthotopic liver transplantation.
POEMS Syndrome
The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma.
Polycystic Ovary Syndrome
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Polycythemia
Distal gangrene in a polycythemic recipient fetus in twin-twin transfusion.
Erythrocytosis as a cause of false increase in prothrombin time and activated partial thromboplastin time.
Posterior Leukoencephalopathy Syndrome
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Postpartum Hemorrhage
Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study.
Postthrombotic Syndrome
Current treatment of acute lower extremity deep venous thrombosis.
Risk factors of postthrombotic syndrome before and after deep venous thrombosis treatment.
Pre-Eclampsia
Activation of the novel prothrombinase, fg12, as a basis for the pregnancy complications spontaneous abortion and pre-eclampsia.
Associations of thrombocytopenia, transaminase elevations, and transfusion with laboratory coagulation tests in women with preeclampsia: a cross-sectional study.
Coagulation studies in patients with marked thrombocytopenia due to severe preeclampsia.
Disseminated intravascular coagulation.
Increased sensitivity to thromboplastin synthesis in blood monocytes from pre-eclamptic patients.
Predictive value of 4-Hydroxyglutamate and miR-149-5p on eclampsia.
The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction.
[Clinical characteristics and outcomes of cerebral venous sinus thrombosis during pregnancy and puerperium].
Pre-Excitation Syndromes
Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A dysfunctional factor X (factor X San Giovanni Rotondo) present at homozygous and double heterozygous level: identification of a novel microdeletion (delC556) and missense mutation (Lys(408)-->Asn) in the factor X gene. A study of an Italian family.
The clinical and biological correlates of coagulopathy in children with acute leukemia.
Pregnancy Complications
Activation of the novel prothrombinase, fg12, as a basis for the pregnancy complications spontaneous abortion and pre-eclampsia.
Pregnancy Complications, Infectious
Diagnostic performance of biomarkers in maternal sepsis: A prospective observational study.
Pregnancy, Prolonged
[Procoagulant properties of the amniotic fluid. II. Thromboplastin acceleration in the amniotic fluid in the diagnosis of prolonged pregnancy]
Primary Ovarian Insufficiency
Relationship between mean platelet volume and low-grade systemic coagulation with vitamin D deficiency in primary ovarian insufficiency.
Prion Diseases
Analysis of the prion protein in primates reveals a new polymorphism in codon 226 (Y226F).
Prostatic Neoplasms
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.
Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer.
Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants.
Engineering of human coagulation factor x variants activated by prostate-specific antigen.
Protein S Deficiency
Anticoagulant protein C pathway defective in majority of thrombophilic patients.
Snake Venoms in Diagnostic Hemostasis and Thrombosis.
protein-glutamine gamma-glutamyltransferase deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease.
Clinical audit of inherited bleeding disorders in a developing country.
De Novo Precursor B-Lymphoblastic Leukemia/Lymphoma With Double-Hit Gene Rearrangements (MYC/BCL-2) Presented With Spinal Cord Compression and Acquired Factor XIII Deficiency.
Hemorrhagic Shock after Neonatal Circumcision: Severe Congenital Factor XIII Deficiency.
Inherited bleeding disorders in Indian women with menorrhagia.
Intracranial haemorrhage in patients with congenital haemostatic defects.
Lobar Hemorrhage Induced by Acquired Factor XIII Deficiency in a Patient with Cerebral Amyloid Angiopathy.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Rare bleeding disorders in children: identification and primary care management.
Rare inherited coagulation disorders in India.
The rare inherited coagulation disorders.
Proteinuria
A phase II trial of carbetimer for the treatment of colorectal cancer. A trial of the Northern California Oncology Group.
Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin.
Acquired isolated factor X deficiency associated with systemic amyloidosis. Case report and review of literature.
Acute Kidney Injury Induced by Bothrops Venom: Insights into the Pathogenic Mechanisms.
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
Clinical Characteristics and Abnormal Parameters Evolution in Patients With Novel Coronavirus Infection: A Case Series of 272 Cases in Guangzhou.
Distribution of ABO and Rh blood groups in patients with HELLP syndrome.
Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells.
Membranous glomerulonephritis, antiphospholipid syndrome, and persistent low C3 levels associated with meningococcal disease.
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Use of interleukin-2 in patients with acquired immunodeficiency syndrome.
[Antithrombin III in infantile nephrotic syndrome]
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Pruritus
Heparin-associated hematomas: possible allergic reaction.
Pulmonary Arterial Hypertension
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
A model to assess the risk of peripherally inserted central venous catheter-related thrombosis in patients with breast cancer: a retrospective cohort study.
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Lower Extremity Necrotizing Fasciitis in Diabetic and Nondiabetic Patients: Mortality and Amputation.
The FGL2/fibroleukin prothrombinase is involved in alveolar macrophage activation in COPD through the MAPK pathway.
Too Cold to Clot? Does Intraoperative Hypothermia Contribute to Bleeding After Aortic Surgery?
[Change of coagulation functions and its significance in acute exacerbation of chronic obstructive pulmonary disease].
Pulmonary Embolism
A 78-Year-Old Man with a Pulmonary Embolism Who Developed Skin Necrosis 7 Days After Treatment with the Direct Oral Anticoagulant Factor Xa Inhibitor Apixaban.
A comprehensive evaluation of apixaban in the treatment of venous thromboembolism.
A cost-analysis model for anticoagulant treatment in the hospital setting.
A Novel GNAS Mutation Causing Isolated Infantile Cushing's Syndrome.
A patient with pleuritic chest pain and abnormal blood clotting tests.
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Analysis of Partial Thromboplastin Times in Patients With Pulmonary Embolism During the First 48 Hours of Anticoagulation With Unfractionated Heparin.
Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
Antiphospholipid syndrome presenting as intracardiac thrombus with pulmonary embolism.
Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis.
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care.
Current management of acute symptomatic deep vein thrombosis.
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Direct oral anticoagulants in rare venous thrombosis.
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.
Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.
Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197).
Evaluation of Time to Therapeutic Anticoagulation and Associated Outcomes in Critically Ill, Obese Patients With Pulmonary Embolism Receiving Unfractionated Heparin.
Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.
Factor X inhibitors.
Factor Xa inhibition and sPESI failure in intermediate-high-risk pulmonary embolism.
Fondaparinux in heparin-induced thrombocytopenia.
Free-floating iliofemoral thrombus. A risk of pulmonary embolism.
Heterogeneity of synthetic factor Xa inhibitors.
Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets.
Lack of plasminogen activator inhibitor-1 enhances the preventive effect of DX-9065a, a selective factor Xa inhibitor, on venous thrombus and acute pulmonary embolism in mice.
Low molecular weight heparin in acute stroke.
Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen.
Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement: A Systematic Review and Meta-analysis.
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism.
Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report.
Possible Rivaroxaban Failure during the Postpartum Period.
Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism.
Probable pulmonary embolism with repeat administration of prothrombin complex concentrate in a factor Xa inhibitor patient.
Retrospective evaluation of shortened prothrombin time or activated partial thromboplastin time for the diagnosis of hypercoagulability in dogs: 25 cases (2006-2011).
Review of the initiation of anticoagulant therapy.
Review: Factor Xa inhibitors reduce DVT more than LMWH in total knee or hip replacement.
Rivaroxaban for treatment of venous thromboembolism in older adults.
Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Short-Term Subcutaneous Fondaparinux and Oral Edoxaban for Acute Venous Thromboembolism.
Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
SR-90107 (Sanofi-Synthélabo).
Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
The 'chest pain kit' study: A 'pill in the pocket' concept to improve the pre-hospital therapy of acute coronary syndrome.
The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
The prophylactic role of tranexamic acid to reduce blood loss during radical surgery: A prospective study.
The role of antifibrinolytic agents in gynecologic cancer surgery.
The value of inhibitors of factor Xa for the treatment of pulmonary embolism.
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.
Thrombin-antithrombin III complexes as an additional diagnostic aid in pulmonary embolism.
TLT-1-CONTROLS EARLY THROMBUS FORMATION AND STABILITY BY FACILITATING AIIBB3 OUTSIDE-IN SIGNALING IN MICE.
Transitions of care in anticoagulated patients.
Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism.
Use of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: a case report.
Venous thromboembolism prophylaxis guidelines: use by primary care physicians.
Warfarin hypersensitivity due to gluten-sensitive enteropathy: a case study.
[Clinical Value Evaluation of Perioperative Prophylactic Anticoagulation Therapy for Lung Cancer Patients].
[Critical appraisal: Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Prandoni P, Carnovali M, Marchiori A, Galilei investigators. Arch Intern Med 2004; 164: 1077-83]
[Determination of factor Xa inhibition doses of low-molecular heparin, nadroparin and reviparin in urological patients]
[Disseminated coronary occlusions and massive pulmonary embolism in a 40-year-old woman.]
[Effect of tranexamic acid combined flexion position of hip and knee on perioperative bleeding following unilateral total knee arthroplasty].
[Fondaparinux: The present and the future.]
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
[Recurrent thromboembolisms despite full anticoagulation in a patient with antiphospholipid syndrome].
Pulmonary Fibrosis
Glycogen Synthase Kinase-3? Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury.
Procoagulant, tissue factor-bearing microparticles in bronchoalveolar lavage of interstitial lung disease patients: an observational study.
Purpura
A monoclonal immunoglobulin A (kappa) factor VIII:C inhibitor associated with primary amyloidosis: identification and characterization.
Antiphospholipids antibodies in a 12-month-old presenting with idiopathic thrombocytopenic purpura.
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Immune Thrombocytopenia Purpura Secondary to COVID-19.
Lupus anticoagulant-hypoprothrombinemia syndrome and immunoglobulin-A vasculitis: a report of Japanese sibling cases and review of the literature.
Neonatal congenital Factor X deficiency.
Prolonged partial thromboplastin times in children with fever and petechiae without bacteremia or sepsis.
[Grave transitory hemorrhagic diathesis in pregnancy; thrombokinase intoxication caused by premature detachment of the placenta in familial purpura simplex.]
[Transitions of each inhibitor in a patient with lupus anticoagulant and anti-prothrombin antibody]
Purpura, Thrombocytopenic
Diagnostic efficacy of six plasma proteins in evaluating consumptive coagulopathies. Use of receiver operating characteristic curves to compare antithrombin III, plasminogen, alpha 2-plasmin inhibitor, fibronectin, prothrombin, and protein C.
Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies.
Purpura, Thrombocytopenic, Idiopathic
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.
Low-dose rituximab in the treatment of acquired haemophilia.
Pharmaceutical Approval Update.
The spectrum of bleeding disorders in women with menorrhagia: a report from Western India.
[Presence of lupus-type anticoagulant, in systemic lupus erythematosus and other clinical entities]
Purpura, Thrombotic Thrombocytopenic
Clinical factors and biomarkers predicting outcome in patients with immune-mediated thrombotic thrombocytopenic purpura.
Virus-inactivated plasma - Plasmasafe: a one-year experience.
[Reasons for fresh frozen plasma transfusion in a general hospital]
Q Fever
Acute Q fever in southern Taiwan: atypical manifestations of hyperbilirubinemia and prolonged fever.
[Activated partial thromboplastin time and Q fever]
Rabies
Rabies virus M protein expressed in Escherichia coli and its regulatory role in virion-associated transcriptase activity.
[Vaccination against rabies as a source of thrombokinase.]
Rectal Fistula
[Applicability and indications of colonoscopic screening for Crohn's disease in patients with fistula-in-ano].
Refractive Errors
Risk Factors for Decompression Retinopathy After Glaucoma Surgery.
Renal Insufficiency
A Rare Cause of Coagulopathy in a Patient with Rapidly Progressive Renal Failure.
Acute respiratory failure in adult patients with dengue virus infection.
Anticoagulation options for patients with heparin-induced thrombocytopenia requiring renal support in the intensive care unit.
Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study.
Argatroban.
Biomarkers in newborns with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia.
Bleeding during critical illness: a prospective cohort study using a new measurement tool.
Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.
Chronic peritoneal dialysis in a patient with primary amyloidosis, renal failure, and factor X deficiency.
Continuous venovenous haemofiltration in cancer patients with renal failure: a single-centre experience.
Deciphering the coagulation profile through the dynamics of thrombin activity.
Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin.
Hemodialysis for removal of dabigatran in a patient with gastric hemorrhage.
Human umbilical cord blood-derived CD34+ cells cause attenuation of multiorgan dysfunction during experimental heatstroke.
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
In vivo diagnosis of massive hepatic infarction by computed tomography.
Incidence and Risk Factors for Cannula-Related Venous Thrombosis After Venovenous Extracorporeal Membrane Oxygenation in Adult Patients With Acute Respiratory Failure.
Inhibition by anticoagulant drugs of the progressive hypertension and uremia associated with renal infarction in rats.
Outcomes of patients hospitalized with peptic ulcer disease diagnosed in acute upper endoscopy.
Polyvinylpyrrolidone induced artefactual prolongation of activated partial thromboplastin times in intravenous drug users with renal failure.
Prediction of gastrointestinal bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational cohort study (STROBE compliant).
Spontaneous resolution of acquired factor X deficiency in amyloidosis.
The exploration of risk factors of concurrent bacteraemia in patients critically ill with severe dengue.
[Argatroban: pharmacological properties and anaesthesiological aspects]
[Renal biopsy: Procedures, contraindications, complications.]
Renal Insufficiency, Chronic
Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function.
Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.
Polyvinylpyrrolidone induced artefactual prolongation of activated partial thromboplastin times in intravenous drug users with renal failure.
[Apixaban as therapeutic option in nephropathy patients with heparin-induced thrombocytopenia (HIT)].
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Reperfusion Injury
A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.
DIANNEXIN DOWN-MODULATES TNF-INDUCED ENDOTHELIAL MICROPARTICLE RELEASE BY BLOCKING MEMBRANE BUDDING PROCESS.
Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently.
N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo.
Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice.
Respiratory Distress Syndrome
Efficacy of limited fluid resuscitation in patients with hemorrhagic shock: a meta-analysis.
Fresh frozen plasma/red blood cell resuscitation regimen that restores procoagulants without causing adult respiratory distress syndrome.
Lower Extremity Necrotizing Fasciitis in Diabetic and Nondiabetic Patients: Mortality and Amputation.
[Changes in the blood coagulation potential of premature calves with and without respiratory distress syndrome]
Respiratory Insufficiency
Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
Acute respiratory failure and intravascular coagulation.
Association Between Admission Serum Phosphate Level and All-Cause Mortality Among Patients with Spontaneous Intracerebral Hemorrhage.
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
Effects of phospholipase C, a tissue thromboplastin inhibitor, on pulmonary microembolism after missile injury of the limb.
Emergent surgical evacuation of traumatic intracranial hematoma in patients with preoperative thrombocytopenia: surgical risk and early outcome.
Outcome of Dengue Hemorrhagic Fever-Caused Acute Kidney Injury in Thai Children.
Tourniquet ineffectiveness to reduce the severity of envenoming after Crotalus durissus snake bite in Belo Horizonte, Minas Gerais, Brazil.
Respiratory Tract Infections
Factor X and its deficiency states.
Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications.
Retinal Detachment
[Coagulation factors and fibrinolytic system in subretinal liquid in patients with rheumatogenous retinal detachment]
Retinal Perforations
Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition.
Retinal Vein Occlusion
The possible role of platelet coagulant activities in the pathogenesis of venous thrombosis.
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture.
Retinoblastoma
Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Rhabdomyolysis
Acute renal failure after snakebite: a report of four cases.
Rheumatic Diseases
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays.
Effect of immune complex-containing sera from patients with rheumatic diseases on thromboplastin activity of monocytes.
Rheumatic Heart Disease
Association between Coagulation Function and Cerebral Microbleeds in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease.
Sarcoidosis
Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis.
Sarcoma
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
[On changes in the content of thrombokinase and fibrinogen in the blood during the process of growth of transplantable sarcoma.]
Scleroderma, Diffuse
Progressive systemic sclerosis with the nephrotic syndrome and acquired factor X deficiency.
Scoliosis
Bleeding and coagulation changes during spinal fusion surgery: a comparison of neuromuscular and idiopathic scoliosis patients.
Clotting parameters and thromboelastography in children with neuromuscular and idiopathic scoliosis undergoing posterior spinal fusion.
Clotting parameters in patients with adolescent idiopathic scoliosis undergoing posterior spinal fusion and instrumentation.
Scrub Typhus
The clinical differences between dengue and scrub typhus with acute respiratory failure in southern Taiwan.
Seizures
Factor X deficiency in a cat.
Phase I-II study of recombinant alpha-2 interferon against advanced leukemia and lymphoma in children.
Post-stroke seizure-Do the locations, types and managements of stroke matter?
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
The FDP/FIB Ratio and Blood FDP Level May Be Related to Seizures After Fever in Young Children.
The lupus anticoagulant. High incidence of 'negative' mixing studies in a human immunodeficiency virus-positive population.
Seizures, Febrile
Severe Factor X Deficiency Presenting as Febrile Seizure in an Infant.
The FDP/FIB Ratio and Blood FDP Level May Be Related to Seizures After Fever in Young Children.
Sepsis
Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.
Activated partial thromboplastin time waveform analysis as specific sepsis marker in cardiopulmonary bypass surgery.
Activated partial thromboplastin time waveform analysis: a new tool to detect infection?
Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome.
An explainable machine learning algorithm for risk factor analysis of in-hospital mortality in sepsis survivors with ICU readmission.
Antimicrobial and Anticoagulant Activity of N-chlorotaurine (NCT), N,N-dichloro-2,2-dimethyltaurine (NVC-422) and N-monochloro-2,2-dimethyltaurine (NVC-612) in Human Blood.
Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure.
Challenge and rechallenge: drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis.
Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
Clinical, laboratory, and hemostatic findings in cats with naturally occurring sepsis.
Combination of biphasic transmittance waveform with blood procalcitonin levels for diagnosis of sepsis in acutely ill patients.
Continuous heparinization and circulating adhesion molecules in the critically ill.
DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage.
Delta neutrophil index as a prognostic marker in emergent abdominal surgery.
Diagnostic efficacy of activated partial thromboplastin time waveform and procalcitonin analysis in pediatric meningococcal sepsis.
Disseminated intravascular coagulation and coagulation disorders.
Disseminated intravascular coagulation.
Does continuous heparinization influence platelet function in the intensive care patient?
Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis.
Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation.
Early response in septicemia in newborns and their mothers. Effect of Escherichia coli, Streptococcus agalactiae and tumor necrosis factor on lactoferrin release and the generation of tissue thromboplastin.
Ecotin is a potent inhibitor of the contact system proteases factor XIIa and plasma kallikrein.
Effect of cardiopulmonary bypass on activated partial thromboplastin time waveform analysis, serum procalcitonin and C-reactive protein concentrations.
Experimental gram-negative septicemia: thromboplastin generation in mononuclear phagocytes from different anatomical sites.
Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases.
Factor Xa-evoked relaxation in rat aorta: involvement of PAR-2.
FXa Inhibition and Coagulation Changes During DVT Prophylaxis by Enoxaparin Over the Course of a 15-Day Follow-Up in Septic Patients.
Humoral coagulation and early complications after allogeneic bone marrow transplantation.
Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats.
Intracerebral hemorrhage after liver transplantation.
Mononuclear phagocyte thromboplastin, bacterial counts and endotoxin levels in experimental endogenous gram-negative sepsis.
Normalization of Activated Partial Thromboplastin Time Correlates with Low Levels of Dabigatran in a Patient with Severe Sepsis.
Platelet aggregation as a sign of septicemia in thermal injury. A prospective study.
Platelets as a prognostic marker for sepsis: A cohort study from the MIMIC-III database.
Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis.
Prolonged partial thromboplastin times in children with fever and petechiae without bacteremia or sepsis.
Proteinase inhibitors in severe inflammatory processes (septic shock and experimental endotoxaemia): biochemical, pathophysiological and therapeutic aspects.
Routine coagulation tests on ICU admission are associated with mortality in sepsis: an observational study.
Severe COVID-19 has a distinct phenotype from bacterial sepsis: a retrospective cohort study in deceased patients.
The biphasic transmittance waveform: an early marker of sepsis in patients with neutropenia.
The effect of heparin administration in animal models of sepsis: A prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies*
The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin. An assay for detection of endotoxin.
The role of the E2F1 transcription factor in the innate immune response to systemic LPS.
Transmitting and absorbing new information on the early identification of sepsis patients: the partial thromboplastin time biphasic waveform.
Use of rotational thromboelastometry to predict hemostatic complications in pediatric patients undergoing extracorporeal membrane oxygenation: A retrospective cohort study.
Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit.
[A new warning scoring system establishment for prediction of sepsis in patients with trauma in intensive care unit].
[Coagulation tests in septic surgical patients]
[Correlation of coagulation indicators with inflammatory markers for sepsis in the patients with hematological malignancies].
[Heparin and antiheparin in childhood. 3. Heparin level measurements and their importance in heparin monitoring]
[Meningococcal disease: comparison between clinical forms]
[Mononuclear phagocytes, the hemostasis system and the intravascular coagulation syndrome]
[Risk factors and prognosis of acute kidney injury in children with sepsis in pediatric intensive care unit].
[The abnormal activated partial thromboplastin time biphasic waveform: a red flag in the sepsis? Technique and interest as marker of the sepsis]
Severe Acute Respiratory Syndrome
Venous Thromboembolism Events Following Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Syndrome Coronavirus 2 Based on CT Scans.
Severe Combined Immunodeficiency
Analysis of the defect in IFN-gamma induction of MHC class II genes in G1B cells: identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor.
Identification of regulatory factor X as a novel mismatch repair stimulatory factor.
Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex.
Regulatory factor X, a bare lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex.
Severe Dengue
Acute kidney injury in dengue virus infection.
Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome.
Prothrombin time and partial thromboplastin time as a predictor of bleeding in patients with dengue hemorrhagic fever.
The exploration of risk factors of concurrent bacteraemia in patients critically ill with severe dengue.
Severe Fever with Thrombocytopenia Syndrome
Risk factors associated with fatality of severe fever with thrombocytopenia syndrome: a meta-analysis.
Sexually Transmitted Diseases
A study of coagulation and anti-endothelial antibodies in idiopathic livedo reticularis.
Case report: the anticardiolipin (antibody) syndrome.
Diagnostic Pitfalls in a Man with Systemic Lupus Erythematous.
IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes.
Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome.
The increase of blood anticardiolipin antibody depends on the underlying etiology in cerebral ischemia.
[Clinical and analytical manifestations of primary antiphospholipid antibody syndrome]
[Transverse myelopathy in a patient with systemic lupus erythematosus associated with positive anticardiolipin antibody--a case report]
Shock, Septic
Antithrombin replacement in patients with sepsis and septic shock.
Contact activation in shock caused by invasive group A Streptococcus pyogenes.
Effects of dexamethasone on endotoxin shock in the anesthetized pony: hematologic, blood gas, and coagulation changes.
Kallikrein-kinin system activation in streptococcal toxic shock syndrome.
Lower Extremity Necrotizing Fasciitis in Diabetic and Nondiabetic Patients: Mortality and Amputation.
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
Pre-operative labs: Wasted dollars or predictors of post-operative cardiac and septic events in orthopaedic trauma patients?
Role of thromboelastography in the evaluation of septic shock patients with normal prothrombin time and activated partial thromboplastin time.
Routine coagulation tests on ICU admission are associated with mortality in sepsis: an observational study.
[Risk factors and prognosis of acute kidney injury in children with sepsis in pediatric intensive care unit].
Shwartzman Phenomenon
Glomerular coagulation system in renal diseases.
Thromboplastin content in the vessel walls of different arteries and organs of rabbits.
Sick Sinus Syndrome
Evidence-Based Analysis of the Emergency Temporary Cardiac Pacing (Electrical Stimulation from Metal Wire Electrode).
Sinus Thrombosis, Intracranial
Dural sinus thrombosis in paroxysmal nocturnal hemoglobinuria.
Fatal dural sinus thrombosis associated with heterozygous factor V Leiden and a short activated partial thromboplastin time.
Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients.
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
Sjogren's Syndrome
Microparticles as biomarkers in autoimmunity: from dust bin to center stage.
Smallpox
[Contribution to the study of vaccination physiopathology. Behavior of certain coagulation factors under smallpox vaccine stimulation (platelets, prothrombin time, partial thromboplastin time)]
Soft Tissue Injuries
Preoperative hematological assessment of pediatric patients with cerebral palsy.
Spinal Cord Diseases
Comparison of cardiovascular parameters between patients with ossification of posterior longitudinal ligament and patients with cervical spondylotic myelopathy.
Spinal Cord Injuries
Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats.
Splenic Rupture
Atraumatic splenic rupture in a patient treated with apixaban: A case report.
Atraumatic splenic rupture in amyloidosis.
Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
ST Elevation Myocardial Infarction
Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
Determination of risk factors affecting the in-hospital prognosis of patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention.
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
Stomach Neoplasms
Procoagulant activity of human stomach and colon cancers.
Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer.
Stomach Ulcer
DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
Stomatitis
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Streptococcal Infections
Host factors in experimental group A streptococcal infections; the role of tissue thromboplastin.
Stroke
A case report of parenchymal hematoma after intravenous thrombolysis in a rivaroxaban-treated patient: Is it a true rivaroxaban hemorrhagic complication?
A cost-analysis model for anticoagulant treatment in the hospital setting.
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long?term prevention of thromboembolic complications in patients with atrial fibrillation?
A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Alteplase for Acute Ischemic Stroke after Heparin Reversal with Protamine: A Case Report and Review.
Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial.
An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice.
Anti-Xa Activity and Event Risk in Patients With Direct Factor Xa Inhibitors Initiated Early After Stroke.
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Anticoagulation therapy for atrial fibrillation.
Anticoagulation therapy: Direct factor Xa inhibition improves stroke prevention in patients with AF.
Antiphospholipid antibodies and stroke in the young--a study of three cases.
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions.
Antithrombotic medication for cardioembolic stroke prevention.
Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda.
Antithrombotics in atrial fibrillation and coronary disease.
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial.
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design.
Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study.
Apixaban to prevent stroke in patients with atrial fibrillation: a review.
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model.
Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients with Atrial Fibrillation.
Apolipoprotein E genotype, coagulation, and survival following acute stroke.
Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case-control study.
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute.
Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants.
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa).
Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects.
Biological effects of distension media in bipolar versus monopolar resectoscopic myomectomy: a randomized trial.
Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
Blood coagulation and fibrinolysis in acute ischaemic and haemorrhagic (intracerebral and subarachnoid haemorrhage) stroke: does decreased plasmin inhibitor indicate increased fibrinolysis in subarachnoid haemorrhage compared to other types of stroke?
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Characteristics, Management, and Outcomes of Patients with Atrial Fibrillation Experiencing a Major Bleeding Event While on Rivaroxaban.
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.
Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study.
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.
Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
Clopidogrel hydrogen sulphate for atrial fibrillation.
Comparative effectiveness of oral anticoagulants in everyday practice.
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism.
Comparing Safety and Efficacy of Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Hemophiliacs with Non-Valvular Atrial Fibrillation.
Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.
Controversies: Stroke Prevention in Chronic Kidney Disease.
Correction to: Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Current Perspective on Use of NOAC in Clinical Practice in India.
Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Dexamethasone improves heat stroke-induced multiorgan dysfunction and damage in rats.
Diagnosis and Treatment of Atrial Fibrillation.
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Dilemma of Indication for Thrombolysis in a Patient with Acute Ischemic Stroke Treated with a Novel Oral Anticoagulant.
Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Direct Factor Xa Inhibitors for Long-term Stroke Prevention in Atrial Fibrillation: Could the Lower Dose Fit All?
Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities.
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.
Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor.
Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Edoxaban tosylate.
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†
Edoxaban: a new oral direct factor xa inhibitor.
Edoxaban: a review in nonvalvular atrial fibrillation.
Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time.
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Effect of Heparin on Recanalization in Acute Stroke Patients with Intra-Arterial Thrombi.
Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests.
Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
Efficacy of direct factor Xa inhibitors compared to warfarin in preventing stroke in adults with non-valvular atrial fibrillation: a systematic review protocol.
Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.
Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Factor X inhibitors.
Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis.
Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase.
Factor Xa inhibitors differently modulate electrical activities in pulmonary veins and the sinoatrial node.
Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices.
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation.
Factors Associated With Major Bleeding Events: Insights From the ROCKET AF Trial (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban.
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus.
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.
Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection.
Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report.
Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors.
Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment.
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Impact of Patent Foramen Ovale on Total Knee Arthroplasty Cerebrovascular Accident Perioperative Management.
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan: the Stroke Unit Multicenter Observational (SUMO) Study.
Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats.
Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes.
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Intracranial hemorrhage in patient treated with rivaroxaban.
Intravenous Thrombolysis for Acute Ischemic Stroke in a Patient Receiving Rivaroxaban.
Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study.
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation.
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis.
Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper.
Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks.
Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation.
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Monitoring the anticoagulant effect after a massive rivaroxaban overdose.
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.
New anticoagulant treatments to protect against stroke in atrial fibrillation.
New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome.
New options for stroke prevention in atrial fibrillation.
New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials.
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Newer Oral Anticoagulants: Stroke Prevention and Pitfalls.
Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Novel anticoagulant therapy: principle and practice.
Novel anticoagulants for stroke prevention in atrial fibrillation and chronic kidney disease.
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban.
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Off-label use of reduced dose direct oral factor Xa-inhibitors in subjects with atrial fibrillation: a review of clinical evidence.
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
Optimal Dosing of Intravenous Unfractionated Heparin Bolus in Transient Ischemic Attack or Stroke.
Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
Oral anticoagulants for Asian patients with atrial fibrillation.
Oral anticoagulation and vitamin K deficiency.
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation.
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.
Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations.
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Periprocedural management of rivaroxaban-treated patients.
Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects.
Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses.
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm.
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Population Pharmacokinetic-Pharmacodynamic Modeling Analysis of Intrinsic FXa and Bleeding From Edoxaban Treatment.
Post-stroke seizure-Do the locations, types and managements of stroke matter?
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.
Practical management of patients on apixaban: a consensus guide.
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Preclinical and clinical data for factor Xa and "universal" reversal agents.
Predicting abnormal coagulation in ischemic stroke: reducing delay in rt-PA use.
Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism.
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
Prevention of Stroke in Patients With Atrial Fibrillation.
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Prognosis of spontaneous intracerebral hemorrhage in hemodialysis patients.
Quantification of apixaban in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry.
Quick reference guide to apixaban.
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation.
Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.
Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Recombinant tissue-type plasminogen activator (rt-PA) therapy in an acute stroke patient taking dabigatran etexilate: a case report and literature review.
Rectus Sheath Hematoma Associated with Apixaban.
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy.
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation.
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.
Rivaroxaban in atrial fibrillation.
Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study.
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
Rivaroxaban: a review of its use in acute coronary syndromes.
Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation.
Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
Safety and efficacy of apixaban in the treatment of atrial fibrillation.
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation.
Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.
Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban.
Shortened Activated Partial Thromboplastin Time Is Associated With Acute Ischemic Stroke, Stroke Severity, and Neurological Worsening.
Spontaneous cervical artery dissection is accompanied by a hypercoagulable state and simultaneous inflammatory condition.
Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
Stroke and conditions that mimic it: a protocol secures a safe early recognition.
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy.
Stroke prevention and treatment.
Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions.
Stroke Prevention in Atrial Fibrillation: Impact of Novel Oral Anticoagulants.
Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation.
Successful Peritoneal Dialysis Catheter Placement in a New End-Stage Renal Disease Patient with Combined Antiphospholipid Syndrome and Factor XI Deficiency.
Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature.
Sudden Loss of Vision: An Insight into Rivaroxaban.
Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.
The "Dual-Pathway" Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial.
The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah.
The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis.
The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
The pharmacology of novel oral anticoagulants.
The Potential Role of Edoxaban in Stroke Prevention Guidelines.
The potential role of inflammation in cryptogenic stroke.
The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy.
The role of aspirin for stroke prevention in atrial fibrillation.
The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.
The serial hemostasis-related changes in patients with cerebral infarction: comparison between progressing and non-progressing stroke.
Therapeutic Plasma Exchange for Urgent Rivaroxaban Reversal.
Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke.
Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function.
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Transitions of care in anticoagulated patients.
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation.
Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Use of rivaroxaban in patients with stroke.
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
Vitamin K antagonists. Ready to be replaced?
What did we learn from new oral anticoagulant treatment?
What's new in stroke? The top 10 studies of 2009-2011: part II.
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
[Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893].
[Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure].
[Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism].
[Characteristics of circulation and microcirculation in healthy people of Han nationality at different altitudes].
[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].
[Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
[Effect of plasma fibrinogen level-based defibrase therapy in patients with acute cerebral infarction.]
[Evidence of novel oral anticoagulants (NOAC)].
[Interventional left atrial appendage occlusion. A reasonable alternative to oral anticoagulation - even in the era of the new substances?].
[New antithrombotics for atrial fibrillation.]
[New oral anticoagulants for the prevention of stroke : Open questions in geriatric patients].
[New treatments for stroke and thromboembolism prevention in atrial fibrillation].
[Novel oral anticoagulants (NOAC)].
[Oral factor Xa inhibitors or warfarin for stroke prophylaxis. ROCKET AF and ARISTOTLE studies].
[Perioperative management and therapy of bleeding complications].
[Pharmacology of the new oral anticoagulants].
[Prevention of cardioembolic stroke].
[Prevention of stroke in nonvalvular atrial fibrillation. Oral direct factor Xa inhibitor apixaban: positive experiences in general medical practice].
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Stupor
[Acute hepatic insufficiency in guinea pigs. Experimental model caused by the injection of monoethanolamine oleate]
Subarachnoid Hemorrhage, Traumatic
Emergent surgical evacuation of traumatic intracranial hematoma in patients with preoperative thrombocytopenia: surgical risk and early outcome.
Surgical Wound Infection
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Syphilis
A case of syphilis presenting with prolonged etiology-unrevealed fever, accompanying activated partial thromboplastin time prolongation.
Antiphospholipid antibody syndrome: a case report and review of the literature.
Antiphospholipid antibody syndrome: an unusual cause of stroke in a 22-year-old female.
Chorea and high antiphospholipid antibodies: probable primary antiphospholipid syndrome.
Chorea as a manifestation of the antiphospholipid syndrome in childhood.
Diagnostic Pitfalls in a Man with Systemic Lupus Erythematous.
Non-lupus nephropathy associated with antiphospholipid antibodies.
Perioperative primary thrombosis prophylaxis for colorectal cancer in an asymptomatic antiphospholipid antibody carrier -a case report and literature review-.
Sjögren's syndrome and pregnancy.
The characteristics of beta 2-glycoprotein I-dependent anticardiolipin antibody and blood coagulation status in subjects with classical biological false-positive syphilis reactions.
The tissue thromboplastin inhibition test in diabetics without cerebro-cardiovascular diseases.
[A case of anti-phospholipid antibody syndrome associated with subdural hematoma]
Tachycardia
Acquired factor VIII deficiency presenting with compartment syndrome.
Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue.
Outcomes of patients hospitalized with peptic ulcer disease diagnosed in acute upper endoscopy.
Pediatric Risk of Mortality III Score - Predictor of Mortality and Hospital Stay in Pediatric Intensive Care Unit.
Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
Takayasu Arteritis
Anti-factor IX circulating anticoagulant and immune thrombocytopenia in a case of Takayasu's arteritis.
Telangiectasia, Hereditary Hemorrhagic
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.
Telangiectasis
Angiodysplasia of upper gastrointestinal tract with coagulopathy.
Gross hematuria due to acquired haemophilia in hereditary hemorrhagic telangiectasia.
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.
Tetanus
Hemophilic pseudotumor of the ilium due to plasma thromboplastin component (PTC) deficiency, with post-operative tetanus.
Tetralogy of Fallot
Attributable fraction for cardiac malformations.
Thrombasthenia
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Glanzmann's thrombasthenia in pregnancy: a case and review of the literature.
Impaired platelet procoagulant mechanisms in patients with bleeding disorders.
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Platelet prothrombin converting activity in hereditary disorders of platelet function.
Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity--a comparison with Scott syndrome.
The spectrum of bleeding disorders in women with menorrhagia: a report from Western India.
The use of recombinant factor VIla in a primigravida with Glanzmann's thrombasthenia during delivery.
thrombin deficiency
Apixaban attenuates ischemia-induced myocardial fibrosis by inhibition of Gq/PKC signaling.
Thrombocytopenia
'Lupus' anticoagulant and thrombosis of the hepatic veins (Budd-Chiari syndrome). Report of three patients and review of the literature.
A 17-Year-Old With Chest Pain.
A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia.
A case of Budd-Chiari syndrome with high antiphospholipid antibody in a patient with systemic lupus erythematosus.
A case of cerebral infarction associated with positive antiphospholipid antibody in a systemic lupus patient.
A case of immune thrombocytopenic purpura with prolonged aPTT time: A clotter hidden in a bleeder?
A comparative study of the disease in cattle caused by Theileria parva or T. lawrencei: II. Hematology, clinical chemistry, coagulation studies and complement.
A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
A prospective pilot study of platelet function and its relationship with postoperative bleeding in pediatric cardiac surgery.
Abnormal peri-operative haemorrhage in asymptomatic patients is not predicted by laboratory testing.
ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats.
Accidental fatal aflatoxicosis due to contaminated commercial diet in 50 dogs.
Acute intrinsic renal failure and blood coagulation disorders after a snakebite in a dog.
Acute necrotizing encephalopathy associated with hemophagocytic syndrome.
Acute renal failure after snakebite: a report of four cases.
Adenoviral pneumonia in children.
Adverse gastrointestinal complications after cardiopulmonary bypass: can outcome be predicted from preoperative risk factors?
Albumin dialysis in critically ill patients: use versus omission of intradialytic heparin.
Alkhumra (Alkhurma) virus outbreak in Najran, Saudi Arabia: Epidemiological, clinical, and Laboratory characteristics.
Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April).
An increase of blood anti-beta2-glycoprotein I antibody in Japanese encephalitis associated with cerebral ischemia.
Animal models for antiphospholipid syndrome in pregnancy.
Anti-factor IX circulating anticoagulant and immune thrombocytopenia in a case of Takayasu's arteritis.
Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression.
Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations.
Antiphospholipid antibody syndrome: an unusual cause of stroke in a 22-year-old female.
Antiphospholipid syndrome and multiple ischemic strokes in a patient with myasthenia gravis.
Antiphospholipids antibodies in a 12-month-old presenting with idiopathic thrombocytopenic purpura.
Antiplatelet and Anticoagulant Drugs in Interventional Radiology.
Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement?
Apparent argatroban resistance in a patient with elevated factor VIII levels.
Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.
Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients.
Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
Argatroban.
Assessment of Coagulation by Thromboelastography During Ongoing Postpartum Hemorrhage: A Retrospective Cohort Analysis.
ATGAM associated coagulopathy in renal transplant patients: a report of two unusual cases.
Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome.
Bilateral Orbital Haematomas in an Anticoagulated Patient with Severe H1N1 Influenza.
Blood coagulation abnormalities associated with envenoming by Trimeresurus albolabris in Hong Kong.
Bruising associated with the use of fluoxetine.
Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome.
Chorea and high antiphospholipid antibodies: probable primary antiphospholipid syndrome.
Clearance of fibrin from glomeruli. Renal cortical fibrinolytic response after thromboplastin infusion in the rat.
Clinical and laboratory profile of patients with Kyasanur forest disease: A single-centre study of 192 patients from Karnataka, India.
Clinical features and dynamic ordinary laboratory tests differentiating dengue fever from other febrile illnesses in children.
Clinical significance of anticardiolipin and anti-beta2-glycoprotein I antibodies.
Clinicopathologic findings of naturally occurring Rabbit Hemorrhagic Disease Virus 2 infection in pet rabbits.
Coagulation abnormalities associated with acute Angiostrongylus vasorum infection in dogs.
Coagulation and the hypertensive diseases of pregnancy.
Coagulation defects in rabbits after infusion of dispersed fluorochemicals.
Coagulation profile, haematological and biochemical changes in kids naturally infected with peste des petits ruminants.
Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.
Coagulation studies in patients with marked thrombocytopenia due to severe preeclampsia.
Coagulopathy After Isolated Severe Traumatic Brain Injury in Children.
Coagulopathy and its effect on treatment and mortality in patients with traumatic intracranial hemorrhage.
Coagulopathy associated with hematin treatment for acute intermittent porphyria.
Coagulopathy in COVID-19.
Complement in Secondary Thrombotic Microangiopathy.
Concentration of D-dimers in healthy cats and sick cats with and without disseminated intravascular coagulation (DIC).
Connective tissue disease associated with sclerodermoid features, early abortion, and circulating anticoagulant.
Costly coagulation profile tests prior to performing breast biopsies. Do we really need it?
COVID-19 versus HIT hypercoagulability.
Crimean-Congo hemorrhagic fever.
Deficiency of the contact phase of intrinsic coagulation in a horse.
Detrimental effects of N(omega) nitro-L-arginine methyl ester (L-NAME)in experimental Escherichia coli sepsis in the newborn piglet.
Development of a novel mouse model for dengue virus infection.
Difference in clinical presentation between the first and second phases of Kyasanur Forest disease: an experience from a teaching hospital in South India.
Diffuse hemangiomatosis, coagulopathy and microangiopathic hemolytic anemia.
Disseminated intravascular coagulation associated with colic in 23 horses (1984-1989).
Disseminated intravascular coagulation caused by moojenactivase, a procoagulant snake venom metalloprotease.
Disseminated intravascular coagulation in cats.
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Disseminated intravascular coagulation in six horses.
Disseminated intravascular coagulation in the newborn.
Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids.
Double filtration plasmapheresis for a case of Crimean-Congo hemorrhagic fever.
Early Coagulopathy After Isolated Severe Traumatic Brain Injury: Relationship With Hypoperfusion Challenged.
Effect of a selective PAF antagonist SM-10661 ((+/-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC).
Effect of heparin on chronically induced intravascular coagulation in dogs.
Effects of intravascular clotting on the activation of the complement system: The role of the platelet.
Emergent surgical evacuation of traumatic intracranial hematoma in patients with preoperative thrombocytopenia: surgical risk and early outcome.
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
Ethanol intoxication is associated with a lower incidence of admission coagulopathy in severe traumatic brain injury patients.
Evaluation of a Standardized Protocol Using Lepirudin or Argatroban for Heparin-Induced Thrombocytopenia.
Evaluation of factors predictive of the prognosis in Crimean-Congo hemorrhagic fever: new suggestions.
Evaluation of prognostic factors in the surgical treatment of adrenal gland tumors in dogs: 41 cases (1999-2005).
Evaluation of the potential causes of epistaxis in dogs with natural visceral leishmaniasis.
Experimental Sarcocystis suicanis infections: disease in growing pigs.
Fatal diffuse thrombotic microangiopathy after a bite by the "Fer-de-Lance" pit viper (Bothrops lanceolatus) of Martinique.
Fatal hemorrhage induced by subtilase cytotoxin from Shiga-toxigenic Escherichia coli.
FcRn augments induction of tissue factor activity by IgG-containing immune complexes.
Flow cytometric evaluation of disseminated intravascular coagulation in a canine endotoxemia model.
Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban.
Fondaparinux in heparin-induced thrombocytopenia.
Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients.
Fructose-1,6-bisphosphate inhibits in vitro and ex vivo platelet aggregation induced by ADP and ameliorates coagulation alterations in experimental sepsis in rats.
Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal.
Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis.
Haemostatic trends in HIV-infected individuals in Yaoundé, Cameroon: a pilot study.
Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults.
Heat stroke in dogs: A retrospective study of 54 cases (1999-2004) and analysis of risk factors for death.
Hemangioma of the radius associated with Kasabach-Merritt syndrome: case report and literature review.
Hematin: unique effects of hemostasis.
Hematologic and coagulation abnormalities in acute bovine sarcocystosis.
Hematologic manifestation of childhood celiac disease.
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Hemostasis and the complement system in Argentine hemorrhagic fever.
Hemostatic Abnormalities in COVID-19: An Update.
Hemostatic abnormalities in dogs with hemangiosarcoma.
Hemostatic abnormalities in multiple myeloma and related disorders.
Hemostatic changes in Vietnamese children with mild dengue correlate with the severity of vascular leakage rather than bleeding.
Hemostatic disorders in cats: a retrospective study and review of the literature.
Heparin-induced coagulopathy associated with staphylococcal protein A immunoadsorption treatment columns: an in vitro and in vivo analysis.
Heparin-induced thrombocytopenia and the clinical use of low molecular weight heparins in acute coronary syndromes.
High-dose argatroban for heparin-induced thrombocytopenia in a child using a ventricular assist device.
Higher susceptibility of mast-cell-deficient W/WV mutant mice to brain thromboembolism and mortality caused by intravenous injection of India ink.
Immune Thrombocytopenia Purpura Secondary to COVID-19.
Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice.
Importance of platelets in experimental venous thrombosis in the rat.
Incidence and risk factors of upper gastrointestinal bleeding in mechanically ventilated children.
Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.
Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation.
Infectious canine hepatitis: animal model for viral-induced disseminated intravascular coagulation.
Intra-cardiac thrombus in antiphospholipid antibody syndrome: An unusual cause of fever of unknown origin with review of literature.
Intracardiac thrombosis and acute myocardial infarction as initial presentation of antiphospholipid syndrome.
Intracerebral hemorrhage after liver transplantation.
Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator.
Ischemic stroke as initial manifestation of systemic lupus erythematosus: A case report and review of the literature.
Kasabach-Merritt syndrome complicating treatment of a closed femoral fracture.
Laboratory findings in patients with avian-origin influenza A (H7N9) virus infections.
Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities.
Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.
Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.
Malignant histiocytosis in a cat.
Mammary gland carcinoma in a dog with peripheral blood and bone marrow involvement associated with disseminated intravascular coagulation.
Meningoencephalitis, myocarditis and disseminated intravascular coagulation in a patient with scrub typhus.
Modulators of the coagulation cascade: focus and recent advances in inhibitors of tissue factor, factor VIIa and their complex.
Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Multicenter retrospective study of transcatheter arterial embolisation for life-threatening haemorrhage in patients with uncorrected bleeding diathesis.
Multifocal lymphangioendotheliomatosis with thrombocytopenia: a newly recognized clinicopathological entity.
Myocardial infarction as the presenting manifestation of systemic lupus erythematosus with antiphosphatidylserine antibodies.
Neurotoxic envenoming by South American coral snake (Micrurus lemniscatus helleri): case report from eastern Ecuador and review.
Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome.
Orally administered dextran sulfate is absorbed in HIV-positive individuals.
Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging.
Pathogenic natural anti-cardiolipin antibodies: the experience from monoclonal gammopathy.
Pathogenic serum IgG anticardiolipin antibodies and the idiotypic network.
Perioperative anticoagulation management in antiphospholipid syndrome.
Pharmaceutical Approval Update.
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults.
Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption.
Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988.
Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.
Prevalence of hematologic toxicity from copperhead envenomation: an observational study.
Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3.
Primary antiphospholipid syndrome with multiorgan arterial and venous thromboses.
Primary pulmonary hypertension. Its association with microangiopathic hemolytic anemia and thrombocytopenia.
Probable intrafamilial transmission of coxsackievirus b3 with vertical transmission, severe early-onset neonatal hepatitis, and prolonged viral RNA shedding.
Problems of diagnosis of disseminated intravascular coagulation (DIC).
Profile of dengue patients admitted to a tertiary care hospital in Mumbai.
Proteins invoked by vitamin K absence and clotting times in clinically ill cats.
Pulsus alternans in a critically ill dog hospitalized for xylitol toxicity.
Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits.
Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome.
Reduced argatroban doses after coronary artery bypass graft surgery.
Relationship between tissue perfusion and coagulopathy in traumatic brain injury.
Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection.
Risk factors and impact of portal vein thrombosis in liver transplantation.
Risk factors associated with fatality of severe fever with thrombocytopenia syndrome: a meta-analysis.
Risk Factors for Early Fatal Outcomes Among Children with Hemophagocytic Lymphohistiocytosis (HLH): A Single-Institution Case-Series in Vietnam.
Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
Rowell's syndrome and associated antiphospholipid syndrome.
SARS: clinical features and diagnosis.
Secondary Immune Thrombocytopenic Purpura Triggered by COVID-19.
Serotonin Syndrome, Disseminated Intravascular Coagulation, and Hepatitis After a Single Ingestion of MDMA in an Asian Woman.
Severe acute respiratory syndrome in a doctor working at the Prince of Wales Hospital.
Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong.
Shock in the pediatric emergency service: five years' experience.
Sjögren's syndrome and pregnancy.
Sporadic cases of Legionnaires' disease: the expanding clinical spectrum.
Studies of the coagulation and complement systems during experimental Rocky Mountain spotted fever in rhesus monkeys.
Studies of the coagulation system and blood pressure during experimental Bolivian hemorrhagic fever in rhesus monkeys.
Studies on Australian snake venoms, Part II: The haematological effects of brown snake (Pseudonaja) species in the dog.
Studies on some blood parameters of crossbred calves with experimental Theileria annulata infections.
Studies on the vascular and hematological changes induced by ellagic acid in rats.
Sublethal trauma model with systemic endotoxemia for the study of microcirculatory disorders after the second hit.
Successful delivery in a pregnant woman with lupus anticoagulant positive systemic lupus erythematosus treated with double filtration plasmapheresis.
Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven).
Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies.
Systemic disseminated Neospora caninum infection with cutaneous lesions as the initial clinical presentation in a dog.
Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
Systemic lupus erythematosus presenting with haemorrhagic manifestation.
The cardiovascular and haematological effects of purified prothrombin activator from the common brown snake (Pseudonaja textilis) and their antagonism with heparin.
The clinical usefulness of the preoperative bleeding time.
The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease.
The effects of indomethacin on the generalized shwartzman reaction.
The Need for Novel Anticoagulation Therapy in Acute Coronary Syndrome.
The pathogenesis of leptospirosis I. Hemorrhages in experimental leptospirosis in guinea pigs.
The pathogenic role of anti-phosphatidylserine antibodies: active immunization with the antibodies leads to the induction of antiphospholipid syndrome.
The successful treatment of multiple organ dysfunction syndrome and severe hypernatremia, secondary to joint supplement toxicity in a dog.
The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia.
Thrombocytopenia following heparin flush.
Thrombocytopenia induced in mice by thromboplastin infusion--essential role of the third complement component.
Thromboelastography Predicts Thromboembolism in Critically Ill Coagulopathic Patients.
Thromboelastometry analysis of thrombocytopenic dengue patients: a cross-sectional study.
Thromboelastometry-guided hemostatic therapy for hemorrhagic shock in the postoperative period of vascular surgery: a case report.
Thrombotic and hemorrhagic complications in children with the lupus anticoagulant.
Thrombotic Microangiopathy and Venous Thrombosis in a Patient With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
Time course of coagulopathy in isolated severe traumatic brain injury.
Toxicity with intravenous injection of crude marijuana extract.
Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell.
Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.
Tufted angioma presenting with subclinical coagulopathy.
Uneventful administration of plasma products in a recipient with T-activated red cells.
Unusual Presentation of Diffuse Large B-Cell Lymphoma With Splenic Infarcts.
Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
Vascular disease in the antiphospholipid syndrome: a comparison with the patient population with atherosclerosis.
Vascular permeability and coagulation during Rickettsia rickettsii infection in dogs.
Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.
Why does activated partial thromboplastin time prolongation occur in severe fever with thrombocytopenia syndrome?
[A case of antiphospholipid syndrome associated with myasthenia gravis]
[A disorder in the coagulation mechanism as a possible cause for the development of an antenatal intracranial hemorrhage]
[Anaesthesia for cesarean section in a patient with acute viral hepatitis (author's transl)]
[Analysis of clinical characteristics of the 12 cases of neonatal dengue fever in Guangzhou in 2014 and literatures review].
[Antiphospholipid syndrome with myocardial infarction and aortic valve involvement]
[Apixaban as therapeutic option in nephropathy patients with heparin-induced thrombocytopenia (HIT)].
[Biological diagnosis of postoperative thrombopenia]
[Clinical and epidemiological characteristic of dengue]
[Crimean-Congo hemorrhagic fever]
[Factor X decrease in thrombopenias in childhood]
[Heatstroke in dogs in southern Germany. A retrospective study over a 5.5-year period].
[Left atrial thrombosis in patients with antiphospholipid antibody syndrome and mesenchymal abnormal septum]
[Unexpected hemorrhage in surgery]
Thrombocytosis
Cerebral and retinal vascular complications of inflammatory bowel disease.
COVID-19 versus HIT hypercoagulability.
Evaluation of thrombocythemia by the thromboplastin generation test.
Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis.
Haemostatic trends in HIV-infected individuals in Yaoundé, Cameroon: a pilot study.
In vitro thrombotic tendency of reactive thrombocytosis in critically ill patients: a prospective case-control study.
Plasma levels of thrombin-activatable fibrinolysis inhibitor in primary and secondary thrombocytosis.
[Abdominal inflammatory pseudotumor (plasma cell granuloma) with anemia and hypergammaglobulinemia]
[Contribution to the problem of thrombocythemia. Thromboplastin formation in the presence of higher thrombocvte concentrations.]
Thromboembolism
Acute Liver Failure after Initiation of Rivaroxaban: A Case Report and Review of the Literature.
Acute management of bleeding in patients on novel oral anticoagulants.
An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
An autoantibody to human plasma prekallikrein blocks activation of the contact system.
Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice.
Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs.
Antithrombotic therapy for stroke prevention in atrial fibrillation.
Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study.
Betrixaban in the prevention of venous thromboembolism in medically ill patients.
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
Comparison of outcomes in patients with intracranial hemorrhage on factor Xa inhibitors versus vitamin K antagonists treated with 4-factor prothrombin complex concentrate.
Detection of lupus anticoagulant in the era of direct oral anticoagulants.
Dilute Russell viper venom time interpretation and clinical correlation: A two-year retrospective institutional review.
Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions.
Effect of heparin on activated partial thromboplastin time in patients undergoing gynecologic or obstetric surgery.
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Factor X inhibitors.
Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation.
Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment.
Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin.
Influence of thromboembolism prophylaxis by low molecular weight heparin CY 216 (Fraxiparine) on several parameters of haemostasis in patients under dialysis and receiving either unfractionated heparin or CY 216.
Intravenous Combined with Topical Tranexamic Acid Administration Has No Additional Benefits Compared with Intravenous Administration Alone in High Tibial Osteotomy: A Retrospective Case-Control Study.
Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist.
Laboratory measurement of the direct oral anticoagulants.
Mouse models of focal arterial and venous thrombosis.
New Anticoagulants for the Prevention of Thromboembolism.
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Perioperative Management of Anticoagulation-Review of Latest Evidence.
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism.
Reversal of novel oral anticoagulants in patients with major bleeding.
Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.
Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism.
Should all patients with non-valvular atrial fibrillation be anticoagulated?
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
Thromboembolism and resistance to activated protein C in children with underlying cardiac disease.
Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia.
Venous thromboembolism prophylaxis guidelines: use by primary care physicians.
[A simple test for the monitoring of plasma anti-XA activity of patients following subcutaneous administration of enoxaparin]
[Decrease of antithrombin III and factor Xa inhibitor as the cause of thromboembolism complications in chronic inflammatory intestinal disease]
[Focus on managing AF and preventing stroke].
[New antithrombotics for atrial fibrillation.]
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
[Preventive effect of liquemin depot in thromboembolism; experimental proof with myotoxin thrombokinase test.]
[Thromboembolism preventing effect of sublethal intravenous thromboplastin doses.]
Thrombophilia
A chromogenic assay for activated protein C resistance.
A rare case of unprovoked venous thromboembolism manifestation in a young patient with antithrombin Type IIB deficiency combined with inferior vena cava anomaly from Lithuania.
Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.
Activated protein C resistance: from phenotype to genotype and clinical practice.
APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.
Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease.
Assessment of the coagulation profile in hemato-oncological patients receiving ATG-based conditioning treatment for allogeneic stem cell transplantation.
Bilateral adrenal gland haemorrhage: an unusual cause.
Blood cells diseases and thrombosis.
c.259A>C in the fibrinogen gene of alpha chain (FGA) is a fibrinogen with thrombotic phenotype.
Changes in blood coagulation markers associated with uterine artery embolization for leiomyomata.
Coagulation management in patients undergoing mechanical circulatory support.
Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory.
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Dysfibrinogenemia and thrombosis. A case report.
Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism.
Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia.
Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis.
Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation.
Factor Xa or thrombin: is factor Xa a better target?
Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma.
Heparin monitoring in acute thrombosis associated with antiphospholipid antibody syndrome.
Higher morning serum cortisol level predicts increased fibrinogen but not shortened APTT.
How I diagnose and manage HIT.
HYPERCOAGULABILITY AND THROMBOSIS: EFFECT OF INJECTED THROMBOKINASE AND ADENOSINE DIPHOSPHATE ON ESTABLISHED MICROTHROMBI IN RABBITS.
Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment.
Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies.
Hypercoagulability in patients with peripheral vascular disease.
Hypercoagulable states in arterial thromboembolism.
Hypocoagulable Tendency on Thromboelastometry Associated With Severity and Anticoagulation Timing in Pediatric Septic Shock: A Prospective Observational Study.
Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors.
Laboratory detection of inherited thrombophilia: a historical perspective.
Laboratory diagnosis of antiphospholipid syndrome.
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Modulation of severity of clinical bleeding by co-inherited thrombophilia is also true for severe factor X deficiency.
Natural inhibitors and fibrinogen/fibrin degradation products in patients with myocardial infarction.
Plasma antithrombin III and thrombin generation time: correlation with hemoglobin A1 and fasting serum glucose in young diabetic women.
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Point of Care Assessment of Coagulation.
Polycations selectively blocking tissue factor-dependent FVII activation: collective in vitro anticoagulation studies.
Pregnant patients with thrombophilia and subsequent adverse pregnancy outcomes have a decreased first trimester response to thrombomodulin in an activated partial thromboplastin time (APTT) system.
Radioimmunoassays for protein C and factor X. Plasma antigen levels in abnormal hemostatic states.
Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis.
Retrospective evaluation of shortened prothrombin time or activated partial thromboplastin time for the diagnosis of hypercoagulability in dogs: 25 cases (2006-2011).
Screening for thrombophilia: a laboratory perspective.
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
The influence of crystalloid and colloid replacement solutions in acute normovolemic hemodilution: a preliminary survey of hemostatic markers.
The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.
The purification and properties of factor X from pig serum and its role in hypercoagulability in vivo.
The serial thromboplastin dilution test: a presumptive test for hypercoagulability.
Thrombin generation assay and hemostatic profile for elucidating hypercoagulability in endogenous canine hyperadrenocorticism.
Whole blood hypercoagulability despite anticoagulation during mechanical cardiac assist.
[Haemostatic activation in head injury]
[Mechanism of hypercoagulability of the blood following vasopuncture: behavior of the thromboplastin generation test and blood thromboplastin factors.]
Thrombophlebitis
Acute thrombophlebitis; mechanism and treatment with oral thromboplastin.
Effects of heparin, typhoid vaccine and thrombophlebitis on factor X metabolism in the dog.
Thrombosis
'Lupus' anticoagulant and thrombosis of the hepatic veins (Budd-Chiari syndrome). Report of three patients and review of the literature.
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development.
A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge.
A Clinical Study on Low-Molecular Weight Heparin Infusion as Anticoagulation for Nocturnal Home Haemodialysis.
A comparative study of heparin responses in arterial and venous thromboembolism using molecular markers for thrombosis.
A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
A comparison of heparinised and non-heparinised normal saline solutions for maintaining the patency of arterial pressure measurement cannulae after heart surgery.
A cost-analysis model for anticoagulant treatment in the hospital setting.
A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
A narrative review of low-dose rivaroxaban in patients with atherothrombotic cardiovascular disease: vascular protection beyond anticoagulation.
A new animal model of venous thrombosis in rats with low flow conditions in the venous blood stream.
A new case of high-molecular-weight kininogen inherited deficiency.
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation.
A novel model of venous thrombosis in the vena cava of rabbits.
A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
A prospective randomized comparative study to determine appropriate edoxaban administration period, to prevent deep vein thromboembolism in patients with total knee arthroplasty.
A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml.
A Sardinian Family with Factor XI Deficiency.
A simple, cost-effective, and rapid separation process for the isolation of anticoagulant active fraction from the fruit extract of Momordica charantia: Characterization of bioactive components and anticoagulant mechanism of active fraction in a mouse model.
Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
Absorption, distribution, metabolism and excretion of YM466, a novel factor Xa inhibitor, in rats.
Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Activated partial thromboplastin time and risk of future venous thromboembolism.
Active aneurysm thrombosis after Kawasaki disease in an adult: Insight into anticoagulation therapy.
Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model.
Active site-labeled prothrombin inhibits prothrombinase in vitro and thrombosis in vivo.
Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of arterial thrombosis.
Acute myocardial infarction and antiphospholipid antibody syndrome: a systematic review.
Acute renal artery and vein thrombosis after renal transplant, associated with a short partial thromboplastin time and factor V Leiden mutation.
Aeruginosin analogs and other compounds with rigid bicyclic structure as potential antithrombotic agents.
AGA Clinical Practice Update: Coagulation in Cirrhosis.
An ethanol extract of Ramulus mori improves blood circulation by inhibiting platelet aggregation.
Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
Andexanet Alfa Use for Small Bowel Obstruction Patient With History of Sugiura Procedure.
Anti-factor Xa activities of zingerone with anti-platelet aggregation activity.
Anti-thrombotic activity and chemical characterization of steroidal saponins from Dioscorea zingiberensis C.H. Wright.
Anti-thrombotic effect of a factor Xa inhibitor TAK-442 in a rabbit model of arteriovenous shunt thrombosis stimulated with tissue factor.
Anti-thrombotic effect of chronic oral treatment with Orbignya phalerata Mart.
Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin.
Anticardiolipin antibodies in patients with pregnancy loss induce factor Xa production in the presence of beta 2-glycoprotein I.
Anticoagulant and antithrombotic effects of chemically modified heparins and pentosanpolysulfate.
Anticoagulant drugs: an update.
Anticoagulant properties of the anti-inflammatory cytokine IL-10 in a factor Xa-activated human monocyte model.
Anticoagulant therapy after acute myocardial infarction.
Anticoagulant therapy for recurrent in-stent thrombosis following carotid artery stenting: A case report.
Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.
Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
Anticoagulation Management during First Five Days of Infant-Pediatric Extracorporeal Life Support.
Anticoagulation Practices during Venovenous Extracorporeal Membrane Oxygenation for Respiratory Failure. A Systematic Review.
Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients.
Antiphospholipid syndrome presenting as intracardiac thrombus with pulmonary embolism.
Antiplatelet and antithrombotic activities of Korean Red Ginseng.
Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin.
Antiplatelet, anticoagulant, and profibrinolytic activities of withaferin A.
Antithrombin activity of an algal polysaccharide.
Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis.
Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling.
Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action.
Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Antithrombotic effect of repeated doses of the ethanolic extract of local olive (Olea europaea L.) leaves in rabbits.
Antithrombotic effects of (n-3) polyunsaturated fatty acids in rat models of arterial and venous thrombosis.
Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals.
Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.
Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.
Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates.
Antithrombotic effects of recombinant human soluble thrombomodulin (rhs-TM) on arteriovenous shunt thrombosis in rats.
Antithrombotic effects of the effective components group of Xiaoshuantongluo formula in vivo and in vitro.
Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs.
Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats.
Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury.
Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis.
Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity.
Apixaban and atrial fibrillation: no clear advantage.
Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.
Apixaban for the treatment of cancer-associated venous thromboembolism and left atrial appendage thrombus refractory to optimal anticoagulation with warfarin: a case report.
Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels.
Apixaban Inhibits Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in Rabbits.
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Approaches to selective peptidic inhibitors of factor Xa.
Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits.
Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
Argatroban.
Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits.
Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor.
Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis.
Association Between Hematologic and Inflammatory Markers and 31 Thrombotic and Hemorrhagic Events in Berlin Heart Excor Patients.
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.
Beneficial effect of sulfamethoxazole and trimethoprim on accelerated coagulation.
Beta-cyclodextrin tetradecasulfate, a novel cyclic oligosaccharide, inhibits thrombus and neointimal formation after coronary vascular injury.
Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Bioprosthesis leaflet thrombosis following self-expanding valve-in-valve transcatheter aortic valve replacement in patient taking factor Xa inhibitor and warfarin: A case report.
Bleeding, Thrombosis, and Transfusion With Two Heparin Anticoagulation Protocols in Venoarterial ECMO Patients.
Blocking of platelets or intrinsic coagulation pathway-driven thrombosis does not prevent cerebral infarctions induced by photothrombosis.
Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis.
Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve.
Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice.
Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants.
Cerebral Microembolization in Left Ventricular Assist Device Associated Ischemic Events.
Changes in blood parameters and coagulation-related gene expression in pregnant rats.
Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits.
Cholesterol Crystal Embolism Induced by Direct Factor Xa inhibitor: A First Case Report.
Clinical and experimental experience with factor Xa inhibitors.
Clinical management of coagulation status and placenta previa in a pregnant woman with Marfan's syndrome after mitral and aortic mechanical heart valve replacement.
Clinical significance of increased thromboplastin activity on the monocyte surface--a brief review.
Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.
Coagulations Studies Do Not Correlate With Each Other or With Hematologic Complications During Pediatric Extracorporeal Membrane Oxygenation.
Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance.
Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice.
Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time.
Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase.
Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
Comparative study of the effect of rivaroxaban and fondaparinux on monocyte's coagulant activity and cytokine release.
Comparison between recombinant and rabbit thromboplastin in the management of patients on oral anticoagulant therapy.
Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots.
Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis.
Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.
Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors.
Comparison of the antithrombotic effects of low molecular weight heparinoid KB-101 and heparin in a rat experimental model.
Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis.
Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study.
Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.
Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Considerations for drug dosing post coronary artery bypass graft surgery.
Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa.
Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents.
Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo.
Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times.
COVID-19 and acute coagulopathy in pregnancy.
CrataBL, a lectin and Factor Xa inhibitor, plays a role in blood coagulation and impairs thrombus formation.
Current management of acute symptomatic deep vein thrombosis.
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
Deep vein thrombosis following hip surgery. Relation to activated factor X inhibitor activity: effect of heparin and dextran.
Delayed Vesicular Urticarial Dermatosis Due to Apixaban.
Delayed-onset heparin-induced thrombocytopenia type-2 during fondiparinux (Arixtra) therapy.
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.
Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors.
Determinants of plasma factor VIIa levels in humans.
Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation.
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
DIC Score: Statistical Relationship with PT, APTT, and Simplified Scoring Systems with Combinations of PT and APTT.
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently.
Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Direct Inhibition Of Factor Viia By Tfpi And Tfpi Constructs.
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).
Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.
Disseminated intravascular coagulation in cats.
Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study.
Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids.
Do preoperative laboratory tests predict blood transfusion needs in cardiac operations?
Dose-dependent antithrombotic effect of warfarin in rabbits.
Downregulation of Clock in circulatory system leads to an enhancement of fibrinolysis in mice.
Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
DU-176b, an oral, direct Factor Xa antagonist.
Dual pathway therapy in acute coronary syndrome.
DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
DX-9065a Daiichi.
DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats.
Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats.
Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Effect of a new inhibitor of factor Xa zifaxaban, on thrombosis in the inferior vena cava in rabbits.
Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
Effect of combined therapy with catheter-directed thrombolysis and factor Xa inhibitor for inferior vena cava thrombosis: A case report.
Effect of factor Xa inhibitors on the platelet-derived microparticles procoagulant activity in vitro and in vivo in rats.
Effect of heparin in nonionic contrast media on blood coagulation and its dose response curve.
Effect of immune complex-containing sera from patients with rheumatic diseases on thromboplastin activity of monocytes.
Effect of potato protease inhibitor on the clotting system and fibrinolysis in the dog.
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis.
Effect of sepimostat mesilate on experimental venous thrombosis in rats.
Effect of the Direct Factor Xa Inhibitor Apixaban in Rat Models of Thrombosis and Hemostasis.
Effect of the Factor Xa Inhibitor Rivaroxaban on Arterial Thrombosis in Wild-Type and Apolipoprotein E-Deficient Mice.
Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa.
Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study.
Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
Effects of ethanol on human blood fibrinolysis and coagulation.
Effects of folic acid combined with vitamin B12 on DVT in patients with homocysteine cerebral infarction.
Effects of fondaparinux and a direct factor Xa inhibitor TAK-442 on platelet-associated prothrombinase in the balloon-injured artery of rats.
Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities.
Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog.
Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: Murine Ortholog of the Fletcher Trait.
Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli.
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts.
Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.
Elevated factor VIII level and stroke in patients without traditional risk factors associated with cardiovascular diseases.
Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.
Engineering a "three-in-one" hirudin prodrug to reduce bleeding risk: A proof-of-concept study.
Engineering of human coagulation factor x variants activated by prostate-specific antigen.
Enhanced induction of heme oxygenase-1 suppresses thrombus formation and affects the protein C system in sepsis.
Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model.
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Epidemiological association between fasting plasma glucose and shortened APTT.
Evaluating prodrug characteristics of a novel anticoagulant fusion protein neorudin, a prodrug targeting release of hirudin variant 2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics.
Evaluating Unfractionated Heparin Fixed Dosing Protocol and Establishing an Institutional Therapeutic Range for UFH in Hospital Setting in Jordan.
Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study.
Evaluation of argatroban and DUP 714 as anticoagulants for blood gas, electrolyte and ionized calcium analyses.
Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia.
Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs.
Evaluation of the antithrombotic activity of Zhi-Xiong Capsules, a Traditional Chinese Medicinal formula, via the pathway of anti-coagulation, anti-platelet activation and anti-fibrinolysis.
Evaluation of the Total Thrombus-Formation System (T-TAS): application to human and mouse blood analysis.
Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding.
Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.
Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor.
Experimental studies on venous thrombosis: effect of coagulants, procoagulants and vessel contusion.
Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding.
Exploring potential anticoagulant drug formulations using thrombin generation test.
Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries.
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels.
Factor X deficiency.
Factor X inhibitors.
Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage.
Factor xa inhibitor attenuates leukocyte adhesion and thrombus formation in an experimental mouse model of the metabolic syndrome.
Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation.
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study.
Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: additional information.
Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit.
Fibrinolytic and Thrombolytic Effects of an Enzyme Purified from the Fruiting Bodies of Boletus pseudocalopus (Agaricomycetes) from Korea.
Flow-simulated thrombin generation profiles as a predictor of thrombotic risk among pre-menopausal women.
Fluorinated Benzyloxyphenyl Piperidine-4-carboxamides with Dual Function against Thrombosis: Inhibitors of Factor Xa and Platelet Aggregation.
Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban.
Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Fondaparinux: use in thromboprophylaxis of acute medical patients.
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial.
Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus.
Functional expression of a novel Kunitz type protease inhibitor from the human blood fluke Schistosoma mansoni.
Further studies on the presence of functional tissue factor activity on the subendothelium of normal human and rabbit arteries.
FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.
FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834.
Generation of a humanized FXII knock-in mouse-A powerful model system to test novel anti-thrombotic agents.
Genome-wide association study of peripheral artery disease in the Million Veteran Program.
Giant deep vein thrombus complicating endovascular cooling therapy after cardiac arrest in a boy with hypertrophic cardiomyopathy.
Heme oxygenase-1 inducer hemin prevents vascular thrombosis.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Heparin 1986. Indications and effective use.
Heparin cofactor II inhibits thrombus formation in a rat thrombosis model.
Heparin improves BMSC cell therapy: Anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy.
Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4.
Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice.
Heparin-Like Chitosan Hydrogels with Tunable Swelling Behavior, Prolonged Clotting Times, and Prevented Contact Activation and Complement Activation.
Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis.
Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis.
HIT paradigms and paradoxes.
Homology model of human prothrombinase based on the crystal structure of Pseutarin C.
How I diagnose and manage HIT.
Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins.
HYPERCOAGULABILITY AND THROMBOSIS: EFFECT OF INJECTED THROMBOKINASE AND ADENOSINE DIPHOSPHATE ON ESTABLISHED MICROTHROMBI IN RABBITS.
Hypercoagulability. Should every patient with venous thrombosis be tested?
Immobilisation of an anti-platelet adhesion and anti-thrombotic drug (EP224283) on polydopamine coated vascular stent promoting anti-thrombogenic properties.
Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots.
Impact of neutrophil apoptosis on haemostatic activation in chronic liver disease patients.
Impact of Total Antithrombotic Effect on Bleeding Complications in Patients Receiving Multiple Antithrombotic Agents.
Importance of platelets in experimental venous thrombosis in the rat.
Improved efficacy/safety profile of factor XIa inhibitor BMS-724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys.
In vitro and in vivo studies of AT-1362, a newly synthesized and orally active inhibitor of thrombin.
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
In vitro blood compatibility of functional group-grafted and heparin-immobilized polyurethanes prepared by plasma glow discharge.
In vitro procoagulant and anticoagulant properties of Naja naja naja venom.
In vivo antithrombotic properties of a heparin from the oocyte test cells of the sea squirt Styela plicata(Chordata-Tunicata).
Incidence and Risk Factors for Cannula-Related Venous Thrombosis After Venovenous Extracorporeal Membrane Oxygenation in Adult Patients With Acute Respiratory Failure.
Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy.
Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists.
Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition.
Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site.
Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig.
Inhibition of complement-mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low-molecular weight heparin.
Inhibition of Factor Xa : a potential target for the development of new anticoagulants.
Inhibition of feline collateral vessel development following experimental thrombolic occlusion.
Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors.
Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.
Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty.
Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro.
Inhibitors of serine proteinases from blood coagulation cascade - view on current developments.
Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo.
Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation.
Intracardiac thrombosis and acute myocardial infarction as initial presentation of antiphospholipid syndrome.
Intravenous recombinant soluble human thrombomodulin prevents venous thrombosis in a rat model.
Intrinsic pathway of coagulation and arterial thrombosis.
Investigation of the anticoagulant and antithrombotic effects of chlorogenic acid.
Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats.
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.
Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Isolation and Characterization of Poecistasin, an Anti-Thrombotic Antistasin-Type Serine Protease Inhibitor from Leech Poecilobdella manillensis.
Lack of plasminogen activator inhibitor-1 enhances the preventive effect of DX-9065a, a selective factor Xa inhibitor, on venous thrombus and acute pulmonary embolism in mice.
Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure.
Left atrial thrombus formation after brief interruption of rivaroxaban.
Letter by Borst Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1".
Locally activity-released bifunctional fusion protein enhances antithrombosis and alleviates bleeding risk.
Losartan and captopril treatment rescue normal thrombus formation in microfibril associated glycoprotein-1 (MAGP1) deficient mice.
Low intensity warfarin therapy.
Low molecular weight heparin in acute stroke.
Low-dose fibrinolytic therapy. Results and new concepts.
Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.
Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.
Low-molecular-weight heparins and new strategies for the treatment of patients with established venous thrombosis.
Lufaxin, a Novel Factor Xa Inhibitor From the Salivary Gland of the Sand Fly Lutzomyia longipalpis Blocks Protease-Activated Receptor 2 Activation and Inhibits Inflammation and Thrombosis In Vivo.
Lupus anticoagulant syndrome: case report.
Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.
Macromolecular complex assembly of prothrombinase is a central process of thrombosis.
Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.
Mechanism of protein-z-mediated inhibition of coagulation factor xa by z-protein-dependent inhibitor: a molecular dynamic approach.
Mechanisms of thromboembolism at arterial plaques.
Medical management of acute superficial vein thrombosis of the saphenous vein.
Modified APC-resistance test: variable ratios with respect to source of factor V-deficient plasma.
Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
Molecular dynamics simulations of the binary complex of human tissue factor (TF(1-242) ) and factor VIIa (TF(1-242) /fVIIa) on a 4:1 POPC/POPS lipid bilayer.
Moving Up the Coagulation Cascade: Potential Factor X Inhibition for Percutaneous Coronary Intervention.
Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen.
Nanomechanical clinical coagulation diagnostics and monitoring of therapies.
New anticoagulants.
New Anticoagulants: Anti IIa vs Anti Xa-Is One Better?
New antithrombotic strategies for resistant thrombotic processes.
New developments in antiplatelet and antithrombotic therapy.
New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy.
New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome.
New targets for antithrombotic drugs.
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
No deterioration after 13 years in a stability study of a rabbit brain, plain, thromboplastin, RBT 1010, in rubber-stoppered ampoules.
No discriminating power in FPA measurements during fibrinaemia in hip replaced patients generating DVT.
Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis.
Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis.
Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin.
Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin.
Novel direct factor Xa inhibitory compounds from Tenebrio molitor with anti-platelet aggregation activity.
Novel inhibitors of factor X for use in cardiovascular diseases.
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.
Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation.
Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review.
Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis.
Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series.
Overview of Current Evidence on the Impact of the Initial High Dose of the Direct Factor Xa Inhibitor Rivaroxaban on Thrombus Resolution in the Treatment of Venous Thromboembolism.
Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.
Partial thromboplastin time: prediction of adverse events and poor prognosis by low abnormal values.
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes.
Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.
Perspectives on factor Xa inhibition.
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism.
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses.
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165.
Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis.
Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells.
Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.
Plasminogen activator inhibitor type 1 in platelets induces thrombogenicity by increasing thrombolysis resistance under shear stress in an in-vitro flow chamber model.
Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists.
Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.
Pleiotropic actions of factor Xa inhibition in cardiovascular prevention - mechanistic insights and implications for anti-thrombotic treatment.
Possible Rivaroxaban Failure during the Postpartum Period.
Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation.
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.
Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism.
Practical recommendations on incorporating new oral anticoagulants into routine practice.
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.
Predictors of left ventricular thrombus formation in patients with dilated cardiomyopathy: role of activated protein C resistance.
Preoperative fibrinogen plasma concentration is associated with perioperative bleeding and transfusion requirements in scoliosis surgery.
Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.
Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism.
Prevalence and Risk Factors for Thrombotic Complications Following Venovenous Extracorporeal Membrane Oxygenation: A CT Scan Study.
Prevalence and risk factors of deep vein thrombosis in patients undergoing lumbar spine surgery.
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
Prevention of Stent Thrombosis in Rats by a Direct Oral Factor Xa Inhibitor Edoxaban.
Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model.
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity.
Procoagulant Adaptation of a Blood Coagulation Prothrombinase-like Enzyme Complex in Australian Elapid Venom.
Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant.
Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and Rabbit.
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature.
Pros and cons of new oral anticoagulants.
Protease-activated receptor 4: a critical participator in inflammatory response.
Protection of pregnant mice with phospholipase C and with Arvin against foetal death induced by bacterial lipopolysaccharide.
Protein C and fibrinolysis: a link between coagulation and fibrinolysis.
Prothrombin fragments in cardiovascular disease.
Pulmonary Thromboembolism in COVID-19: Venous Thromboembolism or Arterial Thrombosis?
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
Rare case of acquired haemophilia and lupus anticoagulant.
Rare inherited coagulation disorders in India.
Rate-limiting roles of tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow.
Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement.
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Reactions of activated factor X-phosphatide mixtures in vitro and in vivo.
Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients.
Recent insights on biochemical and molecular basis for developing antihaemostatic agents: A review.
Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
Recombinant soluble human thrombomodulin: a randomized, blinded assessment of prevention of venous thrombosis and effects on hemostatic parameters in a rat model.
Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders.
Reduced Smoke-like Echo and Resolved Thrombus in the Left Atrium with Rivaroxaban Therapy in an Acute Cardioembolic Stroke Patient.
Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity.
Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.
Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies.
Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban.
Resolution of Internal Carotid Arterial Thrombus by the Thrombolytic Action of Dabigatran: A first case report.
Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban.
Resolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis: A case report and literature review.
Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding and Death After Factor Xa Inhibitor Reversal in Major Bleeding Patients.
Reversal of target-specific oral anticoagulants.
Reversible Neurological Adverse Reaction to Apixaban.
Risk Factors for Thrombosis, Overshunting and Death in Infants after Modified Blalock-Taussig Shunt.
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
Rivaroxaban for treatment of venous thromboembolism in older adults.
Rivaroxaban in patients with a recent acute coronary syndrome.
Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1.
Rivaroxaban therapy resulting in the resolution of right atrial thrombosis resistant to ordinary control with warfarin in a patient with atrial fibrillation.
Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.
Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Rivaroxaban: direct factor Xa inhibition to treat acute deep vein thrombosis.
Role of factor xa inhibitors in cancer-associated thrombosis: any new data?
Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs.
Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots.
Roles of factor Xa beyond coagulation.
RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit.
Rutin-Loaded Silver Nanoparticles With Antithrombotic Function.
Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.
Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.
Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons.
Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time.
Sequential treatment of deep leg vein thrombosis with porcine plasmin and low dose streptokinase.
Serotonin as a factor in depression of collateral blood flow following experimental arterial thrombosis.
Severe acute respiratory syndrome coronavirus nucleocapsid protein does not modulate transcription of human FGL2 gene.
Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
Signal detection for bleeding associated with the use of direct oral anticoagulants.
Simultaneous testing of the heparin effect on the soluble phase and platelet component of hemostasis.
Size matters.
Small size fullerenol nanoparticles inhibit thrombosis and blood coagulation through inhibiting activities of thrombin and FXa.
Sodium pentosan polysulfate efficacy as thromboprophylaxis agent in high-risk women following gynecological surgery.
Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
Spectrophotometric analysis of thrombolytic activity: SATA assay.
Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE.
Spotlight on fondaparinux sodium in acute coronary syndromes.
SR-90107 (Sanofi-Synthélabo).
Stroke risk factor, pattern and outcome in patients with cancer.
Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.
Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors.
Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals.
Studies on coagulation incompatibilities for xenotransplantation.
Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
Successful treatment with rivaroxaban of an extended deep vein thrombosis complicated by pulmonary embolism in a patient with familial antithrombin III deficiency: a case report.
Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.
Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis.
Surface characterization and in vitro blood compatibility of poly(ethylene terephthalate) immobilized with insulin and/or heparin using plasma glow discharge.
Surgical experience on patients with serum lupus anticoagulants. A report of two cases.
Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa.
Swim exercise inhibits hemostatic abnormalities in a rat model of obesity and insulin resistance.
Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats.
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.
Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis.
Testing strategies for diagnosing lupus anticoagulant: decision analysis.
The "Dual-Pathway" Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial.
The activated partial thromboplastin time in early diagnosis of myocardial infarction.
The activated seven lupus anticoagulant assay detects clinically significant antibodies.
The anaesthetist and the antiphospholipid syndrome.
The anticoagulant, antithrombotic and haemorrhagic effect of long-term warfarin on experimental venous and arterial thrombosis in the rat.
The antithrombotic effect of heparin in deep venous thrombosis: relation to four heparin assays.
The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications.
The Clinical Findings and Prophylactic Treatment in Children with Factor X Deficiency.
The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
The dual FXa/thrombin inhibitor SATI prevents fibrin and platelet deposition in hypercoagulant rats.
The effect of endothelin-1 on vena jugularis thrombus model in rabbits.
The effect of heparin administration in animal models of sepsis: A prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies*
The effect of taurolidine on experimental thrombus formation.
The efficacy of long-term oral anticoagulant therapy and its laboratory assessment.
The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis.
The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis.
The heparin target organ--the endothelium. Studies in a rat model.
The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease.
The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.
The influence of Annexin32, a new Ca(2+)-dependent phospholipid-binding protein, on coagulation time and thrombosis.
The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents.
The lupus anticoagulant. High incidence of 'negative' mixing studies in a human immunodeficiency virus-positive population.
The management of heparin-induced thrombocytopenia.
The pathophysiologic role of fat in dysbaric osteonecrosis.
The possible role of platelet coagulant activities in the pathogenesis of venous thrombosis.
The race to an orally active Factor Xa inhibitor: recent advances.
The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
The role of cellular cooperation in thromboplastin synthesis.
The role of intravascular coagulation in pregnancy related acute renal failure.
The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
The use of rivaroxaban for the treatment of thrombotic complications in four dogs.
The value of FDP/FIB and D-dimer/FIB ratios in predicting high-risk APL-related thrombosis.
The venous antithrombotic profile of naroparcil in the rabbit.
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.
Thromboelastometry and Thrombelastography Analysis under Normal Physiological Conditions - Systematic Review.
Thromboembolic risk factors in patients undergoing kidney transplant: implication of abnormally short activated partial thromboplastin time.
Thromboembolism in cancer patients: pathogenesis and treatment.
Thrombogenicity of small-diameter prosthetic grafts: relative contributions of graft-associated thrombin and factor Xa.
Thrombophilia Associated with Anti-DFS70 Autoantibodies.
Thrombosis and hormone replacement therapy in postmenopausal women.
Thrombosis in patients with the lupus anticoagulant.
Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome.
Thrombosis of Large Aneurysm Induced by Flow-Diverter Stent and Dissolved by Direct Factor Xa Inhibitor.
Thrombotic and hemorrhagic complications in children with the lupus anticoagulant.
Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences.
Thrombus weight as a measure of hypercoagulability induced by drugs.
Tissue factor and cardiovascular disease: quo vadis?
Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix.
Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications.
Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis.
TLT-1-CONTROLS EARLY THROMBUS FORMATION AND STABILITY BY FACILITATING AIIBB3 OUTSIDE-IN SIGNALING IN MICE.
To bleed or not to bleed? Is that the question for the PTT?
Toxic characteristics of the synthetic lipid A derivative DT-5461 in rats and monkeys.
Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons.
Transitions of care in anticoagulated patients.
Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators.
Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release ofanticoagulant activity.
Two new closely related rat models with relevance to arterial thrombosis--efficacies of different antithrombotic drugs.
Use of an argatroban systemic infusion and purge solution in a patient with a percutaneous ventricular assist device with suspected heparin-induced thrombocytopenia.
Use of rotational thromboelastometry to predict hemostatic complications in pediatric patients undergoing extracorporeal membrane oxygenation: A retrospective cohort study.
Use of the subcutaneous heparin pump during pregnancy.
Vascular biology-the role of tissue factor.
Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability.
Venous thromboembolism prophylaxis guidelines: use by primary care physicians.
Warfarin-Induced Skin Necrosis in the Presence of Acute Hepatic Injury and May-Thurner Syndrome.
Which test to measure the anticoagulant effect of rivaroxaban? The anti-xa assay.
[A case of congenital factor XI (plasma thromboplastin antecedent) deficiency with large organized thrombus in the vena cava inferior]
[Anti-Xa molecules]
[Anticoagulant therapy in a pregnant patient with prosthetic mitral valve-emergency for caesarian section and postoperative bleeding].
[Antithrombotic effect of protein C activator from a snake venom]
[Cardiac abnormalities in antiphospholipid syndrome]
[Construction and expression of a fusion protein made of tissue-type plasminogen activator and hirudin in Pichia pastoris]
[Control of oral anticoagulation. Current concepts]
[Current biological surveillance of oral anticoagulant treatment]
[DETERMINATION OF THE POSSIBILITY OF DICOUMARIN PREVENTION OF THROMBUS FORMATION CAUSED BY INTRAVENOUS ADMINISTRATION OF MASSIVE DOSES OF THROMBOPLASTIN.]
[Direct and indirect effects of epoietin alpha in an experimental model of thrombosis and bleeding in the rabbit]
[Endothelial microparticles (EMP) in physiology and pathology].
[Intraoperative coagulation activity--a defined group of trauma surgery patients]
[Is the activated partial thromboplastin time suitable for monitoring of thrombosis therapy with high-dose standard heparin?]
[Left atrial thrombosis in patients with antiphospholipid antibody syndrome and mesenchymal abnormal septum]
[New data on thromboplastin formation in obstetrical and gynecological thromboses. Therapeutic deductions]
[Novel oral anticoagulants--issues in clinical practice].
[Paraplegia following removal of an epidural catheter]
[Pathophysiology and treatment of thrombosis. 1. Hypercoagulable state. (1) Study on the role of tissue thromboplastin in the formation of thrombosis]
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
[Prevention of intravascular blood coagulation in rats by DIP-alpha-thrombin administration]
[Proceedings: Hypercoagulability and compensated intravascular coagulation in chronic kidney insufficiency and after kidney transplantation]
[Recurrent thromboembolisms despite full anticoagulation in a patient with antiphospholipid syndrome].
[Relation of Thromboelastography with Coagulation Function and Plt Count in Different Coagulation States].
[Relative value of different antiphospholipid antibodies detected in a department of internal medicine: retrospective study of 124 patients]
[Splenic vein thrombosis with pancytopenia and fever: antiphospholipid antibody syndrome]
[Study on the safety and effectiveness of low-dose tranexamic acid in operation of multi-level continuous thoracic ossification of ligament flavum].
[The antithrombotic and thrombolytic activity of a plasminogen activator isolated from a monolayer cell culture]
[The reactivity of the anticoagulatory system in sympathectomized animals under stress conditions due to acoustic trauma]
[The thromboplastin formation test in thrombosis and thrombophilic conditions.]
[THROMBOPLASTIN ("INTRINSIC ACTIVATOR OF PROTHROMBIN") IN OCCLUSIVE VASCULAR DISEASES AND IN THROMBOSES.]
Thrombotic Microangiopathies
Complement in Secondary Thrombotic Microangiopathy.
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Thymoma
Novel factor X deficiency. Normal partial thromboplastin time and associated spindle cell thymoma.
[High thrombokinase activity in a thymoma during myasthenia gravis]
Thyroid Diseases
Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery.
Thyroid Neoplasms
Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time in a patient with Hashimoto thyroiditis-associated thyroid cancer: A case report.
Thyroiditis
Haemostatic effects of levothyroxine and selenomethionine in euthyroid patients with Hashimoto's thyroiditis.
Tics
[Anti-Xa molecules]
Transposition of Great Vessels
Attributable fraction for cardiac malformations.
Trichinellosis
The effect of thymus factor X (TFX Polfa) on the clinical course of human trichinellosis.
Tuberculosis
Analysis of the shotgun expression library of the Mycobacterium tuberculosis genome for immunodominant polypeptides: potential use in serodiagnosis.
Tuberculosis, Pulmonary
[Action of p-aminosalicylic acid on the prothrombin and thromboplastin level in pulmonary tuberculosis.]
Typhoid Fever
Effects of heparin, typhoid vaccine and thrombophlebitis on factor X metabolism in the dog.
Unconsciousness
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Polytrauma Defined by the New Berlin Definition: A Validation Test Based on Propensity-Score Matching Approach.
Uremia
Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia.
Thrombotic Role of Blood and Endothelial Cells in Uremia through Phosphatidylserine Exposure and Microparticle Release.
Ureteral Obstruction
Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis.
Urinary Bladder Neoplasms
Clotting profile in cattle showing chronic enzootic haematuria (CEH) and bladder neoplasms.
Urinary Tract Infections
Attributable fraction for cardiac malformations.
Development of cephradine-induced acquired factor v inhibitors: a case report.
Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
Uterine Hemorrhage
Acquired hemophilia A manifesting as plasma transfusion-uncontrolled severe bleeding 2 weeks after chorioamnionitis-induced abortion.
Effect of systematic nursing on patients with dysfunctional uterine bleeding and rehabilitation.
Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
Replacement therapy for congenital Factor X deficiency.
Severe factor X deficiency in pregnancy: case report and review of the literature.
Uterine Inertia
New approach to the risk variables for administration of fibrinogen in patients with postpartum hemorrhage by using cluster analysis.
Uterine Prolapse
The influence on coagulation of transdermal estrogen hormone replacement therapy as a preoperative preparation of the tissue before vaginal hysterectomy.
Varicose Veins
Biological findings from the PheWAS catalog: focus on connective tissue-related disorders (pelvic floor dysfunction, abdominal hernia, varicose veins and hemorrhoids).
Compression stockings attenuate the expression of proteins associated with vascular damage in human varicose veins.
Risk factors and impact of portal vein thrombosis in liver transplantation.
Vascular Diseases
Activated protein C resistance: prevalence and implications in peripheral vascular disease.
Antiplatelet and anticoagulant drugs in coronary vascular disease.
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
Platelet-derived microparticles in alloxan-induced diabetes in rabbits.
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
[THROMBOPLASTIN ("INTRINSIC ACTIVATOR OF PROTHROMBIN") IN OCCLUSIVE VASCULAR DISEASES AND IN THROMBOSES.]
Vascular Malformations
Surgery in patients with vascular malformations of the head and neck: value of coagulation disorders.
Vascular System Injuries
A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.
Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.
Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.
Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1.
Assessment of an ELISA kit for platelet-derived microparticles by joint research at many institutes in Japan.
Coagulation factor V: a plethora of anticoagulant molecules.
Coagulation factor Xa synergistically interacts with serotonin in inducing vascular smooth muscle cell proliferation.
Cytometric analysis of high shear-induced platelet microparticles and effect of cytokines on microparticle generation.
Dissimilar interaction of factor VIII with endothelial cells and lipid vesicles during factor X activation.
Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa.
Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation.
Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo.
Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.
Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats.
Experimental model of lower limb ischemia in rats and the effect of YM466, an oral direct factor Xa inhibitor.
Function and clinical significance of platelet-derived microparticles.
Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes.
Gene targeting in hemostasis. tissue factor.
HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase.
How do HMG-CoA reductase inhibitors prevent stroke?
In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice.
Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury.
Inhibition of factor Xa and neointima formation after vascular injury.
New antithrombotic strategies for resistant thrombotic processes.
New insights into the spatiotemporal localization of prothrombinase in vivo.
Platelet tissue factor pathway inhibitor modulates intravascular coagulation.
Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool.
Quantitation of coated platelet potential during collection, storage, and transfusion of apheresis platelets.
Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats.
Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation.
Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation.
Residual factor VIII-like cofactor activity of thioredoxin and related oxidoreductases.
Slounase, a Batroxobin Containing Activated Factor X Effectively Enhances Hemostatic Clot Formation and Reducing Bleeding in Hypocoagulant Conditions in Mice.
The procoagulant activity of tissue factor expressed on fibroblasts is increased by tissue factor-negative extracellular vesicles.
Tissue factor: a key molecule in hemostatic and nonhemostatic systems.
Venous Thromboembolism
A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty.
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery.
A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
A genetic association study of activated partial thromboplastin time in European Americans and African Americans: the ARIC Study.
A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
A network meta-analysis of direct factor Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.
A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics.
A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal.
Accidental Rivaroxaban Overdose in a Patient with Pulmonary Embolism: Some Lessons for Managing New Oral Anticoagulants.
Activated partial thromboplastin time and risk of future venous thromboembolism.
Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes.
Activated partial thromboplastin time: results of a case-control study evaluating six commercial reagents in assessing the risk of venous thromboembolism.
Acute management of bleeding in patients on novel oral anticoagulants.
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Antithrombotic drugs in vascular medicine: a historical perspective.
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.
Apixaban for extended treatment of venous thromboembolism.
Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation.
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model.
Apixaban: A Review in Venous Thromboembolism.
Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide.
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects.
Challenges in the prevention of venous thromboembolism in the elderly.
Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists.
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
Clinical management of rivaroxaban-treated patients.
Clinical trials with factor Xa inhibition in the prevention of postoperative venous thromboembolism.
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism.
Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-AF study.
Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.
Comparison of the effects of heparin and the direct factor Xa inhibitor, rivaroxaban, on bone microstructure and metabolism in adult rats.
Complete response to rivaroxaban in a case of invaginated thrombus thought to have extended through a patent foramen ovale with an accompanying pulmonary embolism.
CORR Insights(®): Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism.
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
Dabigatran: ready for prime time?
Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label study.
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding.
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.
Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.
Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis.
Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide.
Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
Edoxaban in patients with atrial fibrillation.
Edoxaban tosylate.
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism.
Edoxaban Was Effective for the Treatment of Deep Vein Thrombosis and Pulmonary Thromboembolism in a Cancer Patient with Antithrombin III Deficiency.
Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-Valvular Atrial Fibrillation and Venous Thromboembolism.
Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing.
Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.
Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age.
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency.
Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism.
Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion.
Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis.
Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban.
Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux.
Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.
Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban.
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation.
Factor Xa Inhibitors in Acute Coronary Syndromes and Venous Thromboembolism.
Factor Xa inhibitors--new anticoagulants for secondary haemostasis.
Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
Fondaparinux in the management of patients with ST-elevation acute myocardial infarction.
Fondaparinux: a new antithrombotic agent.
Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders.
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants.
Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report.
Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism.
Heparin therapy for venous thrombosis and pulmonary embolism.
Heterogeneity of synthetic factor Xa inhibitors.
Homozygous methylentetrahydrofolate reductase C667T genotype anticipates age at venous thromboembolism by one decade.
Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine.
Identifying and reducing the incidence of post discharge Venous Thromboembolism (VTE) in orthopaedic patients: a systematic review.
Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
In vitro assessment of edoxaban anticoagulant effect in pediatric plasma.
Inhibition of Factor Xa : a potential target for the development of new anticoagulants.
Intravenous Thrombolysis for Acute Ischemic Stroke in a Patient Receiving Rivaroxaban.
Is Aspirin as Effective as the Newer Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip and Knee Arthroplasty? An Analysis From the National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man.
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.
Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis.
Management of venous thromboembolism: past, present, and future.
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Monitoring and reversal strategies for new oral anticoagulants.
Monitoring of hemostatic abnormalities in major orthopedic surgery patients treated with edoxaban by APTT waveform.
Monitoring the anticoagulant effect after a massive rivaroxaban overdose.
New Anticoagulants - Promising and Failed Developments.
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
New Oral Anticoagulants for Venous Thromboembolism: Focus on Factor Xa and Thrombin Inhibitors.
New oral anticoagulants: not quite there yet.
New oral anticoagulants: prevention of VTE in phase III studies in total joint replacement surgery and the hospitalized medically-ill patients.
Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Old and new anticoagulant drugs: a minireview.
Oral anticoagulation with edoxaban.
Oral anticoagulation with edoxaban. Focus on current phase III clinical development.
Oral apixaban for the treatment of acute venous thromboembolism.
Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement: A Systematic Review and Meta-analysis.
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review.
Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Overview of Current Evidence on the Impact of the Initial High Dose of the Direct Factor Xa Inhibitor Rivaroxaban on Thrombus Resolution in the Treatment of Venous Thromboembolism.
Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.
Periprocedural management of rivaroxaban-treated patients.
Phamacokinetics of rivaroxaban in adolescents.
Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery.
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
PK evaluation of fondaparinux sodium for the treatment of thrombosis.
Plasma accumulation of fondaparinux 2.5 mg in patients after total hip arthroplasty.
Population Pharmacokinetic-Pharmacodynamic Modeling Analysis of Intrinsic FXa and Bleeding From Edoxaban Treatment.
Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery.
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Preclinical and clinical data for factor Xa and "universal" reversal agents.
Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time.
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Principles for diagnosis and treatment of pulmonary embolism.
ProC Global: the first functional screening assay for the complete protein C pathway.
Pulmonary Venous Thromboembolism in an Acutely Ill Medical Patient Receiving Rivaroxaban.
Quality improvement: Adherence to nurse-driven heparin protocols.
Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Recurrent Venous Thromboembolism in Two Patients With Cancer Taking Rivaroxaban.
Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times.
Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH.
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies.
Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
Review: Factor Xa inhibitors reduce DVT more than LMWH in total knee or hip replacement.
Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism.
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Rivaroxaban limits complement activation compared to warfarin in antiphospholipid syndrome patients with venous thromboembolism.
Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice.
Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Rivaroxaban: a review of its use in acute coronary syndromes.
Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban.
Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date.
SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: A pilot study.
Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.
Short-Term Subcutaneous Fondaparinux and Oral Edoxaban for Acute Venous Thromboembolism.
Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition.
Subcutaneous unfractionated heparin compared with low-molecular-weight heparin for the initial treatment of venous thromboembolism.
Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
Successful use of fondaparinux in a patient with a mechanical heart valve replacement and a history of heparin-induced thrombocytopenia.
The Cost-Effectiveness of Oral Direct Factor Xa Inhibitors Compared with Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement Surgery.
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
The discovery and development of rivaroxaban.
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
The in vitro anticoagulant effect of rivaroxaban in children.
The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
The relative contributions of antithrombin III during heparin treatment, and of clinically recognisable risk factors, to early recurrence of venous thromboembolism.
The role of factor Xa inhibitors in venous thromboembolism treatment.
The use of factor Xa inhibitors following opening-wedge high tibial osteotomy for venous thromboembolism prophylaxis.
Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism.
Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis.
Treatment of venous thromboembolism with new oral anticoagulants according to patient risk.
Treatment of venous thrombosis in the cancer patient.
Trousseau's syndrome: cancer-associated thrombosis.
Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.
Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time.
Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism.
Use of newer anticoagulants in patients with chronic kidney disease.
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
Venous thromboembolism prevention through the use of novel Factor Xa inhibitors.
Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
Vitamin K antagonists. Ready to be replaced?
YM-150, a Factor Xa inhibitor for the prevention of venous thromboembolism and coronary artery disease.
[Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism].
[Determination of factor Xa inhibition doses of low-molecular heparin, nadroparin and reviparin in urological patients]
[Lengthened activated thromboplastin time in the course of tinzaparin therapy of accidental venous thromboembolism. Pilot study]
[New oral anticoagulants from the perspective of trauma surgery].
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
[Prevention of venous thromboembolism after major orthopedic surgery: update and contribution of a specific synthetic inhibitor of factor Xa]
[Prevention of venous thromboembolism in surgical patients].
[Safety and economics of fondaparinux administration in the laparoscopic surgery].
[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Venous Thrombosis
'Lupus' anticoagulant and thrombosis of the hepatic veins (Budd-Chiari syndrome). Report of three patients and review of the literature.
A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge.
A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
A comprehensive evaluation of apixaban in the treatment of venous thromboembolism.
A cost-analysis model for anticoagulant treatment in the hospital setting.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation.
A prospective randomized comparative study to determine appropriate edoxaban administration period, to prevent deep vein thromboembolism in patients with total knee arthroplasty.
A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients.
A Single-Center Retrospective Evaluation of the Use of Oral Factor Xa Inhibitors in Patients With Cerebral Venous Thrombosis.
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Activation of the factor VII-tissue factor pathway.
Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data.
Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement.
AGA Clinical Practice Update: Coagulation in Cirrhosis.
An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Anti-thrombosis effect of diosgenin extract from Dioscorea zingiberensis C.H. Wright in vitro and in vivo.
Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor antistasin following subcutaneous administration in the rhesus monkey.
Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
Anticoagulation-related intracranial hemorrhages.
Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients.
Antiphospholipid syndrome and factor V Leiden. Three cases with recurrent venous thrombosis.
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist.
Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Antithrombotic and bleeding effects of a low molecular weight heparin fraction.
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Antithrombotic effects of (n-3) polyunsaturated fatty acids in rat models of arterial and venous thrombosis.
Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration.
Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.
Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries.
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report.
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.
Characterization of an immunologic polymorphism (D79H) in the heavy chain of factor V.
Cholesterol Crystal Embolism Induced by Direct Factor Xa inhibitor: A First Case Report.
Clinical and experimental experience with factor Xa inhibitors.
Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus.
Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase.
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.
Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.
Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis.
Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.
Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Current management of acute symptomatic deep vein thrombosis.
Deep vein thrombosis following hip surgery. Relation to activated factor X inhibitor activity: effect of heparin and dextran.
Deep Venous Thrombosis with Decreased Cerebral Blood Flow to the Thalamus was Completely Restored by Factor Xa Inhibitor.
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
Development of an experimental model of pre-thrombosis in rats based on Wessler's principle using a calibrated venous stasis.
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Different clinical presentations of a lupus anticoagulant in the same family.
Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Direct oral anticoagulants in rare venous thrombosis.
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa.
Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study.
Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
Efficacy of an intravenous low-molecular-weight dermatan sulphate (Desmin) in patients with acute proximal deep venous thrombosis and silent pulmonary embolism. A pilot study.
Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism.
Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.
Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.
Exploiting the antithrombotic effect of the (pro)thrombin inhibitor bothrojaracin.
Factor X inhibitors.
Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis.
Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase.
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Giant deep vein thrombus complicating endovascular cooling therapy after cardiac arrest in a boy with hypertrophic cardiomyopathy.
Hemostatic properties of the lymph: relationships with occlusion and thrombosis.
Heparin and warfarin: use of anticoagulants in the prevention and treatment of venous thrombosis and pulmonary embolism.
Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time.
HIT paradigms and paradoxes.
Importance of platelets in experimental venous thrombosis in the rat.
Improved anticoagulant effect of fucosylated chondroitin sulfate orally administered as gastro-resistant tablets.
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy.
Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance.
Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors.
Intravenous recombinant soluble human thrombomodulin prevents venous thrombosis in a rat model.
Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers.
Low molecular weight heparin in acute stroke.
Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.
Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.
Lupus anticoagulant syndrome: case report.
Measurement of a newly developed thrombomodulin addition activated partial thromboplastin time assay in patients with deep venous thrombosis.
Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.
Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen.
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors.
Nonbenzamidine tetrazole derivatives as factor Xa inhibitors.
Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients.
Novel therapeutic agents in the management of hemorrhage and thrombosis.
Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis.
Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement: A Systematic Review and Meta-analysis.
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Oral rivaroxaban for symptomatic venous thromboembolism.
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism.
Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses.
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Possible Rivaroxaban Failure during the Postpartum Period.
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.
Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism.
Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban.
Prevalence and Risk Factors for Thrombotic Complications Following Venovenous Extracorporeal Membrane Oxygenation: A CT Scan Study.
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Preventive and therapeutic approach to venous thromboembolic disease and pulmonary embolism--can death from pulmonary embolism be prevented?
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity.
Primary sclerosing cholangitis in the presence of a lupus anticoagulant.
Pulmonary Thromboembolism in COVID-19: Venous Thromboembolism or Arterial Thrombosis?
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
Rapid profiling of cantharidin analogues in Mylabris phalerata Pallas by ultra-performance liquid chromatography-quadrupole time-of-flight-tandem mass spectrometry.
Rare inherited coagulation disorders in India.
Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients.
Rectus Sheath Hematoma Associated with Apixaban.
Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times.
Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis.
Reversible Neurological Adverse Reaction to Apixaban.
Review of the initiation of anticoagulant therapy.
Review: Factor Xa inhibitors reduce DVT more than LMWH in total knee or hip replacement.
Risk factors of postthrombotic syndrome before and after deep venous thrombosis treatment.
Rivaroxaban for treatment of venous thromboembolism in older adults.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Rivaroxaban: direct factor Xa inhibition to treat acute deep vein thrombosis.
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit.
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time.
Short-Term Subcutaneous Fondaparinux and Oral Edoxaban for Acute Venous Thromboembolism.
Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
Spontaneous rectus sheath hematoma during rivaroxaban therapy.
SR-90107 (Sanofi-Synthélabo).
Stroke risk factor, pattern and outcome in patients with cancer.
Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
Successful treatment with rivaroxaban of an extended deep vein thrombosis complicated by pulmonary embolism in a patient with familial antithrombin III deficiency: a case report.
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.
The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
The efficacy of long-term oral anticoagulant therapy and its laboratory assessment.
The lupus anticoagulant. High incidence of 'negative' mixing studies in a human immunodeficiency virus-positive population.
The possible role of platelet coagulant activities in the pathogenesis of venous thrombosis.
The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
The use of rivaroxaban for the treatment of thrombotic complications in four dogs.
The venous antithrombotic profile of naroparcil in the rabbit.
Thrombosis of Large Aneurysm Induced by Flow-Diverter Stent and Dissolved by Direct Factor Xa Inhibitor.
Transitions of care in anticoagulated patients.
Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators.
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Two new closely related rat models with relevance to arterial thrombosis--efficacies of different antithrombotic drugs.
Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability.
Venous thromboembolism prophylaxis guidelines: use by primary care physicians.
Warfarin-Induced Skin Necrosis in the Presence of Acute Hepatic Injury and May-Thurner Syndrome.
[A case of anti-phospholipid antibody syndrome associated with subdural hematoma]
[Change of coagulation functions and its significance in acute exacerbation of chronic obstructive pulmonary disease].
[Effect of tranexamic acid combined flexion position of hip and knee on perioperative bleeding following unilateral total knee arthroplasty].
[Factor Xa Inhibitor for the Treatment of Cerebral Venous Thrombosis with Intracerebral Hemorrhage during Anticoagulation Therapy:A Case Report].
[Fondaparinux: The present and the future.]
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
[New oral anticoagulants : Better than vitamin K antagonists?]
[Pharmacology of the new oral anticoagulants].
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
[Recurrent thromboembolisms despite full anticoagulation in a patient with antiphospholipid syndrome].
[Risk factors of deep venous thrombosis associated with peripherally inserted central venous catheter in upper extremity in ICU].
[Study on the safety and effectiveness of low-dose tranexamic acid in operation of multi-level continuous thoracic ossification of ligament flavum].
Ventricular Dysfunction, Left
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Vertebral Artery Dissection
Novel Oral Anticoagulants as Treatment for Vertebral Artery Dissection: Case Report.
Virus Diseases
Assessment of aPTT-based clot waveform analysis for the detection of haemostatic changes in different types of infections.
Cutaneous histopathologic findings in 'antiphospholipid syndrome'. Correlation with disease, including human immunodeficiency virus disease.
Xanthine oxidoreductase activity in human liver disease.
Vitamin E Deficiency
Studies on vitamin E and selenium deficiency in young pigs. IV. Effect on coagulation system.
Vitamin K Deficiency
Coagulopathy in the nephrotic syndrome.
Evidence for a warfarin-sensitive serum factor that participates in factor X activation by Lewis lung tumor cells.
Macroscopic hematuria as presenting symptom of celiac disease.
Vitamin K deficiency in newborns: a case report in alpha-1-antitrypsin deficiency and a review of factors predisposing to hemorrhage.
[Effects of cefotaxime on the coagulation system, especially their dependence on vitamin K-related factors]
Vitamin K Deficiency Bleeding
Spontaneous Retrobulbar Hemorrhage in a Previously Healthy Infant.
von Willebrand Disease, Type 3
Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
von Willebrand Diseases
A two-center retrospective review of the hematologic evaluation and laboratory abnormalities in suspected victims of non-accidental injury.
Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.
Acquired type 3-like von Willebrand syndrome preceded full-blown systemic lupus erythematosus.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Combined hereditary factor XI (plasma thromboplastin antecedent) deficiency, von Willebrand's disease, and xeroderma pigmentosum in a Japanese family.
Dextran 40-induced coagulopathy confused with von Willebrand disease.
Effect of intravenous adrenalin infusion and corticosteroid treatment in patients with von Willebrand's disease.
Evaluation of laboratory methods to improve characterization of dogs with von Willebrand disease.
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Frequency of inherited bleeding disorders in women with menorrhagia.
Gastrointestinal angiodysplasia: a possible component of von Willebrand's disease.
Intracranial haemorrhage in patients with congenital haemostatic defects.
Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification.
Mild Bleeders: Diagnosis is Elusive in Large Number of Patients.
Multicenter retrospective study of transcatheter arterial embolisation for life-threatening haemorrhage in patients with uncorrected bleeding diathesis.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.
Preoperative screening for coagulopathy using prothrombin time and partial thromboplastin time in patients requiring primary cranial vault remodeling.
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.
Screening and diagnosis of coagulation disorders.
The spectrum of bleeding disorders in women with menorrhagia: a report from Western India.
Use of a questionnaire to predict von Willebrand disease status and characterize hemorrhagic signs in a population of dogs and evaluation of a diagnostic profile to predict risk of bleeding.
Vascular type Ehlers-Danlos syndrome is associated with platelet dysfunction and low vitamin D serum concentration.
von Willebrand factor as a regulator of intrinsic factor X activation.
[Infective morbidity of replacement therapy in congenital coagulation deficiencies and its effects on demand of coagulation factors]
[Successes and failures of the activated partial thromboplastin time in the preoperative evaluation]
Waldenstrom Macroglobulinemia
Antibody studies of factor VIII inhibitor in a case with Waldenström's macroglobulinemia.
[Recurrence of Waldenström macroglobulinemia accompanied by factor X deficiency].
[Thromboplastin formation in Waldenström's macroglobulinemia and in multiple myeloma]
Whipple Disease
Monocyte procoagulant activity in Whipple's disease.
Whooping Cough
Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation.
Wilms Tumor
Acquired factor VII deficiency associated with Wilms tumor.
Wound Infection
Coagulation Laboratory Testing Is Predictive of Wound Complications Following Microdiscectomy.
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Xanthomatosis
Evaluation of plaque stability of advanced atherosclerotic lesions in apo e-deficient mice after treatment with the oral factor xa inhibitor rivaroxaban.
Xeroderma Pigmentosum
Combined hereditary factor XI (plasma thromboplastin antecedent) deficiency, von Willebrand's disease, and xeroderma pigmentosum in a Japanese family.
Yellow Fever
Alboserpin, a factor xa inhibitor from the mosquito vector of yellow Fever, binds heparin and membrane phospholipids and exhibits antithrombotic activity.
Isolation and characterization of the gene encoding a novel factor Xa-directed anticoagulant from the yellow fever mosquito, Aedes aegypti.